Glycoside synthase variants for antibody drug complex engineering
By using glycoside synthetase variants to modify the polysaccharide structure of the antibody Fc region, homogenous glycosylation of the antibody is achieved, ADCC activity and cytotoxicity are improved, and the problem of reduced activity caused by heterogeneous polysaccharides in the antibody Fc region in the existing technology is solved, making it suitable for cancer treatment.
Patent Information
- Application Number
- CN202380076118.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-11-09
- Filing Date
- 2023-09-22
- Publication Date
- 2025-09-09
AI Technical Summary
The heterogeneous glycan structure in the Fc region of existing monoclonal antibodies leads to reduced ADCC activity, limiting their cytotoxic effect, and existing endoglycosidases are unable to completely remove all glycan types, affecting therapeutic effects.
Specific glycosylation synthetase variants, such as SEQ ID NO: 1 or SEQ ID NO: 2, are used to modify the polysaccharide structure of the antibody Fc region to homogenize it, and then bind to the modified polysaccharide to form an engineered biocomplex with efficient transglycosylation activity.
The homogenous glycosylation of the antibody is achieved, the ADCC activity and cytotoxicity are improved, and the therapeutic effect of the antibody is enhanced, making it suitable for cancer treatment.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
[0001] Cross-reference to related applications
[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 382,951, filed on November 9, 2022, the entire contents of which are incorporated herein by reference.
[0003] Sequence Listing
[0004] This application contains a sequence listing, which has been submitted electronically in ASCII XML format pursuant to Rule ST. 26 and is incorporated herein by reference in its entirety. The ASCII copy was created on September 21, 2023, is named G3004-01800PCT_20230921_SequenceListing.xml, and is 12,350 bytes in size. Technical Field
[0005] The present invention relates to a glycosylated antibody complex and a method for preparing the same. Background Art
[0006] Many surface carbohydrates are expressed in malignant tumor cells. For example, the carbohydrate antigen Globo H (Fucα1→2Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glc) was first isolated as a ceramide-linked glycolipid and identified in 1984 from breast cancer MCF-7 cells. (Bremer EG et al. (1984) J Biol Chem 259:14773-14777). Previous studies have also shown that Globo H and stage-specific embryonic antigen 3 (Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1) (SSEA-3, also known as Gb5) were observed on breast cancer cells and breast cancer stem cells (WW Chang et al. (2008) Proc Natl Acad Sci USA, 105(33):11667-11672). Furthermore, SSEA-4 (Stage-Specific Embryonic Antigen-4) (Neu5Acα2 → 3Galβ1 → 3GalNAcβ1 → 3Galα1 → 4Galβ1 → 4Glcβ1) has been widely used as a cell surface marker for pluripotent human embryonic stem cells and has been used to isolate mesenchymal stem cells and enrich for neural progenitor cells (Kannagi R et al. (1983) EMBO J, 2:2355-2361). These findings support the idea that the Globo series of antigens (Globo H, SSEA-3, and SSEA-4) may be unique targets for cancer therapy and could be used as direct therapeutic agents to effectively target cancer cells.
[0007] Programmed death 1 (PD-1) is an inhibitory receptor expressed on T cells, B cells, and monocytes (Ishida et al. (1992) EMBO J. 11: 3887-2895; Agata et al. (1996) Int. Immunol. 8: 765-772). PD-L1 and PD-L2 are ligands for PD-1 and have been shown to downregulate T cell activation and cytokine secretion upon binding to PD-1 (Freeman et al. (2000) J Exp Med 192:1027-34; Latchman et al. (2001) Nat Immunol 2:261-8). Binding of PD-1 to PD-L1 or PD-L2 leads to downregulation of immune responses. Therefore, blocking the PD-1 / PD-L1 antigen pathway has been proposed as a way to attenuate central and peripheral immune responses against cancer. Targeting the PD-1 and PD-L1 antigen pathways has demonstrated clinical efficacy in over 15 cancer types, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, and Hodgkin's lymphoma (Sharma et al. (2015) Science 348(6230):56-61). However, many patients remain unresponsive to PD-1 or PD-L1 antigen therapy. In some cases, patients demonstrate an initial response but develop resistance over time. Therefore, there is an urgent need to identify the mechanisms of resistance to PD-1 or PD-L1 combination therapy.
[0008] Therapeutic monoclonal antibodies (mAbs) have been developed for the treatment of many diseases, including cancer, autoimmunity, and infectious diseases (Adams, GP and Weiner, LM (2005) Nat. Biotechnol. 23: 1147-1157; Aggarwal, SR (2012) Nat. Biotechnol. 30: 1191-1197; Aggarwal, SR (2014) Nat. Biotechnol. 32: 323-330). Several mAbs have been approved for cancer therapy. These mAbs recognize specific biomarkers on the surface of tumor cells and enhance apoptosis through various mechanisms, such as initiating antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) or blocking signaling pathways. The Herceptin 2 receptor is the most prominent biomarker in breast cancer, enabling Roche to develop two related monoclonal antibodies, Herceptin (trastuzumab) and Perjeta (pertuzumab). The EGFR receptor is also a well-known target for monoclonal antibody development. For example, Vectibix (panitumumab) and Erbitux (cetuximab) are being developed by Amgen and Merck, respectively, as targeted therapies for metastatic colorectal cancer. Furthermore, Rituxan (rituximab, Roche) and Arzerra (ofatumumab, GlaxoSmithKline), designed to recognize the CD20 receptor, are commonly used to treat non-Hodgkin's B-cell lymphoma and chronic lymphocytic leukemia.Recently, Taiwan-based OBI Pharma, Inc. is developing OBI-888 and OBI-898 antibodies based on the ganglioside biomarkers Globo H and SSEA-4. These markers are found in breast, lung, ovarian, gastric, and small cell lung cancers (Hakomori, SI (2008) Biochim. Biophys. Acta. 1780: 325-346; Hakomori, S. and Zhang, Y. (1997) Chem. Biol. 4:97-104; Zhang, S. et al. (1997) Int. J. Cancer 73: 42-49; Zhang, S. et al. (1997) Int. J. Cancer 73:50-56). Erbitux, Rituxan, Arzerra, OBI-888, and OBI-898 kill cancer cells through cytotoxicity via ADCC and CDC. In addition, several monoclonal antibodies have been developed to block the function of protein-protein interactions. For example, Humira (adalimumab, AbbVie) blocks the TNF-α receptor signaling pathway that regulates the autoimmune disease rheumatoid arthritis; Keytruda (pembrolizumab, Merck) blocks the PD-1 receptor to disrupt cancer cell protection in metastatic melanoma. Compared to small molecule drugs, monoclonal antibodies are more specific to their target cells and have relatively fewer side effects on patients. These two important characteristics have made them powerful tools in combating various diseases.
[0009] Monoclonal antibodies (mAbs) have a molecular weight of approximately 150 kDa and are composed of two heavy chains (approximately 50 kDa) and two light chains (approximately 25 kDa), forming three domains separated by a flexible hinge. The two Fab domains contain the variable complementarity-determining regions (CDRs) that recognize antigens. The Fc domain is a constant region with N-glycans that mediate ADCC and CDC cytotoxicity (Jefferis, R. (2009) Nat. Rev. Drug Discoy. 8:226-234). Amino acid N297 in the Fc domain is a conserved N-glycosylation site, which is linked to heterogeneous glycan types, such as biantennary (M3, G0F, G1F, G2F, G0, G1, and G2 complex types) and triantennary (high mannose and hybrid types), and is expressed in various cell systems. X-ray structural analysis reveals that the core trehalose of the Fc glycans blocks specific carbohydrate-carbohydrate interactions between Fc and FcγRIIIa, reducing the binding constant by approximately 100-fold (Ferrara, C. et al. (2011) Proc. Natl. Acad. Sci. USA 108: 12669-12674), and also reduces cell killing efficiency. CHO cells are the most commonly used cell system in the biopharmaceutical industry. CHO cells typically produce monoclonal antibodies containing glycan compositions primarily in the G0F, G1F, and G2F forms. These glycan forms limit the ADCC activity of monoclonal antibodies due to the reduced ADCC binding efficiency caused by trehalose. Although modified CHO cell systems have been developed to reduce glycan co-expression in mAbs by knocking out the FUT8 (α-1,6-fucosyltransferase 8) gene (Yamane-Ohnuki, N. and Satoh, M. (2009) MAbs, 1 230-236; Yamane-Ohnuki, N. et al. (2004) Biotechnol. Bioeng. 87:614-622) or upregulating the bisecting GlcNAc (N-acetylglucosamine) transferase GnT-III (Umana, P. et al. (1999) Nat. Biotechnol. 17: 176-180), it is still of great significance to find better and more general methods to obtain the desired N-glycans on mAbs. Furthermore, it has been reported that removal of Fc glycans results in a loss of ADCC activity (Kurogochi, M. et al. (2015) PLoS One 10: e0132848). These data suggest that the cytotoxicity of monoclonal antibodies can be effectively controlled by attaching N-glycans to the Fc region.
[0010] Enzymatic modification of the Fc region offers a solution for creating homogeneous monoclonal antibodies. Lai-Xi Wang and colleagues attempted chemoenzymatic remodeling by removing a mixture of glycans and then combining homogeneous glycans (Huang, W. et al. (2012) J. Am. Chem. Soc. 134: 12308-12318). Several endo-β-N-acetylglycosaminidase (ENGase) enzymes have been reported to remove mixed glycans from monoclonal antibodies. For example, EndoD (Tai, T. et al. (1975) J. Biol. Chem. 250: 8569-8575), EndoH (Tarentino, AL et al. (1974) J. Biol. Chem. 249: 818-824), EndoLL (Kurogochi, M. et al. (2015) PLoS One 10: e0132848), and EndoM (Kadowaki, S. et al. (1990) Agric. Biol. Chem. 54: 97-106) are capable of hydrolyzing glycans with high mannose or terminal mannose types. EndoS (Collin M and Olsén A. (2001) EMBO J. 20: 3046-3055) and EndoSd (Shadnezhad, A. et al. (2016) Future Microbiol 11: 721-736) are capable of hydrolyzing both non-fucosylated and fucosylated N-glycans on the Fc domain, but not high-mannose types. To date, no single endoglycosidase can fully hydrolyze all glycan types on a single antibody. The crystal structure of EndoS was recently solved, revealing five functional domains (Trastoy, B. et al. (2014) Proc. Natl. Acad. Sci. USA 111: 6714-6719). The endoglycosidase domain is highly conserved, with a rigid β-barrel structure suitable for site-specific mutagenesis studies. Glycoside synthases of antibody Fc domains have also been reported. EndoD-N322Q (Fan, SQ et al. (2012) J. Biol. Chem. 287: 11272-11281) and EndoM-N175Q (Umekawa, M., Li, C. et al. (2010) J. Biol. Chem. 285: 511-521) transfer only short-chain complex N-glycans to the Fc.Endo-F3-D165Q (Giddens, JP et al. (2016) J. Biol. Chem. 291:9356-9370) transfers glycans only to the fucosylated Fc domain. EndoS-D233Q (Huang, W. et al. (2012) J. Am. Chem. Soc. 134: 12308-12318) is able to bind to various biantennary complex forms, while EndoS2-D184M (Li., T., Tong et al. (2016) J. Biol. Chem. 291: 16508-16518) binds to wild-type substrates, including complex, high-mannose, and hybrid forms.
[0011] The use of antibody-drug conjugates (ADCs) for localized delivery of cytotoxic or cytostatic drugs to kill or inhibit tumor cells in cancer therapy (Syrigos and Epenetos (1999) Anticancer Research 19:605-614; Niculescu-Duvaz and Springer (1997) Adv. Drg. Del. Rev. 26:151-172; U.S. Patent No. 4,975,278) allows for targeted delivery of the drug moiety to tumors where it accumulates intracellularly, whereas systemic administration of unbound cytotoxic or cytostatic drugs can produce unacceptable levels of toxicity to normal cells as well as the tumor cells being sought to be eliminated (Baldwin et al., 1986, Lancet pp. (Mar. 15, 1986):603-05; Thorpe, 1985, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review," in Monoclonal Antibodies '84: Biological and Clinical Applications, A. Pinchera et al. (eds.), pp. 475-506. Both polyclonal and monoclonal antibodies have been reported to be suitable for use in these strategies (Rowland et al., 1986, Cancer Immunol. Immunother. 21:183-87). Drugs used in these approaches include daunomycin, doxorubicin, methotrexate, and vindesine (Rowland et al., 1986, supra). Some cytotoxic drugs tend to be inactive or less active when bound to large antibodies or protein receptor ligands. Summary of the Invention
[0012] In one aspect, the present invention provides a method for preparing an engineered biocomplex, comprising contacting a biomolecule with a glycosynthase and a modified glycan, thereby obtaining a first engineered biocomplex, wherein the biomolecule further comprises an N-linked initial glycan; wherein the glycosynthase comprises SEQ ID NO: 1 or SEQ ID NO: 2, and the glycosynthase comprises a mutation within residues 176-186, residues 225-237, or residues 273-289 of SEQ ID NO: 1, or within residues 178-188, residues 227-239, or residues 275-291 of SEQ ID NO: 2; wherein the modified glycan comprises a substrate moiety and a first reactive moiety; wherein the substrate moiety is configured to react with the glycosynthase; and wherein the biomolecule comprises an antibody or antigen-binding fragment thereof, a protein, or a peptide.
[0013] In another aspect, the present invention provides an engineered biocomplex comprising: a biomolecule and a modified glycan coupled to the biomolecule; wherein the modified glycan comprises: (i) a first polyethylene glycol (PEG) moiety, and (ii) a first reactive moiety or a resultant moiety thereof from a bioorthogonal reaction; wherein the resultant moiety comprises a triazole moiety, a DBCO-derived moiety, or a maleimide-derived moiety; and wherein the biomolecule comprises an antibody or antigen-binding fragment thereof, a protein, or a peptide.
[0014] In another aspect, the present invention provides a pharmaceutical composition comprising a plurality of engineered biocomplexes of the present invention and a pharmaceutically acceptable carrier.
[0015] In another aspect, the present invention provides a method for treating cancer, comprising administering an effective amount of the pharmaceutical composition of the present invention to a patient in need thereof.
[0016] In another aspect, the present invention provides a therapeutic composition comprising the following formula:
[0017] CLD;
[0018] wherein C is a reactive moiety configured to react in a biorthogonal reaction;
[0019] wherein L is a linker unit comprising a hydrophilic portion, a cleavable portion, and a spacer; and wherein D is a therapeutic agent. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1This section summarizes the various aspects of the homogeneous platform process. (A) The mAb and glycan mixture is heterogeneous, which is removed by wild-type EndoSz and α-fucosidase to generate mAb-GlcNAc. Subsequently, EndoSd-D232M and EndoSz-D234M are used to conjugate the glycan-oxazoline to generate a homogeneous mAb. (B) In the glycan cleavage step, only EndoSz enzyme is used to generate mAb-GlcNAc-F, and the product after conjugation is a homogeneous mAb-glycan-F. (C) An exemplary image of a biantennary glycan.
[0021] Figure 2 LC / MS / MS results of a Herceptin-GlcNAc glycopeptide. Wild-type Herceptin was mixed with wild-type EndoSz and α-fucosidase to remove glycans from the Fc region. The results showed that all glycans were removed, resulting in >99% Herceptin-GlcNAc.
[0022] Figure 3 : Exemplary detection method for a homogeneous platform (demonstrated by EndoSz-D234M). (A) HPLC analysis method. The retention time of native Herceptin (green) is 12.5 minutes, while the retention time of Herceptin-GlcNAc (magenta) shifts to 11.4 minutes. During the transglycosylation of NSCT-oxa, Herceptin-G2S2 (blue) can be clearly distinguished by 1N-G2S2 (hemiglycosylation) and 2N-G2S2 (full glycosylation), with retention times of 12.6 and 13.9 minutes, respectively. During the transglycosylation process, the peak shifts sequentially from Herceptin-GlcNAc to Herceptin-1N-G2S2 and Herceptin-2N-G2S2, enabling the inventors to monitor the process. (B) SDS-PAGE results for comparison. Hemiglycosylated and fully glycosylated Herceptin-G2S2 were difficult to identify.
[0023] Figure 4 : Multiple sequence alignment of exemplary EndoS2, EndoS, EndoSz and EndoSd. The loop around the active site is marked in light blue.
[0024] Figure 5Time-dependent transglycosylation results. (A) Transglycosylation of NSCT-Oxa by EndoSz-D234M using a 20:1 molar ratio of NSCT-Oxa to Herceptin-GlcNAc. (B) EndoSd-D232M using a higher molar ratio of 150:1 (NSCT-Oxa: Herceptin-GlcNAc). The reaction started with 100% Herceptin-GlcNAc. The percentages of Herceptin-1N-G2S2 and Herceptin-2N-G2S2 formed were plotted based on the efficiency. Both enzymes achieved >90% Herceptin-2N-G2S2 transglycosylation efficiency.
[0025] Figure 6 : Relative transglycosylation activities in different exemplary mutants. (A) EndoSz (B) EndoSd.
[0026] Figure 7 : Demonstration of the efficacy of homogeneous monoclonal antibodies: ADCC analysis results. (A) ADCC results of Herceptin and Herceptin-G2S2. The data show that Herceptin has higher ADCC activity. EC of Herceptin and Herceptin-G2S2 50 The transglycosylation efficiency and ADCC of various monoclonal antibodies were 15.29 (μg / mL) and 5.10 (μg / mL), respectively.
[0027] Figure 8 Overall structure of apo EndoSz. (A) The glycosidase (red), leucine-rich repeats (yellow), hybrid Ig (light blue), carbohydrate-binding motif (orange), and C-3HB (purple) domains are shown in cartoon form. (B) Top and side views showing the electrostatic surface. (C) View of the EndoSz protective surface.
[0028] Figure 9Structure of the complex biantennary glycan bound to EndoSz-D234M. (A) 2Fo-Fc electron density map outlined at 1.0σ, shown as a blue mesh. (B) Structure of the N-glycan bound in the β-barrel (gray sticks), flanked by loops (as noted). EndoSz-D234M is shown in transparent gray. (C) Cartoon representation of the substrate, EndoSz-D234M, and the complex N-linked glycan. The product is shown as a dashed rectangle. (D) Variable loops in the conservation map are labeled (green). Loops 1 (red ribbon), 2 (orange ribbon), 3 (yellow ribbon), 4 (green ribbon), 5 (blue ribbon), 6 (cyan ribbon), 7 (purple ribbon), and 8 (wheat ribbon) surrounding the active site are labeled. The α(1-6) antennae of the CT N-glycan are labeled.
[0029] Figure 10 Sugar substrate selectivity is dominated by loop 4 between EndoSz and EndoS2. (A) Superimposed structures of EndoSz / CT-N-glycan and EndoS2 / HM-N-glycan. The tilted helix 3 (labeled H3) in EndoSz structurally distorts the large loop 4, hindering the binding of labeled HM-N-glycan. Loop 4 is indicated by a red arrow. EndoSz / CT-N-glycan (green) and EndoS2 / HM-N-glycan (blue) are colored separately. (B) Superimposed structures of EndoS2 / HM-N-glycan and unbound EndoS2. EndoS2 / HM-N-glycan (blue) and unbound EndoS2 (wheat hue) are colored separately.
[0030] Figure 11 The movement of loop 2 shapes two binding grooves upon N-glycan binding. (A) 3D view of the superimposed structures of apo- and holo-EndoSzD234M. apo-EndoSz-D234M (blue) and holo-EndoSz-D234M (gold) are shown as cartoons. The bound N-glycans in holo-EndoSz-D234M are shown as balls and sticks. The key residue W154 (stick) and interacting residues Man (-2) and NAG (-8) are labeled. (B) Electrostatic surfaces of the unbound (left) and N-glycan-bound (right) EndoSz-D234M structures. W154 is indicated by a black circle. (C) Sequence alignment and conservation map of loop 2 of EndoSz-D234M.
[0031] Figure 122D diagram of EndoSz-D234M-glycan interactions. (A) GlcNAc (-1) conformation A. (B) GlcNAc conformation B. Bound CT N-glycans are shown as purple sticks. EndoSz interacting residues with hydrogen bonds (orange) and hydrophobic interactions (red) are shown as orange sticks and red sticks, respectively. Hydrogen-bonded residues (blue) and residues with hydrophobic contacts (black) are labeled.
[0032] Figure 13 : SDS-PAGE and CE-SDS analysis of mAb-(NSCT-di-N3)2 production. (A) SDS-PAGE of R4702 (anti-TROP2 monoclonal antibody), (B) SDS-PAGE of TX05 (anti-HER2 monoclonal antibody), and (C) CE-SDS analysis.
[0033] Figure 14 : MW analysis results by complete MS.
[0034] Figure 15 LC and HC MS spectra of R4702-MCCA-ADC (ADC-1) and R4702-DBCO-ADC (ADC-2) incubated with HSA: (A) ADC-1 on day 0 and day 6; (B) ADC-2 on day 0 and day 6; (C) DAR profile. LC0, LC1, HC0, HC1, HC2, and HC3 contribute spectra of light and heavy chains with 0, 1, 2, and 3 drug payloads, respectively.
[0035] Figure 16 : Time-dependent drug release of R4702-MCCA-ADC (ADC-1) and R4702-DBCO-ADC (ADC-2) in human plasma.
[0036] Figure 17 : Human tumor cell line cytotoxicity analysis. A series of dilutions of ADC were used to evaluate the in vitro cytotoxicity of several human tumor cell lines. Tumor cells were cultured with ADC for 6 days and the cells were cytotoxicated by CellTiter-Glo ® Analyze live cells. Calculate the IC of each ADC using Prism. 50(A) The efficacy of R4702-MCCA-ADC (ADC-1) and R4702-DBCO-ADC (ADC-2) was evaluated using NCI-H1975-C797S (human lung cancer) and DU-145 (human prostate cancer) tumor cells. (B) The efficacy of TX05-MCCA-ADC (ADC-3) and TX05-DBCO-ADC (ADC-4) was evaluated using NCI-N87 (human gastric cancer) and Capan-1 (human pancreatic cancer) tumor cells.
[0037] Figure 18 : Evaluation of in vivo efficacy in an NCI-H1975-C797S human lung cancer xenograft mouse model. NCI-H1975-C797S cells were cultured and subcutaneously implanted into the right flank of BALB / c nude mice. When the average tumor volume reached 150-200 mm 3 Tumor-bearing mice were treated with a single dose of 10 or 3 mg / kg. Tumor volume (A) and body weight (B) were monitored twice weekly until day 22. Tumor growth inhibition (TGI) was calculated using the following formula: Ti and Ci represent the mean tumor volumes of the treatment group and the vehicle group at the end of the study (day 22), while T1 and C1 represent the mean tumor volumes of the treatment group and the vehicle group at the start of test item administration.
[0038] ACN: acetonitrile; ADCC: antibody-dependent cellular cytotoxicity; DBCO: dibenzocyclooctyne; CDC: complement-dependent cytotoxicity; CDR: complementarity-determining region; FA: formic acid; FUT8: α-1,6-fucosyltransferase 8; GlcNAc: N-acetylglucosamine; HFIP: 1,1,1,3,3,3-hexafluoro-2-propanol; IPTG: isopropyl-β-D-thiogalactopyranoside; TFA: trifluoroacetic acid; DMSO: dimethyl sulfoxide; NaOAc: sodium acetate. NaOH: sodium hydroxide; HIC: hydrophilic chromatography; ADC: antibody-drug conjugate; mAb: monoclonal antibody; ISTD: internal standard; HSA: human serum albumin; PBS: phosphate-buffered saline; HC: heavy chain; LC: light chain; DAR: drug-antibody ratio; HRMS: high-resolution mass spectrometry; DL: drug linker; NSCT: sialylated complex-type N-glycan; ADC-1: R4702-MCCA-ADC; ADC-2: R4702-DBCO-ADC; ADC-3: TX05-MCCA-ADC; ADC-4: TX05-MCCA-ADC. DETAILED DESCRIPTION
[0039] Antibody-drug conjugates (ADCs) are a promising method for delivering therapeutics or imaging agents to target cells with reliable specificity and efficiency. Conjugation of a drug (e.g., a therapeutic or imaging agent) to an antibody typically occurs at lysine or cysteine residues on the antibody. Therefore, the drug-to-antibody ratio (DAR) of an ADC is determined by the amount of lysine or cysteine residues present on the antibody. However, in practice, not every antibody in a conjugation reaction binds in the same manner, resulting in ADC isoforms with varying DARs and binding sites. Importantly, conjugation via lysine or cysteine residues requires the use of a reducing agent, a further consideration as it may affect the antibody conformation and, consequently, the efficacy of the ADC. In light of the aforementioned technical issues, the present invention relates to an engineered antibody conjugate configured to conjugate a drug via glycans on the antibody. Preparation of the engineered antibody conjugate of the present invention involves glycosylation (e.g., N-glycosylation) to couple appropriate glycans to the antibody.
[0040] N-glycosylation is one of the most complex post-translational modifications, often resulting in significant heterogeneity in glycan structures, including high-mannose, hybrid, and complex forms, depending on the recombinant expression system. Commercially available therapeutic antibodies typically exist as a mixture of glycoforms, which is not optimal for the therapeutic activity of each antibody. Recently, glycoside engineering has attracted attention to controlling Fc glycosylation to improve efficacy. Endoglycosidases, a family of at least 18 glycoside hydrolases (GHs) from Streptococcus pyogenes, have recently become a focus of glycoside engineering for therapeutic antibodies. These enzymes catalyze the hydrolysis of the β-1,4 linkage between two N-acetylglucosamines (GlcNAc) in the N-linked glycan core of human IgG. Furthermore, these enzymes remove complex glycans from the IgG Fc domain.
[0041] To bind to the loaded drug, the glycans coupled to the antibody need to be modified to provide functional groups for binding. The functional groups of the modified glycans can affect the glycosylation efficiency of the endoglycosidase. As a result, the isoform of the glycosylated antibody may be poor. Although endoglycosidases are known in the art, their ability to isoglycosylate unmodified glycans does not predict their ability to isoglycosylate modified glycans. Therefore, identifying effective endoglycosidases and suitable modified glycans is crucial to solving the above technical problems.
[0042] One aspect of the present invention relates to a method for preparing an engineered biocomplex. The biocomplex can be a glycosylated antibody or antigen-binding fragment thereof, a glycoprotein, or a glycopeptide. Another aspect of the present invention relates to one or more engineered biocomplexes. Yet another aspect of the present invention relates to a pharmaceutical composition comprising the engineered biocomplex. Yet another aspect of the present invention relates to a method for treating cancer using the pharmaceutical composition. Yet another aspect of the present invention relates to a therapeutic complex.
[0043] Embodiments of the present invention relate to selected glycosynthase variants that exhibit significant transglycosylation activity to transfer a wide range of high-mannose, hybrid, or complex N-glycans from activated oligosaccharides to fucosylated or non-fucosylated GlcNAc-peptides, proteins, or IgG, with minimal or negligible product hydrolysis. These novel glycosynthases operate with surprisingly high efficiency to provide homogeneously glycosylated glycopeptides, glycoproteins, and therapeutic antibodies and Fc fragments thereof with a variety of defined glycoforms. Furthermore, embodiments of the present invention can provide glycoengineered antibodies with enhanced effector functions, such as FcγIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as pharmacological properties. Embodiments of the present invention also allow for rapid investigation of the effects of varying Fc glycosylation on effector functions of therapeutic antibodies.
[0044] According to an embodiment of the present invention, novel glycosynthetases comprise a sequence selected from SEQ ID NOs: 1-2. These mutants exhibit unexpectedly improved transglycosylation activity and reduced hydrolysis activity. Thus, they can catalyze the efficient transfer of activated oligosaccharide donors to core GlcNAc-acceptors, which can be fucosylated or non-fucosylated.
[0045] According to certain embodiments, the glycosynthase may have at least about 80% (e.g., 80%, 85%, 90%, 95%, or 98% (or a value between the two numbers listed)) sequence identity to SEQ ID NOs: 1-2 and possess the desired transglycosylation activity or a fragment thereof having transglycosylation activity. In some embodiments, the glycosynthase is as described in U.S. Patent No. 11,203,645, filed on June 27, 2019, which is incorporated herein by reference.
[0046] definition
[0047] It should be noted that, as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. The term "the" refers to more than one. As used herein, the term "plurality" can mean 2, 3, 4, 5, 6, 7, 8, 9, 10, or more.
[0048] As used herein, the terms "comprise," "include," or "have" are intended to describe the presence of state features, integers, steps, operations, components, and / or combinations thereof, but do not preclude the possibility of the presence or addition of one or more other features, integers, steps, operations, components, or combinations thereof. Only the transitional phrases "consisting of" and "consisting essentially of" shall be closed or semi-closed transitional phrases, respectively.
[0049] As used herein, the terms "may" and "may" are used interchangeably in the present invention and indicate that the referenced component, component, structure, function, functionality, purpose, advantage, operation, step, process, equipment, system, device, result or clarification has the ability to be used, included or produced, or otherwise represents the claim indicated in the statement using (or referencing) the term in a specific embodiment.
[0050] As used herein, the term "about" refers to a measurable value, such as an amount, duration, etc., and is intended to encompass variations of ±20%, ±10%, ±5%, ±1%, or ±0.1% of the specified value, as such variations are appropriate.
[0051] As used herein, "substantially" means sufficient to achieve the intended purpose. Thus, the term "substantially" allows for minor, insignificant variations from an absolute or perfect state, dimension, measurement, result, etc., such as would be expected by one of ordinary skill in the art, without significantly affecting overall performance. When applied to numerical values or numerically expressible parameters or characteristics, "substantially" means within ten percent.
[0052] As used herein, the term "coupled" refers to the attachment of two components either directly to one another or indirectly to another component.
[0053] As used herein: μm refers to micrometer, μm^3 or um^3 refers to cubic micrometer, pL refers to picoliter, nL refers to nanoliter, and μL (or uL) refers to microliter.
[0054] As used herein, the term "glycan" refers to polysaccharides, oligosaccharides, or monosaccharides. A glycan can be a monomer or polymer of sugar residues and can be linear or branched. A glycan can include natural sugar residues (e.g., glucose, N-acetylglucosamine, N-acetylneuraminic acid, galactose, mannose, fucose, hexose, arabinose, ribose, xylose, etc.) and / or modified sugars (e.g., 2'-fluororibose, 2'-deoxyribose, mannose phosphate, 6'-sulfo N-acetylglucosamine, etc.).
[0055] As used herein, the terms "fucose", "core fucose" and "core fucose residue" are used interchangeably to refer to the α-1,6-position fucose linked to N-acetylglucosamine.
[0056] As used herein, the terms "N-glycan," "N-linked glycan," "N-linked glycosylation," "Fc glycan," and "Fc glycosylation" are used interchangeably and refer to glycans attached via N-acetylglucosamine (GlcNAc) to the amide nitrogen of asparagine residues in Fc-containing polypeptides. The term "Fc-containing polypeptide" refers to a polypeptide, such as an antibody, that comprises an Fc region.
[0057] As used herein, the terms "glycosylation pattern" and "glycosylation profile" are used interchangeably and refer to the characteristic "fingerprint" of N-glycan species that are enzymatically or chemically released from a glycoprotein or antibody, and subsequently analyzed for their carbohydrate structure, for example, using LC-HPLC or MALDI-TOF MS. See, for example, Current Analytical Chemistry, Vol. 1, No. 1 (2005), pp. 28-57; which is incorporated herein by reference in its entirety.
[0058] As used herein, the term "glycoengineered Fc" refers to an Fc region in which the N-glycans have been enzymatically or chemically altered or modified. As used herein, the term "Fc glycoengineering" refers to an enzymatic or chemical process used to prepare a glycoengineered Fc.
[0059] As used herein, the term "N-linked initial glycan" refers to an N-linked glycan that is initially attached to a biomolecule prior to processing the biomolecule in a reaction performed according to embodiments of the present invention. A glycan can be a polysaccharide, oligosaccharide, or monosaccharide, or can be a monomer or polymer of sugar residues, and can be linear or branched, as described herein.
[0060] As used herein, the term "bioconjugate" refers to a molecule formed by the combination of at least two entities, at least one of which, or both, are biological entities. Each of these entities can be biological. For example, a bioconjugate can be a polypeptide bound to a glycan, a protein bound to a glycan, or an antibody or antigen-binding fragment thereof bound to a glycan. In some embodiments, a bioconjugate can further comprise a non-biological portion, such as a chemical entity. The chemical entity can be therapeutic, diagnostic, or provide other functionality. As used herein, "bioconjugate" and "engineered bioconjugate" are interchangeable and refer to a complex produced or obtained using laboratory-based techniques.
[0061] As used herein, terms such as "antibody-drug conjugate" or "immune complex" refer to the linkage of an antibody or antigen-binding fragment thereof with another agent (e.g., a chemotherapeutic agent, a toxin, an immunotherapeutic agent, an imaging probe, etc.). The linkage can be a covalent bond or a non-covalent interaction, such as through electrostatic forces. Various linkers known in the art can be used to form antibody-drug conjugates. In addition, antibody-drug conjugates can be provided in the form of a fusion protein, which can be expressed by a polynucleotide encoding the immune complex. As used herein, "fusion protein" refers to a protein produced by linking two or more genes or gene fragments that originally encoded separate proteins (including peptides and polypeptides). Translation of the fusion gene produces a single protein with functional properties derived from each original protein.
[0062] In the context of the glycosylation profile of the Fc region, the terms "homogeneous," "uniform," "uniformly," and "isomorphic" are used interchangeably to refer to a single glycosylation pattern represented by a single desired N-glycan species with little or no trace of precursor N-glycans, including, for example, less than 95%, 96%, 97%, 98%, 99% of the starting precursor material.
[0063] Table 1. Lists the four classes of amino acids.
[0064]
[0065] As used herein, the terms "IgG," "IgG molecule," "monoclonal antibody," "immunoglobulin," and "immunoglobulin molecule" are used interchangeably.
[0066] As used herein, terms such as "Fc receptor" or "FcR" describe receptors that bind to the Fc region of an antibody. Preferred FcRs are native human FcR sequences. Furthermore, preferred FcRs are those that bind to IgG antibodies (gamma receptors), including receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. FcγRII receptors include FcγRIIA ("activating receptor") and FcγRIIB ("inhibiting receptor"), which have similar amino acid sequences but differ primarily in their cytoplasmic domains. The activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-based activation motif (ITIM) in its cytoplasmic domain (see M. in Daëron (1997) Annu. Rev. Immunol. 15:203-234 for review). For review of FcRs, see Ravetch and Kinet (1991) Annu. Rev. Immunol 9:457-92; Capel et al. (1994) Immunomethods 4:25-34; Haas et al. (1995) J. Lab. Clin. Med. 126:330-41). The term "FcR" herein encompasses other FcRs, including those to be identified in the future. The term also includes the neonatal receptor FcRn, which is responsible for the transfer of maternal IgG to the fetus (Guyer et al. (1976) J. Immunol. 117:587, and Kim et al. (1994) J. Immunol. 24:249).
[0067] As used herein, the term "effector function" refers to the biochemical events resulting from the interaction of an antibody Fc region with an Fc receptor or ligand. Exemplary "effector functions" include C1q binding; complement-dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; and downregulation of cell surface receptors (e.g., B cell receptor; BCR). Such effector functions can be assessed using various assays known in the art.
[0068] As used herein, the terms "antibody-dependent cell-mediated cytotoxicity" or "ADCC" refer to a form of cytotoxicity in which secreted Ig binds to Fc receptors (FcRs) present on certain cytotoxic cells (e.g., natural killer (NK) cells, neutrophils, and macrophages), enabling these cytotoxic effector cells to specifically bind to antigen-bearing target cells and subsequently kill them with cytotoxins. Antibodies "arm" the cytotoxic cells and are essential for this killing. Among the primary cells mediating ADCC, NK cells express only FcγRIII, while monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991). To assess ADCC activity of a molecule of interest, an in vitro ADCC assay, such as that described in U.S. Patent No. 5,500,362 or U.S. Patent No. 5,821,337, can be performed. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cells. Alternatively, or additionally, ADCC activity of a molecule of interest can be assessed in vivo, for example, in an animal model such as that described in Clynes et al. (1998) PNAS (USA) 95:652-656.
[0069] "Humanized" forms of non-human (eg, murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. In one embodiment, a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit, or non-human primate having the desired specificity, affinity, and / or capacity. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or the donor antibody. Such modifications are made to further refine antibody performance. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature 321:522-525. (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992). See also the following review articles and references cited therein: Vaswani and Hamilton, Ann. Allergy, Asthma & Immunol. 1:105-115 (1998); Harris, Biochem. Soc. Transactions 23:1035-1038 (1995); Hurle and Gross, Curr. Op. Biotech. 5:428-433 (1994).
[0070] As used herein, the terms "hypervariable region," "HVR," or "HV" refer to regions of an antibody variable domain that are highly variable in sequence and / or form structurally defined loops. Generally, antibodies contain six hypervariable regions; three located in the VH (H1, H2, H3) and three located in the VL (L1, L2, L3). Many descriptions of hypervariable regions are used and are encompassed herein. The Kabat complementarity determining regions (CDRs) are based on sequence variability and are the most commonly used (Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). The Chothia term refers to the location of loop structures (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).
[0071] "Framework" or "FW" residues are those variable domain residues other than the hypervariable region residues as herein defined.
[0072] The terms "variable domain residue numbering as in Kabat" or "amino acid position numbering as in Kabat" and variations thereof refer to the numbering system used for the compiled heavy chain variable domain or light chain variable domain of antibodies, see Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to shortening or insertion of a FR or HVR of the variable domain. For example, the heavy chain variable domain may include a single amino acid insertion after residue 52 of H2 (residue 52a according to Kabat) and residues inserted after heavy chain FR residue 82 (e.g., residues 82a, 82b, and 82c according to Kabat, etc.). For a given antibody, the Kabat numbering of the residues can be determined by alignment of the homologous region of the antibody sequence with the "standard" Kabat numbering sequence.
[0073] As used herein, the term "antigen-binding fragment" refers to one or more portions of an antibody that retain the ability to specifically interact with an antigenic epitope (e.g., by binding, steric hindrance, stabilization / destabilization, spatial distribution). Examples of binding fragments include, but are not limited to, single-chain Fv (scFv), camelid antibodies (e.g., VHH), disulfide-linked Fv (sdFv), Fab fragments, F(ab') fragments, monovalent fragments consisting of the VL, VH, CL, and CH1 domains; F(ab)2 fragments, which are bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region; Fd fragments consisting of the VH and CH1 domains; Fv fragments consisting of the VL and VH domains of a single arm of an antibody; dAb fragments (Ward et al., Nature 341:544-546, 1989), which consist of the VH domain; and isolated complementarity-determining regions (CDRs) or other epitope-binding fragments of antibodies.
[0074] "Single-chain Fv" or "scFv" antibody fragments comprise the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. Generally, scFv polypeptides further comprise a polypeptide linker between the VH and VL domains, which enables the scFv to form the desired structure for antigen binding. For a review of scFv, see Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore, eds., Springer-Verlag, New York, pp. 269-315 (1994).
[0075] The term "diabody" refers to a small antibody fragment with two antigen-binding sites. This fragment (VH-VL) comprises a heavy-chain variable domain (VH) and a light-chain variable domain (VL) connected in a single polypeptide chain. By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93 / 1161; and Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993).
[0076] A "human antibody" is an antibody having an amino acid sequence that corresponds to an antibody produced by a human and / or has been made using any of the techniques disclosed herein for making human antibodies. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues.
[0077] "Affinity matured" antibodies are antibodies with one or more alterations in one or more HVRs that result in an improvement in the antibody's affinity for the antigen compared to a parent antibody that does not have these alterations. In one embodiment, affinity matured antibodies have nanomolar or even picomolar affinities for the target antigen. Affinity matured antibodies are produced by procedures known in the art. Marks et al., Bio / Technology 10:779-783 (1992) describe affinity maturation by shuffling VH and VL domains. Random mutagenesis of CDR and / or framework residues is described in: Barbas et al., Proc Nat. Acad. Sci. USA 91:3809-3813 (1994); Schier et al., Gene 169:147-155 (1995); Yelton et al., J. Immunol. 155:1994-2004 (1995); Jackson et al., J. Immunol. 154(7):3310-9 (1995); and Hawkins et al., J. Mol. Biol. 226:889-896 (1992).
[0078] A "blocking" antibody or "antagonist" antibody is an antibody that inhibits or reduces the biological activity of the antigen to which it binds. Certain blocking or antagonist antibodies substantially or completely inhibit the biological activity of the antigen.
[0079] As used herein, an "agonist antibody" is an antibody that mimics at least one functional activity of a polypeptide of interest.
[0080] A "disorder" is any condition that would benefit from treatment with the antibodies of the present invention. This includes chronic and acute disorders or diseases, including those pathological conditions that predispose a mammal to the disorder in question. Non-limiting examples of disorders to be treated herein include cancer.
[0081] The terms "cell proliferative disorder" and "proliferative disorder" refer to disorders that are associated with some degree of abnormal cell proliferation. In one embodiment, the cell proliferative disorder is cancer.
[0082] As used herein, "tumor" refers to all neoplastic cell growth and proliferation, whether malignant or benign, as well as all precancerous and cancerous cells and tissues. As used herein, the terms "cancer," "cancerous," "cell proliferative disorder," "proliferative disorder," and "tumor" are not mutually exclusive.
[0083] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth / proliferation. A "tumor" comprises one or more cancerous cells. Examples of cancers include, but are not limited to, carcinomas, lymphomas (e.g., Hodgkin's lymphoma and non-Hodgkin's lymphoma), blastomas, sarcomas, and leukemias. More specific examples of such cancers include lung cancer, breast cancer, head and neck cancer, esophageal cancer, stomach cancer, bladder cancer, pancreatic cancer, colorectal cancer, cervical cancer, endometrial cancer, ovarian cancer, laryngeal cancer, prostate cancer, thyroid cancer, and oral cancer.
[0084] As used herein, "treatment" refers to clinical intervention that attempts to alter the natural course of the individual or cell being treated and can be performed prophylactically or during the course of clinical pathology. Desired therapeutic effects include preventing the onset or recurrence of the disease, alleviating symptoms, alleviating any direct or indirect pathological consequences of the disease, preventing or reducing inflammation and / or tissue / organ damage, reducing the rate of disease progression, ameliorating or alleviating the disease state, and alleviating or improving prognosis. In some embodiments, the antibodies of the present invention are used to delay the development of a disease or condition.
[0085] An "individual" or "subject" is a vertebrate. In certain embodiments, the vertebrate is a mammal. Mammals include, but are not limited to, farm animals (such as cattle), sports animals, pets (such as cats, dogs, and horses), primates, mice, and rats. In certain embodiments, the vertebrate is a human.
[0086] "Mammal" for therapeutic purposes refers to any animal classified as a mammal, including humans, poultry and farm animals, and zoo, sport or pet animals such as dogs, horses, cats, cows, etc. In certain embodiments, the mammal is a human.
[0087] An "effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
[0088] A "therapeutically effective amount" of a substance / molecule of the present invention may vary depending on factors such as the disease state, age, sex, and weight of the individual, as well as the ability of the substance / molecule to elicit a desired response in the individual. A therapeutically effective amount is also an amount in which any toxic or deleterious effects of the substance / molecule are offset by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective to achieve the desired prophylactic result, at the dosage and for the period of time necessary. Typically, but not necessarily, a prophylactic dose will be less than a therapeutically effective amount because the subject is using a prophylactic dose prior to or at an earlier stage of disease.
[0089] "Combination" refers to a combination therapy in which the amount of ADC and / or the amount of other biological or chemical drugs has a therapeutically effective and synergistic effect that exceeds therapeutic additive when administered sequentially or concurrently (e.g., co-administered and / or co-dosage form) on the same day or different days of a treatment cycle.
[0090] As used herein, the term "cytotoxic agent" refers to a substance that inhibits or prevents the function of cells and / or causes cell destruction. The term is intended to include radioactive isotopes (e.g., 211 At 131 I. 125 I. 90 Y. 186 Re、 188 Re、 153 Sm, 212 Bi, 32 P. 60 C, and radioactive isotopes of lutetium-177, strontium-89, and samarium (153Sm), chemotherapeutic agents, and toxins, such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant, or animal origin, including synthetic analogues and derivatives thereof.
[0091] The term "photodynamic therapy (PDT)," sometimes referred to as photochemotherapy, is a form of phototherapy involving light and photosensitizing chemicals, used in combination with molecular oxygen to induce cell death (phototoxicity). It is used clinically to treat a variety of diseases, including wet age-related macular degeneration, psoriasis, and atherosclerosis, and has shown some efficacy in antiviral treatment (including herpes). It is also used to treat malignant cancers, including head and neck cancer, lung cancer, bladder cancer, skin cancer, and prostate cancer (Wang, SS et al., Cancer Journal. 8 (2): 154-63. 2002). The “photodynamic therapy agent” is selected from the group consisting of Photofrin, Laserphyrin, Aminolevulinic acid (ALA), Silicon Phthalocyanine Pc 4, m-tetrahydroxyphenylchlorin (mTHPC), Chlorin e6 (Ce6), Allumera, Levulan, Foscan, Metvix, Hexvix, Photochlor, Photosens, Photrex, Lumacan, Visonac, Amphinex, Verteporfin, Purlytin, ATMPn, Zinc phthalocyanine (ZnPc), Protoporphyrin IX (PpIX), Pyropheophorbide a a, PPa) or pheophorbide a (PhA).
[0092] A "chemotherapeutic agent" is a compound used to treat cancer. Examples of chemotherapeutic agents include monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), mertansine (also known as DM1), anthracycline, pyrrolobenzodiazepine, α-amanitin, tubulysin, benzodiazepine, erlotinib (TARCEVA ® , Genentech / OSI Pharm.), bortezomib (VELCADE ®, Millenium Pharm.), fulvestrant (FASLODEX ® , Astrazeneca), sunitinib (SUTENT ® , SU11248, Pfizer), letrozole (FEMARA ® , Novartis), imatinib mesylate (GLEEVEC ® , Novartis), PTK787 / ZK 222584 (Novartis), oxaliplatin (ELOXATIN ® , Sanofi), leucovorin, rapamycin (Sirolimus, RAPAMUNE ® , Wyeth), lapatinib (TYKERB ® , GSK572016, GlaxoSmithKline), lonafarnib (SARASAR ® , SCH 66336), sorafenib (NEXAVAR ® , BAY43-9006, Bayer Labs.) and gefitinib (IRESSA ® , Astrazeneca), AG1478, AG1571 (SU 5271; Sugen); alkylating agents such as thiotepa and CYTOXAN ®Cyclophosphamide; alkyl sulfonates, such as busulfan, improsulfan, and piposulfan; aziridines, such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimine and methylamelamine, including altretamine, triethylenemelamine, and methylamelamine. amine), triethylenephosphoramide, triethylenethiophosphoramide, and trimethylomelamine; polyacetogenins (especially bullatacin and bullatacinone); camptothecins (including the synthetic analogue topotecan); bryostatin; callystatin. tin); CC-1065 (including its synthetic analogs adozelesin, carzelesin, and bizelesin); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycins (including its synthetic analogs KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sarcodictyin; spongistatin Nitrogen mustards, such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, and uracil mustard;Nitrosoureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics, such as enediyne antibiotics (e.g., calicheamicins, especially calicheamicin gamma and calicheamicin omega (Angew Chem. Intl. Ed. Engl. (1994) 33:183-186); dynemicins, including dynemicin A; bisphosphonates, such as clodronate; esperamicin; and neocarzinostatin chromophores. chromophore and related pigment proteins (enediyne antibiotic chromophores), aclacinomysin, actinomycin, authramycin, azaserine, bleomycin, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN; ®Doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin n), mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, Ubenimax, zinostatin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine, guanine); pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine; androgens such as caprostenone, dromostanolone propionate, epitiostanol, mepitiostane, and testolactone; antiadrenal drugs such as aminoglutethimide, mitotane, and trilostane; and folic acid supplements such as folinic acid;aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformthine; elliptinium acetate acetate); epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids, such as maytansine and ansamitocin; mitoguazone; mitoxantrone; mopidamol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2''-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A, and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxanes such as TAXOL;® Paclitaxel (Bristol-Myers Squibb Oncology, Princeton, NJ), ABRAXANE™ Cremophor-free, albumin-engineered nanoparticle formulations of paclitaxel (American Pharmaceutical Partners, Schaumberg, Ill.), and TAXOTERE ® doxetaxel (Rhône-Poulenc Rorer, Antony, France); chloranbucil; GEMZAR ® Gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; navelbine ® Vinorelbine; novantrone; teniposide; edatrexate; daunorubicin; aminopterin; xeloda; ibandronate; CPT-11; the topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids, such as retinoic acid; capecitabine (XELODA ® , Roche); and pharmaceutically acceptable salts, acids and derivatives of any of the above.
[0093] The definition of “chemotherapeutic agent” also includes: (i) antihormonal agents that modulate or inhibit hormonal effects on tumors, such as antiestrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX ®Tamoxifen), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone and FARESTON toremifene; (ii) aromatase inhibitors, which inhibit the aromatase enzyme that regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazole, glutethimide, MEGASE ® megestrol acetate, AROMASIN ® exemestane, formestane, fadrozole, RIVISOR ® Vorozole, FEMARA ® Letrozole and ARIMIDEX ® anastrozole; (iii) antiandrogens, such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); (iv) aromatase inhibitors; (v) protein kinase inhibitors; (vi) lipid kinase inhibitors; (vii) antisense oligonucleotides, particularly those that inhibit the expression of genes in signal transduction pathways involved in abnormal cell proliferation, such as, for example, PKC-α, Ralf, and H-Ras; (viii) ribonuclease inhibitors, such as VEGF expression inhibitors (e.g., ANGIOZYME ® (ix) vaccines, such as gene therapy vaccines, e.g., ALLOVECTIN ® Vaccines, LEUVECTIN ® Vaccines and VAXIDs ® Vaccine; PROLEUKIN ® rIL-2;LURTOTECAN ® Topoisomerase 1 inhibitor; ABARELIX ® rmRH; (x) anti-angiogenic agents, such as bevacizumab (AVASTIN ® , Genentech); and (xi) pharmaceutically acceptable salts, acids and derivatives of any of the above.
[0094] Protein kinase inhibitors include tyrosine kinase inhibitors, which inhibit, to a certain extent, the tyrosine kinase activity of tyrosine kinases (such as ErbB receptors). Examples of tyrosine kinase inhibitors include drugs that target EGFR, such as: (i) antibodies that bind to EGFR, including MAb 579 (ATCC CRL HB 8506), MAb 455 (ATCC CRL HB8507), MAb 225 (ATCC CRL 8508), MAb 528 (ATCC CRL 8509) (see, U.S. Patent No. 4,943,533, Mendelsohn et al.) and variants thereof, such as chimerized 225 (C225 or cetuximab; ERBITUX ®, Imclone) and reshaped human 225 (H225) (WO 96 / 40210, Imclone Systems Inc.); antibodies that bind to type II mutant EGFR (U.S. Patent No. 5,212,290); humanized and chimeric antibodies that bind to EGFR (U.S. Patent No. 5,891,996); and human antibodies that bind to EGFR, such as ABX-EGF (WO 98 / 50433); (ii) anti-EGFR antibodies that bind to cytotoxic agents (EP 659439A2); and small molecules that bind to EGFR, including ZD1839 or gefitinib (IRESSA™; Astra Zeneca), erlotinib HCl (CP-358774, TARCEVA™; Genentech / OSI), and AG1478, AG1571 (SU 5271; Sugen), quinazolines such as PD-L1 inhibitors, and cytotoxic agents. 153035, 4-(3-chloroanilino)quinazoline, pyridopyrimidines, pyrimidopyrimidines, pyrrolopyrimidines, such as CGP 59326, CGP 60261 and CGP 62706, as well as pyrazolopyrimidines, 4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidine, curcumin (diferuloyl methane), methane), 4,5-bis(4-fluoroanilino)phthalimide), tyrphostin containing a nitrothiophene moiety; PD-0183805 (Warner-Lambert); antisense molecules (e.g., those that bind to nucleic acids encoding ErbB); quinoxaline (U.S. Patent No. 5,804,396); tyrphostin (U.S. Patent No. 5,804,396); ZD6474 (Astra Zeneca); PTK-787 (Novartis / Schering AG); pan-ErbB inhibitors such as CI-1033 (Pfizer); Affinitac (ISIS 3521; Isis / Lilly); imatinib mesylate (Gleevac; Novartis); PKI 166 (Novartis); GW2016 (Glaxo SmithKline); CI-1033 (Pfizer); EKB-569 (Wyeth); Semaxanib (Sugen); ZD6474 (AstraZeneca); PTK-787 (Novartis / Schering AG);INC-1C11 (Imclone); or as described in U.S. Patent No. 5,804,396; WO 99 / 09016 (American Cyanamid); WO 98 / 43960 (American Cyanamid); WO 97 / 38983 (Warner Lambert); WO 99 / 06378 (Warner Lambert); WO 99 / 06396 (Warner Lambert); WO 96 / 30347 (Pfizer, Inc); WO 96 / 33978 (Zeneca); WO 96 / 3397 (Zeneca); and WO 96 / 33980 (Zeneca).
[0095] "Anti-angiogenic agents" refer to compounds that block or interfere with the development of blood vessels to some extent. Anti-angiogenic factors can be, for example, small molecules or antibodies that bind to growth factors or growth factor receptors involved in promoting angiogenesis. Exemplary anti-angiogenic agents are antibodies that bind to vascular endothelial growth factor (VEGF), such as bevacizumab (AVASTIN®). ® , Genentech).
[0096] The term "cytokine" is a general term for proteins released by one cell population that act on another cell as intercellular mediators. Examples of such cytokines are lymphotropic hormones, monocyte-stimulating hormones, and conventional polypeptide hormones. Cytokines include growth hormones such as human growth hormone, N-methionine human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and luteinizing hormone (LH); liver growth factor; fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor-α and -β; Mullerian inhibitory substance; mouse gonadotropin-related peptide; inhibins; activins; vascular endothelial growth factor; integrins; thrombopoietin (TPO); nerve growth factors such as NGF-β; platelet-derived growth factor; transforming growth factors (TGFs) such as TGF-α and TGF-β; insulin-like growth factors-I and -II; erythropoietin (EPO); osteoinductive factors; interferons, such as interferon-α, -β, and -γ; colony-stimulating factors (CSFs), such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs), such as IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12; tumor necrosis factors, such as TNF-α or TNF-β; and other polypeptide factors, including LIF and kit ligand (KL). As used herein, the term cytokine includes proteins from natural sources or from recombinant cell culture, as well as biologically active equivalents of native sequence cytokines.
[0097] As used herein, the term "prodrug" refers to a precursor or derivative form of a pharmaceutically active substance that is less cytotoxic to tumor cells than the parent drug and can be enzymatically activated or converted to the more active parent form. See, for example, Wilman, "Prodrugs in Cancer Chemotherapy," Biochemical Society Transactions, 14, pp. 375-382, 615th Session, Belfast (1986) and Stella et al., "Prodrugs: A Chemical Approach to Targeted Drug Delivery," Directed Drug Delivery, Borchardt et al. (eds.), pp. 247-267, Humana Press (1985). Prodrugs of the present invention include, but are not limited to, phosphate-containing prodrugs, thiophosphate-containing prodrugs, sulfate-containing prodrugs, peptide-containing prodrugs, D-amino acid-modified prodrugs, glycosylated prodrugs, β-lactam-containing prodrugs, optionally substituted phenoxyacetamide-containing prodrugs, or optionally substituted phenylacetamide-containing prodrugs, 5-fluorocytosine and other 5-fluorouridine prodrugs, which can be converted into more active non-cytotoxic drugs. Examples of cytotoxic drugs that can be derivatized into prodrug forms for use in the present invention include, but are not limited to, the chemotherapeutic agents described above.
[0098] As used herein, the phrase "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable organic or inorganic salt of an ADC. Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)). A pharmaceutically acceptable salt may involve the inclusion of another molecule, such as an acetate ion, a succinate ion, or other counter ion. A counterion can be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a pharmaceutically acceptable salt can have more than one charged atom in its structure. Where multiple charged atoms are part of a pharmaceutically acceptable salt, there may be multiple counterions. Thus, a pharmaceutically acceptable salt may have one or more charged atoms and / or one or more counterions.
[0099] "Pharmaceutically acceptable solvates" refer to the combination of one or more solvent molecules and the ADC. Examples of solvents that form pharmaceutically acceptable solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.
[0100] The complex N-linked oligosaccharides on each CH2 domain of IgG are crucial for the structure of the Fc region and, consequently, its interaction with Fc receptors (Krapp et al., 2003; Woof and Burton, 2004). The oligosaccharide chains of the IgG Fc domain contain several N-acetyl-glucosamine (GlcNAc) and mannose (Man) residues, ultimately followed by galactose (Gal) and fucose (Fuc) residues, as well as sialic acid (Sia or NANA for N-acetylneuraminic acid). A GlcNAc with or without α1-6 Fuc is attached to Asn297. GlcNAc pi-4 is attached to this first GlcNAc. Man β1-4 is subsequently found, to which are attached two arms, Man α1-6 and Man α1-3. Both arms contain additional GlcNAc β1-2, which can be attached to or not to Gal β1-4. Thus, carbohydrate chains can contain 0, 1, or 2 galactose residues, defined as G0, G1, and G2 glycoforms, respectively. Further variations occur, including the presence of bisecting GlcNAcβ1-4 and capping of one or two terminal galactose residues with sialic acid or even Galɑ1-3 residues. Enzymatic cleavage of Fc-glycans by endoglycosidases results in distortion of the Fc region, significantly reducing IgG binding to Fcγ receptors (Allhorn et al., 2008). Despite sharing 37% sequence identity, EndoS and EndoS2 catalyze the hydrolysis of the β-1,4 linkage between two N-acetylglucosamines (GlcNAc) in the N-linked glycan core of human IgG. However, in addition to complex glycans, EndoS2 hydrolyzes hybrid and oligomannose structures to a greater extent than EndoS (Sjögren et al., 2015).
[0101] Methods for preparing engineered biocomplexes.
[0102] Since the introduction of the first antibody therapies in the 1980s, over 240 therapeutic antibodies have been tested in clinical trials, and the field is steadily expanding (Chan and Carter, 2010). The role of IgG-Fc glycans in antibody function has garnered significant attention in the development of therapeutic monoclonal antibodies. Consequently, efforts to improve the efficacy of therapeutic antibodies have focused on engineering Fc-glycans that specifically interact with selected Fcγ receptors (Sondermann et al., 2013; Bournazos et al., 2014; Monnet et al., 2014; Quast and Lünemann, 2014). Some important glycan modifications that significantly influence effector function include: i) the lack of a core fucose residue linked to a reducing-terminal GlcNAc residue, which results in increased affinity for FcγRIIIa and thus enhances antibody-dependent cellular cytotoxicity (Iidaet et al., 2006); ii) sialic acid-rich glycans on IgG, which are purported to enhance the anti-inflammatory response of IgG by increasing interaction with the DC-SIGN receptor on dendritic cells and macrophages (Anthony et al., 2008; Anthony and Ravetch 2010; Pincetic et al., 2014); and iii) the presence of a bisecting GlcNAc residue, which induces potent ADCC compared to its parental counterpart. Recent improvements in biotechnological tools for controlling the Fc-glycosylation state of IgG have facilitated the development of therapeutic antibodies with predefined glycoforms. Accordingly, the glycosynthetases of the present invention represent a significant advancement in the field of glycoengineering of peptides, proteins, and antibodies of interest, allowing for the attachment of a wide range of high-mannose, hybrid, and complex N-glycans for functional and structural studies.
[0103] One aspect of the present invention provides a method for preparing an engineered biocomplex. The method comprises contacting a biomolecule with a glycosynthase and a modified glycan, thereby obtaining a first engineered biocomplex. The biomolecule comprises an antibody or antigen-binding fragment thereof, protein, or peptide coupled to an N-linked initial glycan. The modified glycan comprises a substrate portion and a first reactive portion, wherein the substrate portion is configured to interact with the glycosynthase. In some embodiments, contacting the biomolecule with the glycosynthase and the modified glycan comprises contacting a plurality of biomolecules with the glycosynthase and the modified glycan, thereby obtaining a plurality of first engineered biocomplexes. In certain embodiments, the plurality of first engineered biocomplexes in the plurality of first engineered biocomplexes have an isomeric profile of at least or greater than 80%, 85%, 90%, 95%, or 99%. High isomeric profile indicates fewer isomers within the plurality of first engineered biocomplexes and indicates that the engineered biocomplexes prepared using the methods of the present invention have improved consistency and efficacy. Without wishing to be bound by theory, the glycosynthetases and / or modified glycans of the present invention are attributed to favorable hyperisomorphism.
[0104] In some embodiments, the method further comprises contacting the first engineered biocomplex with a loaded drug complex or a salt thereof, thereby obtaining a second engineered biocomplex. In some embodiments, the second engineered biocomplex is an ADC having a therapeutic agent bound to an antibody via a modified glycan. The structures and properties of the loaded drug complex and the second engineered biocomplex are described in more detail below.
[0105] In some embodiments, contacting the first engineered biocomplex with a loaded drug complex or a salt thereof comprises contacting the first engineered biocomplex with a first loaded drug complex and a second loaded drug complex, wherein the first loaded drug complex and the second loaded drug complex are different. In certain embodiments, the first loaded drug complex and the second loaded drug complex differ in each loaded drug of the two loaded drug complexes, each reactive moiety unit (C) of the two loaded drug complexes, and / or each linker unit (L) of the two loaded drug complexes.
[0106] Glycosylation (deglycosylation and transglycosylation). In some embodiments, contacting a biomolecule with a glycosynthase and a modified glycan comprises coupling the modified glycan to an N-linked original glycan. The modified glycan can be directly or indirectly linked to the N-linked original glycan. In some embodiments, coupling the modified glycan to the N-linked original glycan comprises removing the N-linked original glycan from the biomolecule, thereby obtaining a deglycosylated biomolecule; and contacting the deglycosylated biomolecule with a glycosynthase in the presence of the modified glycan.
[0107] Removal of the original N-linked glycans from a biomolecule can be complete or partial. In embodiments where only a portion of the original N-linked glycans are removed, the modified glycan will be coupled to the residues of the original N-linked glycans. In certain embodiments, after the step of removing the original N-linked glycans, a GlcNAc monosaccharide (which may be fucosylated or non-fucosylated) will remain on the biomolecule, and the modified glycan will be coupled to the GlcNAc monosaccharide.
[0108] In some embodiments, removal of N-linked initial glycans from a biomolecule can be performed using a glycosynthase of the present invention. The glycosynthase of the present invention comprises SEQ ID NO: 1 or SEQ ID NO: 2, and the glycosynthase comprises a mutation within residues 176-186, residues 225-237, or residues 273-289 of SEQ ID NO: 1, or a mutation within residues 178-188, residues 227-239, or residues 275-291 of SEQ ID NO: 2. The glycosynthase of the present invention is described in more detail below.
[0109] Alternatively, N-linked initial glycans of a biomolecule can be removed by using a glycosynthase different from the glycosynthases of the present invention. In certain embodiments, removing N-linked initial glycans from a biomolecule to obtain a deglycosylated biomolecule comprises mixing the glycosynthase and the biomolecule in the absence of modified glycans at a ratio of 1:500 to 1:1, 1:500 to 1:10, 1:500 to 1:20, 1:500 to 1:30, 1:500 to 1:50, 1:100 to 1:1, 1:100 to 1:10, 1:100 to 1:20, 1:100 to 1:30, 1:100 to 1:50, 1:50 to 1:1, 1:50 to 1:10, 1:50 to 1:20, or 1:50 to 1:30. However, the methods of the present invention are not limited thereto. Depending on the circumstances, the ratio may vary.
[0110] In the present invention, exemplary glycoside synthetases for transglycosylation at a core fucosylated or non-fucosylated GlcNAc-acceptor are provided, wherein the core fucosylated or non-fucosylated GlcNAc-acceptor comprises a core fucosylated or non-fucosylated GlcNAc-peptide, a protein, and an IgG Fc domain or a fragment thereof.
[0111] In some embodiments, two glycosynthase variants, EndoSd-D232M and EndoSz-D234M, are provided, which possess glycosynthase activity and are capable of producing homogenous monoclonal antibody remodeling. In addition to the previously reported EndoSd from Streptococcus dysgalactiae subsp. Dysgalactiae (NCBI GenBank Accession No. ANI26082.1), the inventors have identified and isolated novel enzymes based on the sequences of EndoS and EndoSd using protein BLAST databases. The inventors also identified EndoSz from Streptococcus equi subsp. Zooepidemicus Sz105 (NCBI GenBank Accession No. KIS14581.1) as another candidate, although it is a putative protein. The inventors generated EndoSd and EndoSz mutants based on multiple sequence alignments. The results show that these two mutant enzymes possess unexpectedly improved / enhanced glycosylation synthase activity for conjugating biantennary complex glycans to monoclonal antibodies. Suitable monoclonal antibodies for binding are obtained / derived from a wide range of targets, including various biomarkers or different IgG types. The inventors herein demonstrate satisfactory binding results for OBI-888, Herceptin, Perjeta, Erbitux, Rituxan, OBI-898, Vectibix, Humira, Keytruda, and Bavencio. The inventors also confirmed the enzyme efficiency in the binding reaction and compared ADCC activity between heterogeneous and homogeneous monoclonal antibodies in relevant cell systems.
[0112] In some embodiments, the present invention provides glycosynthase variants, wherein the variant has at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence and / or structural homology and exhibits improved transglycosylation activity towards a wide range of high mannose, hybrid and complex N-glycans on fucosylated and non-fucosylated GlcNAc acceptors, wherein the variant is capable of efficiently transferring an activated oligosaccharide donor to fucosylated and non-fucosylated GlcNAc acceptors to form novel homogenous glycoforms of glycopeptides or glycoproteins or therapeutic antibodies. EndoSz and EndoSd mutants are listed in the table below: In some embodiments, the glycoside synthetase is as described in U.S. Patent No. 11,203,645, filed on June 27, 2019, which is incorporated herein by reference.
[0113] Table 2. List of EndoSz and EndoSd mutants.
[0114]
[0115] Modified polysaccharides. As used herein, "modified polysaccharides" refers to polysaccharides modified with chemical entities. The chemical entity may comprise a polymer and at least one functional group that can serve as a functionalization site or binding site for another moiety. Furthermore, the modified polysaccharide comprises a substrate moiety configured to be catalyzed by a glycosynthase described herein, thereby coupling the modified polysaccharide to a biomolecule. In some embodiments, the structure of the substrate moiety can be selected based on the properties of the glycosynthase. In certain embodiments, the substrate moiety is an oxazoline moiety.
[0116] In one embodiment, the modified glycan is a synthetic glycan oxazoline comprising a variety of high mannose, hybrid, and complex N-glycans having the following formula:
[0117] ,
[0118] Among them, R 1 is -H or N-acetylglucosamine attached via a β-1,4 linkage, R 2 and R 3 are the same or different and are independently selected from the group consisting of:
[0119]
[0120] In some embodiments, the first reactive moiety of the modified glycans of the present invention is configured to react with an unsaturated moiety in a biorthogonal reaction, which can be copper-free click chemistry. In one embodiment, the first reactive moiety comprises an azide group, but the modified glycans are not limited thereto.
[0121] In some embodiments, the modified glycan is a PEGylated glycan modified with a polyethylene glycol (PEG) moiety. Without wishing to be bound by theory, the PEG moiety provides better spacing for the click reaction to occur, and the PEG moiety is selected based on its hydrophilicity, which facilitates biological responses and good biocompatibility for clinical use. In other words, in some embodiments, the PEG moiety can be replaced with other hydrophilic polymer moieties that exhibit appropriate biocompatibility. In certain embodiments, for example, one end of the PEGylated glycan is covalently coupled to a first reactive moiety, and the other end of the PEGylated glycan is coupled to a substrate moiety. For example, the first reactive moiety can be coupled to the PEG moiety, and the substrate moiety can be coupled to the ethylene glycol moiety of the PEGylated glycan.
[0122] Although the length of the PEG moiety is not limited, in some embodiments, the PEG moiety can comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, or 72 ethylene oxide (OCH2CH2) subunits, or ranges bounded by the aforementioned endpoints, for example, 2 to 72, 2 to 60, 2 to 50, 2 to 40, 2 to 30, 2 to 20, 2 to 15, 2 to 10, 2 to 5, 2 to 4, 3 to 72, 3 to 65, 3 to 55, 3 to 45, 3 to 35, 3 to 25, 3 to 15, 3 to 10, 4 to 72, 4 to 60, 4 to 50, 4 to 40, 4 to 30, 4 to 20, 4 to 15, or 4 to 10 OCH2CH2 subunits. In some embodiments, the PEG moiety can be a linear PEG, a branched PEG, or a star PEG. In certain embodiments, the PEG moiety can have 2, 3, 4, 5, 6, 7, or 8 arms. In certain embodiments, the PEG moiety can have a molecular weight of 4K Da, 6K Da, 8K Da, 10K Da, or 20K Da.
[0123] Biomolecule. In some embodiments, the biomolecule comprises an antibody or antigen-binding fragment thereof, and the N-linked initial glycan is located in the constant region of the antibody or antigen-binding fragment. In certain embodiments, the N-linked initial glycan is located in the Fc region of the antibody or antigen-binding fragment, for example, at position N297 of the Fc region. In some embodiments, the biomolecule is an antibody, and one or two N-linked initial glycans are coupled at position N297 of the Fc region of the antibody.
[0124] In some embodiments, the antibody is an IgG, IgM, IgA, IgE, or IgD. A typical IgG is composed of two antigen-binding fragments (Fab) connected to a constant region (Fc) via a flexible region. The Fab domain is responsible for antigen recognition, while the N-glycans at Asn297 of the Fc domain interact with various Fcγ receptors on effector cells (such as FcγRIIIa and FcγRIIb) and the C1q component of complement, which activates effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Almost all therapeutic antibodies are N-glycosylated on each homodimeric Fc domain at a conserved asparagine residue (N297). These N-linked glycans produce over 30 different glycoforms and are typically biantennary complexes with considerable structural heterogeneity. The core heptasaccharide can be differentially modified with core fucose (Fuc), bisecting N-acetylglucosamine (GlcNAc), terminal galactose (Gal), and terminal sialic acid (Sia). The composition of N-glycans can influence the conformation of the Fc domain, thereby modulating antibody stability, pharmacokinetic properties, immunogenicity, effector function, antibody-mediated inflammatory responses, and complement activation. For example, the absence of core fucose and the attachment of a bisecting GlcNAc moiety significantly enhance the antibody's affinity for the FcγIIIa receptor (FcγRIIIa) on effector cells, leading to more efficient target elimination. Furthermore, terminal α-2,6-sialylated glycans, a minor component of antibodies and intravenous immunoglobulin (IVIG), are optimized for enhanced anti-inflammatory properties.
[0125] In some embodiments, the biomolecule is an anti-Globo series antigen antibody or antigen-binding fragment thereof, an anti-HER2 antibody or antigen-binding fragment thereof, an anti-CD20 antibody or antigen-binding fragment thereof, an anti-TNF-α antibody or antigen-binding fragment thereof, an anti-PD-1 antibody or antigen-binding fragment thereof, an anti-PD-L1 antibody or antigen-binding fragment thereof, an anti-TROP2 antibody, an anti-nectin-4 antibody or antigen-binding fragment thereof, an anti-EGFR antibody or antigen-binding fragment thereof, an anti-HER3 antibody or antigen-binding fragment thereof, an anti-cMet antibody or antigen-binding fragment thereof, an anti-B7H3 antibody or antigen-binding fragment thereof, an anti-B7H4 antibody or antigen-binding fragment thereof, an anti-VEGF antibody or antigen-binding fragment thereof, an anti-claudin 18.2 antibody or antigen-binding fragment thereof, an anti-Sirp-α antibody or antigen-binding fragment thereof, a TROP2×HER2 bispecific antibody, or a combination thereof. The Globo series antigens may include Globo H, stage-specific embryonic antigen 4 (SSEA-4), or stage-specific embryonic antigen 3 (SSEA-3).
[0126] In certain embodiments, the antibody is OBI-888 (anti-Globo H monoclonal antibody). Exemplary OBI-888 is described in PCT patent publications (WO2015157629A2 and WO2017062792A1) and patent applications, the contents of which are incorporated by reference in their entirety.
[0127] In certain embodiments, the antibody is OBI-898 (anti-SSEA4 monoclonal antibody). Exemplary OBI-898 is described in PCT patent publication (WO2017172990A1), patent application, the contents of which are incorporated by reference in their entirety.
[0128] In certain embodiments, the antibody is R4702 (an anti-TROP2 monoclonal antibody). An exemplary R4702 is described in PCT patent publication (WO2022222992A1), patent application, the contents of which are incorporated by reference in their entirety.
[0129] In some embodiments, the biomolecule is selected from, but not limited to, Herceptin (trastuzumab), TX05 (trastuzumab biosimilar), Perjeta (pertuzumab), Erbitux (cetuximab), Rituxan (rituximab), Vectibix (panitumumab), Humira (adalimumab), Keytruda (pembrolizumab), Bavencio (avelumab), and R4702 (anti-TROP2 antibody).
[0130] In a further aspect, the present invention provides a composition of a fucosylated or non-fucosylated glycoengineered antibody or antigen-binding fragment comprising an IgG molecule having the same N-glycan structure at every site in the Fc region, wherein the N-glycans are high mannose, hybrid, and complex and are selected from the group consisting of:
[0131] ,
[0132] Among them, R 1 is -H or N-acetylglucosamine linked via a β-1,4 bond, R 2 and R 3 are the same or different and are independently selected from the group consisting of:
[0133]
[0134] In another aspect, the present invention provides engineered biocomplexes with unexpectedly improved effector functions, such as binding to FcγIIIA, ADCC, and modulation of immune responses, compared to unmodified antibodies.
[0135] Loaded drug complex (linker-drug conjugate):
[0136] Another aspect of the present invention provides a loaded drug complex, which can be a therapeutic complex or a linker drug compound represented by the following formula:
[0137] CLD,
[0138] wherein C is a second reactive moiety configured to react with the first reactive moiety of the modified glycan in a biorthogonal reaction; wherein L is a linker unit comprising a hydrophilic moiety; and wherein D is a loaded drug. The loaded drug complex is configured to covalently couple the loaded drug to a biomolecule via the first reactive moiety of the modified glycan.
[0139] Second Reactive Moiety Unit (C): To react with the first reactive moiety of the modified glycan, in some embodiments, the second reactive moiety of the drug-loaded conjugate comprises an unsaturated moiety that reacts with the azide moiety to produce a triazole moiety. The unsaturated moiety can be, but is not limited to, an alkene moiety or an alkyne moiety. In some embodiments, the second reactive moiety is a bioorthogonal group, which is a non-natural and nonperturbing chemical group. Specific examples of the second reactive moiety include, but are not limited to, dibenzocyclooctynyl (DBCO), bicyclononyne (BCN), cycloalkynes, maleimides, α,β-unsaturated carbonyl groups, or sulfonylpyrimidines. However, the methods of the present invention are not limited thereto. Other functional groups suitable for biorthogonal reactions with the first reactive moiety of the modified glycan can also be selected for drug-loaded conjugation.
[0140] Linker Unit (L): The hydrophilic portion of the linker (L) can be selected based on hydrophilicity and biocompatibility for clinical use. In certain embodiments, the hydrophilic portion comprises a second polyethylene glycol (PEG) moiety. In some embodiments, the PEG moiety can be replaced with another hydrophilic polymer moiety that exhibits suitable biocompatibility.
[0141] Although the length of the PEG moiety is not limited, in some embodiments, the PEG moiety can comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, or 72 ethylene oxide (OCH2CH2) subunits, or ranges bounded by the aforementioned endpoints, for example, 2 to 72, 2 to 60, 2 to 50, 2 to 40, 2 to 30, 2 to 20, 2 to 15, 2 to 10, 2 to 5, 2 to 4, 3 to 72, 3 to 65, 3 to 55, 3 to 45, 3 to 35, 3 to 25, 3 to 15, 3 to 10, 4 to 72, 4 to 60, 4 to 50, 4 to 40, 4 to 30, 4 to 20, 4 to 15, or 4 to 10 OCH2CH2 subunits. In some embodiments, the PEG moiety can be a linear PEG, a branched PEG, or a star PEG. In certain embodiments, the PEG moiety can have 2, 3, 4, 5, 6, 7, or 8 arms. In certain embodiments, the PEG moiety can have a molecular weight of 4K Da, 6K Da, 8K Da, 10K Da, or 20K Da.
[0142] In some embodiments, the linker may further comprise a cleavable moiety and a spacer. The cleavable moiety is configured to release the loaded drug from the second engineered complex in vivo. Therefore, functionalities that can be catalyzed or digested by enzymes commonly found in the target in vivo environment may be selected. The enzyme may be a protease, such as matrix metalloproteinase 2 or matrix metalloproteinase 9, or a glycosidase. In certain embodiments, the cleavable moiety is a protease-sensitive peptide, including but not limited to Val-Cit, Val-Ala, Phe-Lys, Glu-Val-Cit, Glu-Val-Ala, Glu-Gly-Cit, Glu-Gly-Ala, Gly-Gly-Phe-Gly, Gly-Gly-Val-Cit, and Gly-Gly-Val-Ala. In other embodiments, the cleavable moiety is a glycosidase-sensitive sugar unit, including but not limited to glucuronic acid, iduronic acid, or galactose.
[0143] In some embodiments, the spacer can be an aromatic group, including, but not limited to, 1,4-phenyl, 2,5-pyridyl, 3,6-pyridyl, 2,5-pyrimidinyl, 2,5-thienyl, or an aminomethylene group such as -NH-CH2-.
[0144] In some embodiments, the Linker unit comprises the formula:
[0145] ,
[0146] wherein (PEG)m is a PEG moiety, and m is an integer selected from 2 to 72, Q SP is a spacer containing an aromatic group or an aminomethylene group, Q CL is a cleavable portion and is configured to be connected to a loaded drug, P is a connector unit configured to be linked to the second reactive moiety.
[0147] In some embodiments, the PEG moiety comprises the formula:
[0148] ,
[0149] The wavy line indicates the P The site of covalent attachment, where R 20 is a PEG attachment unit, wherein the PEG attachment unit is -C(O)-, -O-, -S-, -NH-, -C(O)O-, alkyl-C(O)-NH-, alkyl-NH-C(O)-, alkyl-CO2-, alkyl-S-, or
[0150] , where R 21 is a PEG capping unit; wherein the PEG capping unit is selected from H, SO3H, PO3H2, sugar derivatives, C1-C 10 (hetero)alkyl, C3-C 10 (Hetero)cycloalkyl, C2-C 10 Alkyl-NH2, C1-C 10 Alkyl-COOH, C2-C 10 Alkyl-NH (C1-C3 alkyl), C2-C 10 Alkyl-N(C1-C3 alkyl)2, wherein n is selected from 2 to 72, 4 to 72 or 8 to 72.
[0151] In a specific embodiment, the linker unit (L) has the following structure:
[0152] .
[0153] Loaded drug (D): The loaded drug can be a therapeutic agent or a diagnostic agent. In some embodiments, the diagnostic agent can be used for imaging.
[0154] In some embodiments, the therapeutic agent can be a toxin, a cytokine, a growth factor, a radionuclide, a hormone, an antiviral agent, an antibacterial agent, an immunomodulatory agent, an immunostimulatory agent, an anti-tumor agent, a chemotherapeutic agent, or a combination thereof.
[0155] In some embodiments, the toxin is selected from at least one member of the group consisting of: pyrrolobenzodiazepines (e.g., PBD); auristatins (e.g., MMAE, MMAF); maytansinoids (e.g., maytansine, DM1, DM4, DM21); duocarmycins; nicotinamide phosphoribosyltransferase (NAMPT) inhibitors; terpilacin; enediynes (e.g., calicheamicin); anthracycline derivatives (PNUs) (e.g., doxorubicin); pyrrole-based spindle actuator protein (KSP) inhibitors; cryptophycin; drug efflux pump inhibitors; sandramycins; ectocin (e.g., α-ectocin); and camptothecins (e.g., exatecan, deruxtecan).
[0156] In certain embodiments, the chemotherapeutic agent is a topoisomerase inhibitor, including topoisomerase I inhibitors and topoisomerase II inhibitors. In certain embodiments, the chemotherapeutic agent is a topoisomerase I inhibitor that is a camptothecin (CPT) or a non-camptothecin selected from irinotecan, topotecan, camptothecin, rubitecan, MLN576, exinotecan, belotecan, seconeolitsine, SN-38, Genz-644282, betulinic acid, β-lapachone, karenitecin, gimatecan, namitecan, edotecarin, SW044248, LMP744, T-2513, podocarpusflavone A, indimitecan, lurtotecan, TP3011, or 10-hydroxycamptothecin.
[0157] The loaded drug (D) can be selected as exicin as an example, and the linker drug compound (ie, the loaded drug complex) can be further represented by the following formula:
[0158] .
[0159] In one embodiment, the structure of the linker drug compound (ie, the payload drug complex) is represented by the following formula:
[0160] .
[0161] In one embodiment, the structure of the linker drug compound (ie, the payload drug complex) is represented by the following formula:
[0162] .
[0163] Engineered biocomplexes
[0164] Another aspect of the present invention provides an engineered biocomplex. The engineered biocomplex comprises a biomolecule and a modified glycan coupled to the biomolecule, wherein the modified glycan comprises (i) a first polyethylene glycol (PEG) moiety and (ii) a first reactive moiety or a product thereof from a biorthogonal reaction; wherein the biomolecule comprises an antibody or antigen-binding fragment thereof, a protein, or a peptide. In some embodiments, the first PEG moiety and the first reactive moiety are as described herein.
[0165] In some embodiments where the biomolecule comprises an antibody or antigen-binding fragment thereof, the modified glycan is coupled to the antibody or antigen-binding fragment at its Fc region. In certain embodiments, the modified glycan is located in the Fc region of the antibody or antigen-binding fragment, for example, at position N297 of the Fc region. In some embodiments where the biomolecule is an antibody, one or two N-linked primary glycans are coupled at position N297 of the antibody Fc region, for example, to a GlcNAc monosaccharide at position N297. The GlcNAc monosaccharide can be fucosylated or non-fucosylated.
[0166] In some embodiments, the engineered biocomplex further comprises a drug-loaded moiety, wherein the drug-loaded moiety is coupled to the modified glycan via a product moiety. In such embodiments, the ratio of drug-loaded to biomolecule (e.g., drug-to-antibody ratio) is 2:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, or 10:1.
[0167] In certain embodiments, the drug-loaded moiety has a structure represented by the following formula:
[0168] -LD;
[0169] wherein L is a linker unit comprising a hydrophilic moiety and connected to the product moiety, and D is a drug payload. In some embodiments, the linker unit (L) and the drug payload (D) are as described herein. In some embodiments, the engineered biocomplex is prepared by a method for preparing an engineered biocomplex according to embodiments of the present invention.
[0170] In some embodiments, the resultant moiety can be a moiety generated by a biorthogonal reaction or click reaction between a first reactive moiety and a second reactive moiety as described herein. In certain embodiments, the resultant moiety comprises a triazole moiety. In certain embodiments, the resultant moiety can comprise a DBCO-derived moiety or a maleimide-derived moiety.
[0171] In some embodiments, the present invention provides a plurality of engineered biological complexes, each being an engineered biological complex according to an embodiment of the present invention, wherein the plurality of engineered biological complexes are at least or greater than 80%, 85%, 90%, 95%, or 99% homologous.
[0172] In some embodiments, the engineered biocomplex comprises a first drug-loaded moiety and a second drug-loaded moiety, wherein the first drug-loaded moiety is different from the second drug-loaded moiety. In certain embodiments, the first drug-loaded moiety and the second drug-loaded moiety are different in each of the drug-loaded complexes, each of the reactive moiety units (C) of the two drug-loaded complexes, and / or each of the linker units (L) of the two drug-loaded complexes.
[0173] In certain embodiments where the first drug-loaded moiety and the second drug-loaded moiety have different drug loadings in the two drug-loaded complexes, the drug loaded in the first drug-loaded moiety may be a therapeutic agent, and the drug loaded in the second drug-loaded moiety may be an imaging agent (e.g., an imaging probe). In other embodiments, the drug loaded in the first drug-loaded moiety may be a first therapeutic agent, and the drug loaded in the second drug-loaded moiety may be a second therapeutic agent.
[0174] The engineered biocomplexes of the present invention may include those with anti-cancer activity. In certain embodiments, the engineered biocomplexes include an antibody conjugated (i.e., covalently linked via a linker) to a therapeutic agent / drug payload forming an ADC. When not conjugated to the antibody, the therapeutic agent exhibits a cytotoxic or cytostatic effect. Thus, the biological activity of the therapeutic agent / drug payload is modulated by conjugation to the antibody. In certain embodiments, the ADCs of the present invention are capable of selectively delivering an effective dose of a cytotoxic agent to a tumor, thereby achieving a lower effective dose.
[0175] In some embodiments where the engineered biocomplex is an ADC, the ADC can be represented by the following formula:
[0176] Ab-(LD) n or a pharmaceutically acceptable salt or solvate thereof,
[0177] wherein: Ab is an antibody that binds to TROP2, HER2, Nectin-4, HER3, cMet, B7H3, B7H4, VEGF, Claudin 18.2, Sirp-α, or which binds to one or more tumor-associated antigens or cell surface receptors; D is a drug unit; L is a linker; and n is the drug-to-antibody ratio (DAR) and ranges from 10 to 1.
[0178] Exemplary linkers suitable for use in ADCs are described, for example, in U.S. Patent No. 7,595,292 (WO2005 / 007197). The entire disclosure regarding linkers is incorporated herein by reference. Linkers L connect the antibody to the drug moiety / drug payload via a covalent bond that does not contain a disulfide group. Linkers are bifunctional or multifunctional moieties that can be used to link one or more drug moieties / drug payloads (D) and antibody units (Ab) to form an ADC of Formula I. ADCs can be conveniently prepared using linkers with reactive functionality for binding drugs to antibodies. Cysteine thiols or amines, such as the N-terminus of an antibody (Ab), or amino acid side chains (such as lysine) can form bonds with functional groups of linker reagents, drug moieties / drug payloads, or drug-linker reagents.
[0179] The linker is preferably stable outside the cell. Prior to transport or delivery to the cell, the ADC is preferably stable and intact, i.e., the antibody remains attached to the drug moiety / drug payload. The linker is stable outside the target cell and can be cleaved at an effective rate inside the cell. An effective linker will: (i) maintain the specific binding properties of the antibody; (ii) allow intracellular delivery of the complex or drug moiety / drug payload; (iii) remain stable and intact, i.e., not be cleaved, until the complex is delivered or transported to its target site; and (iv) maintain the cytotoxic, cell-killing, or cell growth-inhibitory effect of the maytansine-like drug moiety / drug payload. The stability of the ADC can be measured by standard analytical techniques, such as mass spectrometry, HPLC, and separation / analysis techniques such as LC / MS.
[0180] In another embodiment, the ADC specifically binds to TROP2, HER2, Nectin-4, HER3, cMet, B7H3, B7H4, VEGF, Claudin 18.2, and Sirp-α. The ADC can inhibit the growth of tumor cells expressing TROP2, HER2, Nectin-4, HER3, cMet, B7H3, B7H4, VEGF, Claudin 18.2, and Sirp-α.
[0181] Another aspect includes diagnostic and therapeutic uses of the compounds and compositions disclosed herein.
[0182] Another aspect is a method for killing tumor cells or cancer cells, or inhibiting their proliferation, which comprises treating cells with a certain amount of an engineered complex or ADC according to an embodiment of the present invention, or a pharmaceutically acceptable salt or solvate thereof, which can effectively kill tumor cells or cancer cells, or inhibit their proliferation.
[0183] Another aspect includes a method of treating a disease or condition in a patient with an engineered complex or ADC, wherein the disease or condition is characterized by overexpression of TROP2, HER2, Nectin-4, HER3, cMet, B7H3, B7H4, VEGF, Claudin 18.2, and Sirp-α.
[0184] Another aspect includes methods of making, preparing, synthesizing, conjugating, and purifying the engineered complexes or ADCs, as well as intermediates for making, synthesizing, and conjugating ADCs.
[0185] pharmaceutical dosage forms
[0186] Another aspect of the present invention provides a pharmaceutical composition comprising a plurality of engineered biocomplexes of the present invention and a pharmaceutically acceptable carrier. Pharmaceutical dosage forms comprising the engineered biocomplexes of the present invention can be prepared for storage by mixing an antibody having a desired degree of purity with one or more optional physiologically acceptable carriers, excipients, or stabilizers (Remington's Pharmaceutical Sciences, 16th edition, Osol, A. ed. (1980)) in the form of an aqueous solution, lyophilized, or other dry dosage form. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed and include buffers such as phosphate, citrate, histidine, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzyl ammonium chloride; hexamethylammonium chloride; benzalkonium chloride, benzethonium chloride); phenol, butyl alcohol, or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; paraben); catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., zinc-protein complexes); and / or nonionic surfactants such as TWEEN™, PLURONICS™, or polyethylene glycol (PEG).
[0187] The dosage forms herein may also contain more than one active compound as necessary for the specific indication being treated, including, but not limited to, those whose complementary activities do not adversely affect each other. Such molecules are suitably present in combination in amounts effective for the intended purpose.
[0188] The active ingredient can also be embedded in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, such as hydroxymethylcellulose or gelatin microcapsules, and poly-methacrylate microcapsules, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. ed. (1980).
[0189] Dosage forms for in vivo administration must be sterile. This can be readily accomplished by filtration through sterile filtration membranes.
[0190] Sustained-release dosage forms can be prepared. Suitable examples of sustained-release dosage forms include semipermeable matrices of solid hydrophobic polymers containing the immunoglobulins of the invention, such matrices in the form of shaped articles, such as films or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol)), polylactides (U.S. Patent No. 3,773,919), copolymers of L-glutamic acid and γ-ethyl-L-glutamic acid, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid can release molecules for over 100 days, certain hydrogels release proteins for shorter periods of time. When encapsulated immunoglobulins remain in the body for extended periods, they may denature or aggregate due to exposure to moisture at 37°C, leading to loss of biological activity and possible changes in immunogenicity. Rational strategies can be designed to achieve stabilization based on the mechanisms involved. For example, if the aggregation mechanism is found to be intermolecular SS bonds formed through sulfo-disulfide exchange, stabilization can be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
[0191] The amount of antibody in the pre-lyophilized dosage form is determined taking into account the desired dose volume, route of administration, and other factors. When the protein of choice is an intact antibody (full-length antibody), exemplary starting protein concentrations range from about 2 mg / mL to about 50 mg / mL, preferably from about 5 mg / mL to about 40 mg / mL, and optimally from about 20 to 30 mg / mL. Proteins are typically present in solution. For example, the protein can be present in a pH buffer having a pH of about 4 to 8, preferably about 5 to 7. Exemplary buffers include histidine, phosphate, Tris, citrate, succinate, and other organic acids. The buffer concentration can range from about 1 mM to about 20 mM or from about 3 mM to about 15 mM, depending on, for example, the desired isotonicity of the buffer and the dosage form (e.g., a reconstituted formulation). A preferred buffer is histidine, as shown below, which can have lyoprotective properties. Succinate has also been shown to be another useful buffer.
[0192] A lyoprotectant is added to the pre-lyophilized dosage form. In preferred embodiments, the lyoprotectant is a non-reducing sugar, such as sucrose or trehalose. The amount of lyoprotectant in the pre-lyophilized dosage form is generally such that upon reconstitution, the resulting dosage form is isotonic. However, hypertonic reconstituted dosage forms may also be suitable. Furthermore, the amount of lyoprotectant should not be so low that an unacceptable amount of protein degradation / aggregation occurs during lyophilization. When the lyoprotectant is a sugar (such as sucrose or trehalose) and the protein is an antibody, an exemplary lyoprotectant concentration in the pre-lyophilized dosage form is about 10 mM to about 400 mM, preferably about 30 mM to about 300 mM, and most preferably about 50 mM to about 100 mM.
[0193] The ratio of protein to lyoprotectant is selected for each protein and lyoprotectant combination. In the case of an antibody as the selected protein and a sugar (e.g., sucrose or trehalose) as the lyoprotectant for producing an isotonic reconstituted dosage form with a high protein concentration, the molar ratio of lyoprotectant to antibody can be from about 100 to about 1500 moles of lyoprotectant to 1 mole of antibody, and preferably from about 200 to about 1000 moles of lyoprotectant to 1 mole of antibody, for example, from about 200 to about 600 moles of lyoprotectant to 1 mole of antibody.
[0194] In preferred embodiments of the present invention, it has been found desirable to add a surfactant to the pre-lyophilized dosage form. Alternatively, or in addition, a surfactant may be added to the lyophilized dosage form and / or the reconstituted dosage form. Exemplary surfactants include nonionic surfactants such as polysorbates (e.g., polysorbate 20 or 80); poloxamers (e.g., poloxamer 188); Triton; sodium dodecyl sulfate; sulfate (SDS); sodium lauryl sulfate; sodium octyl glucoside; lauryl-, myristyl-, linoleyl-, or stearyl sulfobetaine; lauryl-, myristyl-, linoleyl-, or stearyl sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauramidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristylamidopropyl-, palmitoylpropyl-, or isostearamidopropyl-betaine (e.g., lauramidopropyl); myristylamidopropyl-, palmitoylpropyl-, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl or disodium methyl oleyl taurate; and the MONAQUAT™ range (Mona Industries, Inc., Paterson, New Jersey, USA), polyethylene glycol, polypropylene glycol, and copolymers of ethylene glycol and propylene glycol (e.g., Pluronics, PF68, etc.). The amount of surfactant added is such that it reduces aggregation of the reconstituted protein and minimizes the formation of particles after reconstitution. For example, the surfactant may be present in the pre-lyophilized dosage form in an amount of about 0.001-0.5%, and preferably about 0.005-0.05%.
[0195] In certain embodiments of the present invention, a mixture of a lyoprotectant (such as sucrose or trehalose) and a bulking agent (e.g., mannitol or glycine) is used to prepare a pre-lyophilized dosage form. The bulking agent allows for the production of a uniform lyophilized cake without excessive air bubbles, etc.
[0196] Other pharmaceutically acceptable carriers, excipients, or stabilizers, such as those described in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. ed. (1980), may be included in the pre-lyophilized dosage form (and / or lyophilized dosage form and / or reconstituted dosage form) provided that they do not adversely affect the desired properties of the dosage form. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed and include: additional buffers; preservatives; cosolvents; antioxidants, including ascorbic acid and methionine; chelating agents, such as EDTA; metal complexes (e.g., zinc-protein complexes); biodegradable polymers, such as polyesters; and / or salt-forming counterions, such as sodium.
[0197] The pharmaceutical compositions and dosage forms described herein are preferably stable. A "stable" dosage form / composition is one in which the antibody substantially maintains its physical and chemical stability and integrity upon storage. Various analytical techniques for measuring protein stability are available in the art and are reviewed in Peptide and Protein Drug Delivery, 247-301, Vincent Lee, ed., Marcel Dekker, Inc., New York, NY (1991), and Jones, A. Adv. Drug Delivery Rev. 10: 29-90 (1993). Stability can be measured at a selected temperature and for a selected period of time.
[0198] Dosage forms for in vivo administration must be sterile. This is readily achieved by filtration through a sterile filtration membrane, either before or after lyophilization and reconstitution. Alternatively, the entire mixture can be sterilized by autoclaving the ingredients, excluding the protein, at about 120°C for about 30 minutes.
[0199] After the protein, lyoprotectant, and other optional components are mixed together, the dosage form is lyophilized. Many different freeze dryers are available for this purpose, such as the Hull 50 ® (Hull, USA) or GT20 ® (Leybold-Heraeus, Germany) freeze dryer. Freeze drying is accomplished by freezing the dosage form and subsequently subliming ice from the frozen contents at a temperature suitable for primary drying. Under these conditions, the product temperature is below the dosage form's eutectic point, or collapse temperature. Typically, the shelf temperature for primary drying is in the range of approximately -30 to 25°C (assuming the product remains frozen during primary drying) at a suitable pressure, typically approximately 50 to 250 mTorr. The dosage form, size, and type of container (e.g., glass vial) holding the sample, as well as the volume of liquid, will primarily determine the drying time required, which can range from several hours to several days (e.g., 40 to 60 hours). The secondary drying stage can be carried out at temperatures of approximately 0 to 40°C, depending primarily on the type and size of the container and the type of protein used. However, it has been found that a secondary drying step may not be necessary. For example, the shelf temperature for the entire water removal stage of freeze drying can be approximately 15 to 30°C (e.g., approximately 20°C). The time and pressure required for secondary drying will be that required to produce a suitable lyophilized cake, depending on, for example, temperature and other parameters. The secondary drying time depends on the desired residual moisture content in the product and typically takes at least about 5 hours (e.g., 10-15 hours). The pressure can be the same as that used during the primary drying step. Freeze-drying conditions can vary depending on the dosage form and vial size.
[0200] In some cases, it may be desirable to lyophilize the protein dosage form in a container where reconstitution of the protein can be performed to avoid a transfer step. In this case, the container may be, for example, a 3, 5, 10, 20, 50, or 100 cc vial. As a general rule, lyophilization will produce a lyophilized dosage form wherein the moisture content is less than about 5%, and preferably less than about 3%.
[0201] Typically, when the protein is administered to a patient at the desired stage, the lyophilized dosage form can be reconstituted with a diluent such that the protein concentration in the reconstituted dosage form is at least 50 mg / mL, for example, from about 50 mg / mL to about 400 mg / mL, more preferably from about 80 mg / mL to about 300 mg / mL, and most preferably from about 90 mg / mL to about 150 mg / mL. Such high protein concentrations in the reconstituted dosage form are believed to be particularly useful when the reconstituted dosage form is intended for subcutaneous delivery. However, for other routes of administration, such as intravenous administration, lower concentrations of protein in the reconstituted dosage form may be desired (e.g., from about 5 to 50 mg / mL or from about 10 to 40 mg / mL of protein in the reconstituted dosage form). In certain embodiments, the protein concentration in the reconstituted dosage form is significantly higher than the protein concentration in the pre-lyophilized dosage form. For example, the protein concentration in the reconstituted dosage form can be about 2 to 40 times, preferably 3 to 10 times, and most preferably 3 to 6 times (e.g., at least 3 times or at least 4 times) that of the pre-lyophilized dosage form.
[0202] Reconstitution is typically performed at a temperature of approximately 25°C. To ensure complete hydration, other temperatures may be used as needed. The time required for reconstitution will depend, for example, on the type of diluent, the excipients, and the amount of protein. Exemplary diluents include sterile water, bacteriostatic water for injection (BWFI), a pH buffer (e.g., phosphate-buffered saline), sterile saline solution, Ringer's solution, or dextrose solution. The diluent optionally contains a preservative. Exemplary preservatives have been described above, with aromatic alcohols such as benzyl alcohol or phenolic alcohols being preferred preservatives. The amount of preservative used is determined by evaluating the compatibility of different preservative concentrations with the protein and preservative efficacy testing. For example, if the preservative is an aromatic alcohol (e.g., benzyl alcohol), it may be present in an amount of about 0.1-2.0%, preferably about 0.5-1.5%, but most preferably about 1.0-1.2%. Preferably, the reconstituted dosage form has fewer than 6000 particles per vial with a size > 10 μm.
[0203] Therapeutic applications:
[0204] The engineered biocomplexes described herein can be used to treat patients suffering from cancer. Treatment methods include administering to a patient an effective amount of an engineered biocomplex or pharmaceutical composition described herein. Examples of cancers include, but are not limited to, cancers associated with and / or expressing the Globo series of antigens, including, but not limited to, Globo H, SSEA-4, and SSEA-3; and cancers associated with and / or expressing HER2, TROP2, Nectin-4, HER3, cMet, B7H3, B7H4, VEGF, Claudin 18.2, or Sirp-α.
[0205] The subject that can be treated by the methods described herein can be a mammal, more preferably a human. Mammals include, but are not limited to, farm animals, sports animals, pets, primates, horses, dogs, cats, mice, and rats. The human subject in need of treatment can be a human patient suffering from, at risk of, or suspected of having cancer, including, but not limited to, sarcoma, skin cancer, leukemia, lymphoma, brain cancer, lung cancer, breast cancer, oral cancer, esophageal cancer, stomach cancer, liver cancer, bile duct cancer, pancreatic cancer, colon cancer, kidney cancer, cervical cancer, ovarian cancer, and prostate cancer. Subjects suffering from cancer can be identified by routine medical examinations. In particular, the cancer is a cancer that expresses the Globo series of antigens.
[0206] In certain embodiments, the cancer is breast cancer.
[0207] In addition, the engineered biocomplexes described herein can be used to treat patients suffering from autoimmune diseases or inflammatory diseases. The treatment method comprises administering to the patient an effective amount of the glycoengineered antibody or pharmaceutical composition described herein. Examples of autoimmune or inflammatory diseases include, but are not limited to, rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, psoriasis, IgA nephropathy, IgM polyneuropathy, myasthenia gravis, vasculitis, diabetes, Reynaud's syndrome, Crohn's disease, ulcerative colitis, gastritis, Hashimoto's thyroiditis, and leukemia. thyroiditis), ankylosing spondylitis, hepatitis C-associated cryoglobulinemia, chronic focal encephalitis, bullous pemphigoid, hemophilia A, membranoproliferative glomerulonephritis, adult and juvenile dermatomyositis, adult polymyositis, chronic urticaria, primary biliary cirrhosis, neuromyelitis optica, Graves' dysthyroid disease, bullous pemphigoid, membranoproliferative glomerulonephritis, Churg-Strauss syndrome, asthma, psoriatic arthritis, dermatitis, respiratory distress syndrome, meningitis, encephalitis, uveitis, eczema, atherosclerosis, leukocyte adhesion retardation, juvenile-onset diabetes mellitus, Reiter's disease, Behcet's syndrome disease), hemolytic anemia, atopic dermatitis, Wegener's granulomatosis, Omenn's syndrome, chronic renal failure, acute infectious mononucleosis, AIDS and herpes-related diseases, systemic sclerosis, Sjögren's syndrome, glomerulonephritis, dermatomyositis, ANCA, aplastic anemia, autoimmune hemolytic anemia,AIHA), factor VIII deficiency, hemophilia A, autoimmune neutropenia, Castleman's syndrome, Goodpasture's syndrome, solid organ transplant rejection, graft versus host disease (GVHD), autoimmune hepatitis, lymphoid interstitial pneumonitis (HIV), bronchiolitis obliterans (non-transplant), Guillain-Barré syndrome, large vessel vasculitis, giant cell (Takayasu's) arteritis, medium vessel vasculitis, Kawasaki's disease, and polyarteritis nodosa.
[0208] Without further elaboration, it is believed that one skilled in the art can, based on the above description, utilize the present invention to its fullest extent. Therefore, the following specific examples should be construed as merely illustrative and not limiting of the remainder of the present invention in any way. All publications cited herein are hereby incorporated by reference for all purposes or subject matter cited herein.
[0209] Other aspects of the present invention.
[0210] In another aspect, the present invention provides a method for remodeling core fucosylated or non-fucosylated GlcNAc-peptides, proteins, and IgG or IgG-Fc fragments, wherein the method comprises providing a peptide / protein / antibody-GlcNAc receptor or Fc fragment and reacting it with an activated oligosaccharide donor under the catalysis of Streptococcus dysgalactiae subsp. Dysgalactiae and Streptococcus equi subsp. Zooepidemicus Sz105 glycosynthase, thereby preparing pre-existing peptides, proteins, and monoclonal antibodies with substantially, essentially, and / or pure glycoforms having heterogeneous glycosylation states.
[0211] In a further aspect, the present invention provides a method for performing glycan remodeling on a therapeutic IgG or an Fc fragment thereof using a glycosynthase, wherein the method comprises:
[0212] treating a natural or recombinant core-fucosylated or non-fucosylated therapeutic IgG or IgG-Fc fragment carrying heterogeneous N-glycans with an endoglycosidase (e.g., wild-type EndoS2) with or without bacterial α-fucosidase to hydrolyze the bond between the two reducing end GlcNAc residues to form a core-fucosylated or non-fucosylated GlcNAc-IgG receptor;
[0213] Using Streptococcus lactis subsp. lactis and Streptococcus equi subsp. zooepidemicus Sz105 glycosynthases, various predefined oligosaccharide building blocks in the form of activated oligosaccharide donors were transferred to core fucosylated or non-fucosylated GlcNAc-IgG to reconstitute the native β1,4 linkage via transglycosylation, thereby linking the predetermined oligosaccharide to the remodeled core fucosylated or non-fucosylated IgG or its Fc fragment.
[0214] Example
[0215] The following examples further illustrate the embodiments of the present invention. Those skilled in the art will appreciate that these examples are for illustrative purposes only and that modifications and variations are possible without departing from the scope of the present invention. For example, the enzyme variants of the present invention can be used to glycoengineer any glycoprotein or glycopeptide, including antibodies. The examples described herein utilize anti-CD20 antibodies. However, those skilled in the art will appreciate that other glycoproteins or antibodies can be used in a similar manner.
[0216] Material
[0217] The anti-Globo H monoclonal antibody OBI-888 was prepared according to the procedures previously disclosed in PCT patent publications (WO2015157629A2 and WO2017062792A1). The anti-SSEA4 monoclonal antibody OBI-898 was prepared according to the procedures previously disclosed by the inventors in PCT patent publication (WO2017172990A1). The commercial antibodies Herceptin (trastuzumab), Perjeta (pertuzumab), Erbitux (cetuximab), Rituxan (rituximab), Vectibix (panitumumab), Humira (adalimumab), Keytruda (pembrolizumab), and Bavencio (avelumab) were purchased from:
[0218]
[0219] Biantennary glycans and sialylated complex N-glycans (NSCT) were purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan, D4065). NSCT-oxazoline was synthesized according to previously reported methods (Noguchi, M. et al. (2012) Helvetica chimica acta 95:1928-1936). Other glycans (M3, G0, and G2) and Bf-α-fucosidase were prepared according to previous papers (Tsai, TI et al. (2017) ACS Chem. Biol. 12:63-72; Fairbanks, AJ (2013) Pure Appl. Chem. 85, 1847-1863).
[0220] Example 1: Cloning, overexpression and purification of EndoSd-D232M and EndoSz-D234M and mutants
[0221] The EndoSd and EndoSz genes from Streptococcus lactis subsp. lactis (ANI26082.1) and Streptococcus equi subsp. zooepidemicus Sz105 (KIS14581.1) were used in this study. These two enzymes lack a signal peptide at their N-termini. To enhance transglycosylation activity, the inventors aligned the EndoSd and EndoSz protein sequences with EndoS-D233Q (Huang, W. et al. (2012) J. Am. Chem. Soc. 134: 12308-12318). They found that the relative positions of EndoSd and EndoSz are D232 and D234, respectively. The inventors decided to mutate the relative position D to M. Therefore, genes encoding amino acids 20–1067 of EndoSd-D232M and amino acids 20–1011 of EndoSz-D234M were synthesized and subcloned into pGEX-4T-1 using the 5'-BamHI and 3'-XhoI restriction sites. For purification purposes, the inventors inserted six additional histidine residues into the C-termini of EndoSd-D232M and EndoSz-D234M for use on a Ni-NTA affinity column. Other mutants used in this study were generated by site-directed mutagenesis. Primers were designed based on the mutation sites. Mutated vectors were amplified using Pfu DNA polymerase (Protech) using EndoSd-D232M and EndoSz-D234M as template vectors. Subsequently, the template vectors (methylated DNA) were digested with DpnI (Promega) for 2 hours at 37°C. The mutant vectors were transformed into DH5α competent cells for selection. All mutants were confirmed by DNA sequencing.
[0222] All vectors were transformed into BL21(DE3) cells and cultured in TB medium supplemented with ampicillin (50 μg / mL) at 37°C. Protein production was induced with 0.2 mM isopropyl-β-D-thiogalactopyranoside (IPTG) until the cell density reached an OD600 of 0.6. After 5 hours, cells were harvested by centrifugation (BACKMAN / JLA-8.1, 9000 g) for 15 minutes at 25°C. The cell pellet was resuspended in wash buffer containing 50 mM MOPS pH 7.0, 300 mM NaCl, and 10 mM imidazole (100 mL buffer per 1 L cell pellet) and disrupted using a NanoLyzer N-10 homogenizer. After centrifugation at 4°C for 60 minutes at 12,000 g (BACKMAN / JA-10) and pellet removal, the supernatant was mixed with Ni-NTA resin (Roche) and gently rocked overnight at 4°C to completely bind the protein. The resin was loaded onto an open column, and unbound protein was washed with wash buffer until the concentration was less than 1 mg / mL (as defined by Bradford assay, Thermo). Bound protein was eluted with an elution buffer containing 50 mM MOPS, pH 7.0, 300 mM NaCl, and 250 mM imidazole. The eluted fraction was dialyzed into storage buffer containing 50 mM MOPS, pH 6.7, and concentrated using a 30 kDa cutoff cassette using TFF (Millipore laboratory scale). Final samples were analyzed by SDS-PAGE and Bradford analysis for molecular weight (MW) and concentration, respectively.
[0223] Example 2: Deglycosylation of OBI-888 by EndoS-WT and Bf-α-fucosidase to produce mAb-GlcNAc and mAb-GlcNAc(F)
[0224] OBI-888 and Herceptin monoclonal antibodies (10 mg) were incubated with EndoS (10 μg) in 25 mM sodium citrate buffer (pH 6.5) and 100 mM NaCl at 37°C for 4 hours. Complete cleavage of Fc N-glycans was analyzed by 4-12% gradient SDS-PAGE.
[0225] OBI-888-GlcNAc was generated by digesting the N-glycans of OBI-888 (10 mg) with EndoS-WT (10 μg) and Bf-α-fucosidase (10 mg) in Tris-HCl buffer (pH 7.4) for 16 hours at 37°C. The commercial antibodies Herceptin (trastuzumab), Perjeta (pertuzumab), Erbitux (cetuximab), Rituxan (rituximab), Vectibix (panitumumab), Humira (adalimumab), Keytruda (pembrolizumab), and Bavencio (avelumab) (10 mg) were digested using the same protocol as for OBI-888, except that the temperature was 30°C. Complete cleavage of Fc N-glycans was analyzed by 4-12% gradient SDS-PAGE. Fucosylated mAb-GlcNAc (mAbs-GlcNAc-F) was produced only by EndoSz wild type under similar conditions, with a culture time of 4 hours.
[0226] Example 3: Transglycosylation of mAb-GlcNAc and mAb-GlcNAc-F by Glycans
[0227] In the general procedure, mAb-GlcNAc / mAb-GlucNAc-F (5 mg) was incubated with glycan-oxa at a molar ratio of 1:20 and 1:150 (mAb-GlcNAc:NSCT-oxa) in MOPS buffer (50 mM, pH 6.7) at 30°C for 20 minutes in a final volume of 500 μL using EndoSz-D234M (167 μg) or EndoSd-D232M (1002 μg). Transglycosylation efficiency was monitored by HLPC.
[0228] Example 4: Deglycosylation and purification of homogeneous monoclonal antibodies
[0229] The reaction mixture was applied to a prepacked HiTrap Protein-A HP (5 mL, GE) column equilibrated with PBS buffer. Unbound contaminants were washed using a two-step pH gradient: PBS (pH 7.4) and glycine-HCl (pH 5.0), with each step consisting of five column volumes. Bound antibody was eluted with sodium citrate (pH 3.0). The eluted fraction was immediately neutralized to pH 7.4 with Tris-HCl (1 M, pH 9.0) and dialyzed into storage buffer containing 50 mM MOPS (pH 6.7) for mAb-GlcNAc(F) and 5 mM histidine and 150 mM NaCl for mAb-G2S2, respectively, using a 30 kDa cutoff dialysis cassette (Thermo) at 4°C overnight. All samples were concentrated by Amicon centrifugal membrane (30 kDa cutoff, Millipore) and stored at 4°C [mAb-GlcNAc(F)] or -80°C [mAb-G2S2(F)].
[0230] Example 5: LC / MS / MS Analysis of Glycopeptides
[0231] Samples were first processed using a 10 kDa cutoff Amicon Ultra-0.5 device for buffer exchange to ddH2O. Samples were denatured in a 0.1% RapiGest SF solution in 50 mM triethylammonium bicarbonate (TEABC), reduced with 5 mM dithiothreitol (DTT) at 60°C for 30 minutes, and then alkylated with 15 mM iodoacetamide for 30 minutes at room temperature in the dark. The resulting samples were digested in-solution with trypsin (trypsin:sample protein = 1:30) in 50 mM TEABC at 37°C overnight. Following digestion, samples were acidified with 0.5% (v / v) trifluoroacetic acid (TFA) and incubated at 37°C for 45 minutes. The acid-treated samples were centrifuged at 14,000 rpm at 4°C for 30 minutes to precipitate hydrolyzed RapiGest SF byproducts. Samples were analyzed using a Thermo Q-Exactive mass spectrometer (Thermo Scientific) coupled to an Ultimate 3000 RSLC system (Dionex). LC separation was performed using a C18 column (Acclaim PepMap RSLC, 75 μm x 150 mm, Thermo) with mobile phase A consisting of 0.1% FA (formic acid) and mobile phase B consisting of 95% ACN (acetonitrile) / 0.1% FA (formic acid). The analytical solvent gradient is listed in Table 3.
[0232] Table 3. LC solvent gradient
[0233]
[0234] A full MS scan was performed over the m / z range of 300 to 2000, and the ten most intense ions from the MS scan were selected for MS / MS scan.
[0235] Example 6: Enzymatic Binding Analysis by HPLC
[0236] Glycosynthase activity was analyzed by HPLC (Waters e2695) using a 2.1 x 150 mm UPLC glycoprotein amide column (Waters) in two different buffers (buffer A, ddH2O / 0.3% v / v HFIP (1,1,1,3,3,3-hexafluoro-2-propanol), 0.1% v / v TFA; buffer B, ACN, 0.3% v / v HFIP, 0.1% v / v TFA) with the gradients shown in Table 4.
[0237] Table 4. HPLC solvent gradient
[0238]
[0239] Prior to the experiment, the column was washed with 50% ACN and 50% ddH2O for 30 minutes and equilibrated with 15% buffer A and 85% buffer B until the system pressure stabilized. After ensuring baseline stability by injecting a water blank, the process began with a 2 μL sample injection. During the 29-minute run, the flow rate was 0.2 mL / min at a column temperature of 65°C and a sample tray temperature of 5°C.
[0240] Example 7: ADCC analysis of engineered antibodies
[0241] ADCC activity was analyzed using the ADCC Reporter Bioassay Complete Kit (Promega, G7015) using luciferase reporter cells. The relevant cell lines MCF7W (OBI-888), SKBR-3 (Herceptin, Perjeta), BxPC3 (Erbitux), and Raji (Rituxan) were selected for analysis. All cell lines used the same protocol. Target cells were seeded in 96-well cell culture plates and incubated overnight at 37°C in a humidified 5% CO2 incubator. The medium was replaced with serially diluted homologous antibodies and corresponding antibody standards, and the experiment was performed in triplicate. ADCC bioassay effector cells were added to each well at a 3:1 effector cell to target cell ratio. Induction was performed for 6 hours, followed by addition of Bio-Glo Luciferase Assay Buffer. Luminescence (relative light units (RLU)) was measured after 15 minutes using a microplate reader (SpectraMax L, Molecular Devices, Sunnyvale, CA). The fold change in luminescence induction was calculated by the ratio of relative light units (RLU) (induction) to RLU (no antibody control). EC was determined by plotting x (concentration, μg / mL)-y (fold change in induction) and fitting the data to a 4PL nonlinear regression model in PRISM 6 software. 50 Relative potency was estimated by parallel line analysis using a Gen5 microplate reader and Imager software (BioTek Instruments).
[0242] Example 8: Cleavage and conjugation of Herceptin
[0243] Antibodies produced by CHO cells always contain heterogeneous glycans at position N297 of the Fc. To generate homogeneous monoclonal antibodies and enhance ADCC, enzymatic modification of glycan cleavage and transglycosylation is a fundamental step in the homogeneous platform ( Figure 1 ). Regarding glycan cleavage, EndoSd-WT has been reported to hydrolyze biantennary glycans, but it is not a general chitinase (Shadnezhad, A. et al. (2016) Future Microbiol 11:721-736). To illustrate the ability of EndoSz-WT, it was used to hydrolyze native Herceptin and examine the N-glycan profile. The results showed that EndoSz-WT can hydrolyze biantennary hybrids and high mannose glycans. > 99% Herceptin was produced on N297 by EndoSz-WT and α-fucosidase, of which only one N-acetylglucosamine (Herceptin-GlcNAc) ( Figure 2However, in the cleavage step to completely remove glycans, the inventors combined additional enzymes EndoH or EndoM for monoclonal antibodies containing glycosylated Fab (Shadnezhad, A. et al. (2016) Future Microbiol 11: 721-736; Kadowaki, S. et al. (1990) Agric. Biol. Chem. 54: 97-106).
[0244] ENGase also has glycan binding function with appropriate mutations (Huang, W. et al. (2012) J. Am. Chem. Soc. 134: 12308-12318; Li., T., Tong et al. (2016) J. Biol. Chem. 291: 16508-16518). The inventors have established an HPLC method with an amide column for accurately monitoring the transglycosylation process. Figure 3 In the example shown in , the retention time of native Herceptin was 12.5 minutes. After EndoSz-WT and α-fucosidase cleavage, the retention time of Herceptin with one GlcNAc residue (Herceptin-GlcNAc) shifted to 11.4 minutes, and its molecular weight (MW) was calculated by intact mass analysis to be 145,572 Da. In the transglycosylation step of oxazoline sialylated complex N-glycans (NSCT-oxa) and Herceptin-GlcNAc (demonstrated by EndoSz-D234M), it is noteworthy that the column clearly discriminated between hemiglycosylated Herceptin (Herceptin-1N-G2S2) and fully glycosylated Herceptin (Herceptin-2N-G2S2), which were indistinguishable by SDS-PAGE. The retention time of Herceptin-1N-G2S2 was found to be 12.6 minutes with a molecular weight of 147,574 Da, while the retention time of Herceptin-2N-G2S2 was 13.9 minutes with a molecular weight of 149,576 Da. The HPLC method was applicable to all monoclonal antibodies. Therefore, the inventors performed further studies using HPLC analysis.
[0245] Example 9: Transglycosylation Study of EndoSz-D234M and EndoSd-D232M
[0246] Transglycosylation is the most important step in determining the quality of homogenous monoclonal antibodies in a homogenous platform. According to a previous report (Li., T., Tong et al. (2016) J. Biol. Chem. 291: 16508-16518), the D184M mutation used in EndoS2 has high transglycosylation activity. The inventors first generated EndoSz-D234M and EndoSd-D232M through multiple sequence alignment for transglycosylation studies. Figure 4 Generally, a higher sugar ratio results in higher conjugation efficiency. However, in practice, reducing the sugar amount to save costs and process within a reasonable timeframe is the goal of process optimization. Herceptin-GlcNAc and NSCT-oxa were used as research models to evaluate the transglycosylation activity of EndoSz-D234M and EndoSd-D232M within 60 minutes, with an expected formation of >90% Herceptin-2N-G2S2.
[0247] Starting with a 40:1 NSCT-oxa / Herceptin molar ratio, >90% Herceptin-2N-G2S2 was achieved with EndoSz-D234M. Lowering the NSCT-oxa / Herceptin molar ratio to 30:1 achieved >90% Herceptin-2N-G2S2 within 10 minutes. Using a 20:1 NSCT-oxa / Herceptin ratio, Herceptin-2N-G2S2 reached 89.31% at 5 minutes and 91.85% at 10 minutes, and was maintained for 20 minutes before deglycosylation ( Figure 5 A). Using a 10:1 NSCT-Oxa / Herceptin molar ratio, 62.61% of Herceptin-2N-G2S2 was obtained at 5 minutes, 61.48% at 10 minutes, and deglycosylation began. To determine the limit of NSCT-Oxa usage, the NSCT-Oxa / Herceptin ratio was increased to 15:1 (molar ratio). 80.8% of Herceptin-2N-G2S2 was obtained at 5 minutes, and deglycosylation began at 10 minutes. Therefore, the final conditions for transglycosylation using EndoSz-D234M enzyme were 20:1 NSCT-Oxa:antibody molar ratio, with a reaction time of 20 minutes.
[0248] Time dependence of EndoSz-D234M ( Figure 5A) Clearly illustrates the enzyme's behavior. The enzyme rapidly binds to Fc and incorporates glycans at position N297 of Fc, as Herceptin-GlcNAc is reduced to nearly 0% within 5 minutes, with a largely fully glycosylated antibody observed. However, the highly efficient transglycosylation enzyme also contributes to the hydrolytic activity. Deglycosylation occurs in all pathways, with the reaction reaching peak transglycosylation efficiency for a sustained period (20 minutes), highlighting the importance of controlling reaction time in this process. Notably, the data show a decrease in the percentage of Herceptin-2N-G2S2, accompanied by a major increase in the percentage of Herceptin-1N-G2S2 and a smaller percentage of Herceptin-GlcNAc, indicating that the enzyme preferentially selects its target for the hydrolysis reaction.
[0249] In contrast, applying the final transglycosylation conditions of EndoSz-D234M to the EndoSd-D232M enzyme yielded inconsistent results. EndoSd-D232M produced only 46.06% Herceptin-2N-G2S2 at a 20:1 molar ratio (NSCT-Oxa / antibody), demonstrating superior glycosynthetase activity compared to EndoSd-D232M. To obtain a higher yield of fully glycosylated antibody, increasing amounts of EndoSd-D232M and NSCT-Oxa were used to enhance transglycosylation efficiency. When a fivefold amount of EndoSd-D232M enzyme was used, only 60% Herceptin-2N-G2S2 was produced. Increasing the amount of NSCT-Oxa to 80:1 (molar ratio) yielded inconsistent results, ranging from 80-90% Herceptin-2N-G2S2. Finally, stable and reproducible data were obtained with a 150:1 molar ratio of NSCT-oxa. Figure 5 B) EndoSd-D232M demonstrates that EndoSd-D232M slowly transfers NSCT-oxo to N297 (Fc region), despite the use of a larger amount of substrate. Within 5 minutes, the amount of Herceptin-1N-G2S2 (~50%) was greater than that of Herceptin-2N-G2S2 (~40%). Herceptin-2N-G2S2 reached 80% by 10 minutes and 94% by 20 minutes. No deglycosylation was observed within 60 minutes.
[0250] In addition to using Herceptin-GlcNAc as an acceptor, the inventors also investigated the transglycosylation activity of fucosylated Herceptin-GlcNAc (Herceptin-GlcNAc-F), which may be suitable for ADC applications. Using the optimized transglycosylation conditions described above, 94.29% and 94.75% Herceptin-2N-G2S2F were obtained using EndoSz-D234M and EndoSd-D232M, respectively (Table 5). This demonstrates that both enzymes possess transglycosylation activity on fucosylated substrates.
[0251] Table 5. Transglycosylation results of EndoSz-D234M and EndoSd-D232M in different receptors.
[0252]
[0253] In summary, EndoSz-D234M exhibited superior transglycosylation activity compared to EndoSd-D232M. EndoSz-D234M consistently produced >90% Herceptin-2N-G2S2 (Herceptin-2N-G2S2F) with a molar ratio of only 20:1 (NSCT-oxa:antibody), whereas EndoSd-D232M required 7.5-fold more substrate.
[0254] Example 10: Transglycosylation Study of EndoSz and EndoSd Mutations
[0255] Several mutant sites, such as EndoS-D233Q and EndoS2-D184M, have been previously reported to increase transglycosylation activity (Huang, W. et al. (2012) J. Am. Chem. Soc. 134: 12308-12318; Li, T., Tong et al. (2016) J. Biol. Chem. 291: 16508-16518). Recently, Shivatare et al. reported that the EndoS2-T138Q mutation had better activity than EndoS2-D184M (Shivatare, SS et al. (2018) Chem. Commun. 54, 6161-6164). Based on multiple sequence alignment ( Figure 4The equivalent positions T183, D232, D234, D280, S281, and T282 of EndoSz, and T181, D230, D232, D278, S279, and T280 of EndoSd, were selected as targets for site-directed mutagenesis. The EndoSz D234 and EndoSd D232 positions were generated with several different configurations, including positive / negative charge and polar / nonpolar. Transglycosylation activity was determined using the optimal conditions described previously.
[0256] Activity analysis results of EndoSz mutants ( Figure 6 A) shows that EndoSz-D234M has the highest activity (set to 100%), while EndoSz-D234Q (99.9%), EndoSz-D234S (98.8%), and D234F (98.6%) exhibit competitively high activity. In comparison, EndoSz-D234R (4.9%) and EndoSz-D234H (4.5%) exhibit lower activity. Wild-type EndoSz also exhibits slight transglycosylation activity (24.3%). Except for position D234, EndoSz-T183Q (89.1%), EndoSz-D232Q (31.4%), EndoSz-D280Q (34.0%), EndoSz-S281Q (12.9%), and EndoSz-T282Q (16.3%) did not show significantly increased transglycosylation activity compared to EndoSz-D234M.
[0257] In EndoSd mutants ( Figure 6 In Figure B), EndoSd-D232M (set to 100%), EndoSd-D232S (100.8%), and EndoSd-D278Q (108.0%) had similarly high transglycosylation activities, while EndoSd-D232R (9.2%) and EndoSd-D232H (8.1%) had low activities. Wild-type EndoSd had relatively high transglycosylation activity (84%).
[0258] In conclusion, it was shown that EndoSz-D234M and EndoSd-D278Q exhibited relatively better transglycosylation activities on Herceptin-GlcNAc to generate homogeneous Herceptin with NSCT-oxo at the Fc region.
[0259] Example 11: Binding study of EndoSz-D234M to various sugars
[0260] A homogenous platform was designed to bind various glycans on the Fc region of Herceptin. Glycans M3, G0, and G2 were used for investigation using EndoSz-D234M. Results showed that all glycans successfully bound to the Fc region at a molar ratio of 20:1 (NSCT-oxa:antibody). With the exception of M3, G0 and G2 achieved >90% fully glycosylated Herceptin (Table 6).
[0261] Table 6. Transglycosylation results of EndoSz-D234M in different receptors with different glycans.
[0262]
[0263] M3 achieved 78% fully glycosylated Herceptin at 5 minutes and initiated deglycosylation. To optimize binding rate, M3 was increased to a 30:1 molar ratio, achieving 86.3% at 10 minutes before deglycosylation, and to a 40:1 molar ratio, yielding 90% fully glycosylated Herceptin. Final binding conditions with M3 were a 40:1 molar ratio with a 10-minute reaction time, resulting in 92.37% fully glycosylated Herceptin. This homogeneous platform can be applied not only to Herceptin-GlcNAc but also to Herceptin-GlcNAc-F, binding to various glycans on the Fc region, with binding efficiencies exceeding 90%.
[0264] Example 12: Transglycosylation of various antibodies
[0265] The homogeneous platform is a powerful process for establishing homogeneous monoclonal antibodies. Several other monoclonal antibodies were selected for binding studies with EndoSz-D234M, including OBI-888, Perjeta, Erbitux, Rituxan, OBI-898, Vectibix, Humira, Keytruda, and Bavencio. The results demonstrated the effectiveness of the homogeneous platform under conditions where the NSCT-oxa-to-antibody ratio was 20:1 (molar ratio). Figure 7 The percentages of fully glycosylated monoclonal antibodies were as follows: OBI-888-G2S2: 87.57%, Perjeta-G2S2: 92.49%, Erbitux-G2S2: 87.92%, Rituxan-G2S2: 97.57%, OBI-898-G2S2: 89.73%, Vectibix-G2S2: 86.12%, Humira-G2S2: 93.68%, Keytruda-G2S2: 75.81%, and Bavercio-G2S2: 90.73%.
[0266] To evaluate the activity of homogenous glycans on different monoclonal antibodies, the inventors selected five antibodies for ADCC bioassay ( Figure 7 B) Compared to the original monoclonal antibody, the EC50 of all homologous monoclonal antibodies was increased. In particular, OBI-888 showed a 26-fold increase, demonstrating the greatest ADCC improvement.
[0267] Example 13: Overall structure and polysaccharide complex of EndoSz-D234M
[0268] In our research, EndoSz-D234M has been identified as possessing excellent transglycosylation activity on therapeutic IgG antibodies and playing a key role in our homogeneous monoclonal antibody platform. To understand the transglycosylation mechanism, we crystallized and determined the structure of a mutant EndoSz-D234M. We designed a truncated form of EndoSz-D234M at amino acids 99-974 for crystallization and structural analysis. This truncation successfully yielded diffraction-quality crystals of EndoSz-D234M with two space groups: P212121 and P21. The P212121 crystals exhibited higher diffraction resolution (~2.2 Å) than the P21 crystals (~3.1 Å). The structures determined from the two crystal forms exhibited highly similar structures (RMSD 0.75 Å, calculated by SSM), with no significant conformational changes between the two structures. Therefore, the higher resolution structure of EndoSz-D234M in space group P212121 is referenced throughout the manuscript. The crystal structure of EndoSz-D234M shows a monomeric V-shaped structure consisting of five major domains: a glycosidase hydrolase (GH) domain (amino acids 99-445), a leucine-rich repeat domain (amino acids 446-631), a hybrid Ig domain (amino acids 632-764), a carbohydrate binding module (CBM) (amino acids 765-907), and a C-terminal 3-helix bundle domain (amino acids 908-955) ( Figure 8 A). A calcium ion is coordinated in the CBM domain, whose function will be discussed in the next section. The active site of the GH domain displays a highly negatively charged surface region with conserved residues ( Figure 8 B), resulting in an environment with highly conserved catalytic residues and specific endo-β-N-acetylglucosaminidase activity ( Figure 8 C). However, some loops around the active sites of the GH and CBM domains show more variable residues on the surface ( Figure 8 C). In addition, the GH and CBM domains are located at the opposite ends of the V-shaped structure, and they face the same plane ( Figure 8A) The CBM domain may promote or guide EndoSz to target IgG N-glycans by binding to a given position on the IgG protein or one of the two N-linked glycans for further N-glycan cleavage or binding.
[0269] Due to the high-resolution data, additional density at the GH domain was clearly identified with sufficient quality to allow the inventors to construct all 10 parts of the CT N-glycan ( Figure 9 A). As previously described, the structure of the GH domain of EndoSz displays a typical (α / β)8 TIM barrel fold, i.e., an 8-fold repeat of a cyclic structure consisting of β-strands / loops / α-helices. The bound complex (CT) N-glycans consist of a Manβ1-4GlcNAc disaccharide and two glycan antennae α(1-3) and α(1-6) in the (α / β)8-barrel, which are surrounded by a loop on the top barrel ( Figure 9 B). The nomenclature of CT N-glycans used in the immersion experiment is as follows Figure 9 C. The two sugar moieties of CT N-glycans, Manβ1-4GlcNAc, are located in the cavity formed by the flanking loops and the β-barrel core ( Figure 9 B). Figure 9 As shown in Figure B, the loops connecting the α-helix and β-strand can be annotated as loop 1 (β1-β2; amino acids 121-146), loop 2 (β2-α1; amino acids 152-159), loop 3 (β3-α2; amino acids 186-207), loop 4 (β4-α3; amino acids 236-248), loop 5 (β5-α4; amino acids 282-291), loop 6 (β6-α5; amino acids 305-326), loop 7 (β9-α8; amino acids 348-380), and loop 8 (β10-α9; amino acids 402-429). In addition to the Manβ1-4GlcNAc disaccharide, two glycan antennae, α(1-3) and α(1-6), interact with the flanking loops, respectively. Compared with antennae α (1-3), antennae α (1-6) are closer to the edge of the cavity formed by the GH domain and have more interactions with the GH domain ( Figure 9 B). Loops 3 and 4 of the GH domain interact with antennae α(1-6), while loops 1, 2, and 7 interact with antennae α(1-3). Figure 10 As shown in Figure 2, based on the structural comparison between EndoSz-D234M and EndoS2, changes in H3 and loop 4 lead to intrinsic structural changes. Intrinsic structural variations indeed hinder the binding of EndoSz-D234M to triantennary high-mannose triantennary N-glycans. In addition, conservation analysis of the flanking loops ( Figure 9 D) shows that loops 4, 6, 7, and 8 are the most frequently altered regions. In summary, loop 4 is thought to play an important role in substrate selectivity for biantennary glycans rather than triantennary glycans.
[0270] Comparison of the apo and holo EndoSz-D234M structures showed that loop 2 (amino acids 152-159) exhibited significant conformational changes ( Figure 11 A and B). In the apo EndoSz-D234M structure, Trp154 and Arg182 form a typical cation-π interaction. However, in the holo EndoSz-D234M structure, when the structure of loop 2 changes, Trp154 flips its side chain to interact with Man (-2) and NAG (-8) of the core disaccharide through hydrogen bonding and weak π stacking interactions, respectively. The dramatic movement of loop 2 reshapes the asymmetric groove in the GH domain to accommodate the two antennae of the CT N-glycan ( Figure 11 B). EndoSz-D234M and EndoS both have the same tryptophan residue in loop 2 (Trp154 in EndoSz), while the analog residue in EndoS2 is histidine ( Figure 11 C), which may lead to different substrate binding mechanisms. In addition, the flanking residues of Trp154 (His152, Asp153 and Thr155) are highly conserved ( Figure 11 C), highlighting the importance of Trp154 in EndoSz-D234M.
[0271] The bound CT N-glycans make primary contacts with EndoSz-D234M using the reducing end GlcNAc and the trimmed mannose core (-2, -3, and -7). Here, the first GlcNAc (-1) exhibits two conformations, A and B. Conformation A is the predominant conformation, as shown in FIG. Figure 12 A. In configuration A, the O1 atom of GlcNAc(-1) interacts with Gln304, while the O6 and O7 atoms of GlcNAc(-1) do not interact with EndoSz. In addition, the N2 atom of the acetamide group of GlcNAc(-1) has a hydrogen bond with the side chain of Met234. In configuration B ( Figure 12In (B), the O1 atom of GlcNAc(-1) has no interactions, while the O6 and O7 atoms of GlcNAc(-1) interact with Trp359 and Tyr306, respectively. The O2 and O4 atoms of Man(-2) form hydrogen bonds with the side chain of Tyr401 and the indole nitrogen of Trp154, respectively. Furthermore, the sugar ring of Man(-2) forms a π-stacking interaction with Phe151. The O2 atom of Man(-3) forms a hydrogen bond with the side chain of Arg187. The O3, O4, and O6 atoms of Man(-7) form hydrogen bonds with the indole nitrogen of Trp122, Arg120, and the side chain of Asn357, respectively. The primary hydrogen-bonding interactions between CT N-glycans and EndoSz are from the four moieties of the pentasaccharide core, which served as the substrate in the crystallization experiments—GlcNAc (-1), Man (-2), Man (-3), and Man (-7), with no GlcNAc (+1) moiety. Furthermore, GlcNAc (-8) on antennae α (1-3) interacts with Trp154 through a π-π interaction, while GlcNAc (-4) on antennae α (1-6) interacts weakly with His194 through a hydrogen bond with Arg187, resulting in minimal contact between EndoSz-D234M and the bound CT N-glycans. In summary, amino acid residues Arg 120, Trp 122, Phe 151, Trp 154, Arg 187, His 194, Met 234, Gln 304, Tyr 306, Asn 357, Trp 359, and Tyr 401 are the binding sites of EndoSz-D234M.
[0272] Example 14: Preparation of NSCT-2 (oxazoline-NSCT-N3)
[0273] NSCT-1 (235 mg, 0.097 mmol; purchased from Glytech, Inc., catalog number GT-25261; HPLC purity >90%) and triethylamine (605 μL, 0.44 mmol) were dissolved in water (10 mL) and cooled to 0°C. 2-chloro-1,3-dimethyl-1H-benzimidazol-3-ium chloride aqueous solution (1 M, 1.44 mL) was slowly added, and the resulting mixture was stirred at 0 to 5°C for 4 hours. NaOH solution (0.01 M, 1 mL) was added, and the resulting mixture was concentrated under reduced pressure. After evaporating most of the triethylamine, the mixture was eluted using Sephadex. ®The residual mixture was purified using a g-15 column. 0.01 M NaOH was used as the eluent to stabilize NSCT-2. Fractions containing the desired product were combined and freeze-dried to afford NSCT-2 (170 mg) as a white solid. 1H NMR (D2O): δ 6.10 (d, J =7.26 Hz, 1H, H1 of oxazoline), 5.24 (s, 1H, H1 of GluNac), 4.97 (s, 1H, H1 of GluNac),4.76 (s, 1H, H1 of Man), 4.64-4.60 (m, 2H, H1 of two Gals), 4.46 (s, 1H, H1 of Neu5Ac), 4.45 (s, 1H, H1 of Neu5Ac), 4.40 (s, 1H, H3 of β-Man), 4.18 (d, J = 21 Hz, 4H, H2 of two Man and two GluNacs), 3.99-3.48 (m), 2.71 (dd, J1 = 12.9 Hz, J2 = 4.2 Hz, 2H, H3eq of two Neu5Ac), 2.15-2.02 (m, 15H), 1.58 (dd, J1 = J2 = 12.2 Hz, 2H, H3ax of two Neu5Ac).
[0274]
[0275]
[0276] Example 15: Deglycosylation, transglycosylation and purification of monoclonal antibodies
[0277] 15-1. Deglycosylation of a monoclonal antibody by EndoSz-D234M to generate mAb-GlcNAc(Fuc)
[0278] Seven monoclonal antibodies were studied. R4702 is an anti-TROP2 monoclonal antibody, and Enfortumab was produced in-house; the others were commercially available. Herceptin (Roche), Perjeta (Roche), Erbitux (Meck), Rituxan (Roche), and TX05 (anti-HER2 monoclonal antibody; Tanvex) were also used. The monoclonal antibodies were deglycosylated with EndoSz-D234M in 50 mM Tris pH 7.2 at 37°C for 24-49 hours. Only antibodies with high-mannose N-glycan modifications were further treated with EndoH and incubated overnight at 25°C to completely remove the glycans and generate mAb-GlcNAc(Fuc). Complete cleavage of Fc N-glycans was analyzed by SDS-PAGE and CE-SDS.
[0279] EndoSz-D234M, part of the Glycan ADC platform, has been applied to other monoclonal antibodies for deglycosylation and transglycosylation studies, including Herceptin, Perjeta, Rituxan, Erbitux, and Ennosumab. For deglycosylation studies, the monoclonal antibodies were incubated with EndoSz-D234M at a weight ratio of 1:30 (EndoSz-D234M:mAb). For Rituxan and Ennosumab, additional EndoH was added to completely cleave high-mannose glycans. The following results show the percentage of mAb-GlcNAc(Fuc) after deglycosylation: Herceptin-GlcNAc(Fuc): 94.91%, Perjeta-GlcNAc(Fuc): 95.04%, Rituxan-GlcNAc(Fuc): 97.25%, Erbitux-GlcNAc(Fuc): 100%, and Ennosumab-GlcNAc(Fuc): 96.9%. All mAb-GlcNAc(Fuc)s were cleaved to >90% by EndoSz-D234M. For transglycosylation studies of NSCT-2, 20 or 38 equivalents of NSCT-2 were added to mAb-GlcNAc(Fuc) solutions with EndoSz-D234M and incubated at 37°C for 1.5 to 2 hours. Results from CE-SDS analysis showed that the percentages of mAb-(NSCT-di-N3)2 were: Herceptin-(NSCT-di-N3)2: 89.27%, Perjeta-(NSCT-di-N3)2: 94.62%, Rituxan-(NSCT-di-N3)2: 94.88%, Erbitux-(NSCT-di-N3)2: 93.36%, and Ennosumab-(NSCT-di-N3)2: 95.8%. These data demonstrate that EndoSz-D234M, used in the glycan ADC platform, can be applied to a variety of monoclonal antibodies.
[0280] Table 7. Deglycosylation and transglycosylation of various monoclonal antibodies
[0281]
[0282] 15-2. Transglycosylation of mAb-GlcNAc(Fuc) using oxazoline-NSCT-N3 (NSCT-2) to produce mAb-(NSCT-di-N3)2
[0283] Typically, mAb-GlcNAc(Fuc) was incubated with 20-38 equivalents of NSCT-2 at 37°C for 1.5-2 hours to produce mAb-(NSCT-di-N3)2. Transglycosylation efficiency was monitored by SDS-PAGE and CE-SDS.
[0284] 15-3. Purification of mAb-(NSCT-di-N3)2
[0285] Sodium chloride was added to the transglycosylation mixture to a final concentration of 3 M, then applied to a HiTrap Phenyl HP (Cytiva) pre-equilibrated with PBS and 3 M NaCl. Unbound contaminants were washed with 5 CV of equilibration buffer (PBS and 3 M NaCl). mAb-(NSCT-di-N3)2 was eluted using a 20 CV linear gradient from 30 to 100% elution buffer (20 mM sodium phosphate and 20% IPA, pH 7.2). The eluted fractions were applied to a prepacked HiTrap Protein A HP column (Cytiva). Impurities were washed with a two-step pH gradient (100 mM sodium citrate, pH 6.0 and pH 5.5), each 5 CV. Bound antibody was eluted using 50 mM sodium citrate, pH 3.5. The eluted fraction was immediately neutralized to a neutral pH with 1 M Tris-HCl, pH 9.0, and the buffer was exchanged to 20 mM sodium acetate, pH 5.0, using an Amicon centrifugal membrane (30 kDa cutoff, Millipore). The purified mAb-(NSCT-di-N3)2 was stored at -80°C.
[0286] Example 16: ADC preparation
[0287] 16-1. MCCA-PEG 24 Preparation of -VA-PAB-Ixinotecan (linker drug compound 1)
[0288] Step 1:
[0289] N-PM-0015 and DIPEA were added to a DMF suspension containing exinotecan mesylate at room temperature. The suspension became a clear brown solution within 5 minutes. The mixture was stirred at room temperature for 20 hours. After the reaction was complete, the reaction mixture was added to stirring TBME over 30 minutes to obtain a precipitate. After stirring for 30 minutes, the solid was collected by filtration and then dried under high vacuum to obtain crude N-PM-0016. This crude product was used in the next step without further purification.
[0290] Step 2:
[0291] A stirred suspension of N-PM-0016 in DCM was cooled to -20°C. A -10°C pre-cooled TFA solution was added to the N-PM-0016 solution over 60 minutes. The mixture was stirred at -20°C for 10 hours. After the reaction was complete, the reaction mixture was added to stirred TBME over 30 minutes to yield a precipitate. After stirring for 30 minutes, the solid was collected by filtration and subsequently dried under high vacuum to yield crude N-PM-0018. This crude product was used in the next step without further purification.
[0292] Step 3:
[0293] HATU and NMM were added to the DMF solution containing N-DT-0013. The mixture was stirred at room temperature for 2 hours. Over 30 minutes, the DMF solution containing N-PM-0018 and NMM was added to the N-DT-0013 solution at room temperature. The mixture was further stirred at room temperature for 2 hours. After the reaction was complete, the reaction mixture was added to stirred TBME over 30 minutes to obtain a precipitate. After stirring for 30 minutes, the solid was collected by filtration and purified by reverse phase chromatography (eluent: ACN / water). The pure fractions were combined and extracted with 10% MeOH / DCM to obtain N-PM-0017.
[0294]
[0295] 16-2. DBCO-PEG 24 Preparation of -VA-PAB-Ixinotecan (linker drug compound 2)
[0296] Step 1:
[0297] N-(9-Fmoc)-L-glutamate γ-tert-butyl ester monohydrate (152.2 mg, 0.35 mmol), m-PEG24-amine (380.9 mg, 0.35 mmol), and HATU (159.7 mg, 0.42 mmol) were dissolved in DMF / CHCl (1:1) (3.5 mL) at room temperature. NMM (115.8 µL, 1.05 mmol) was added. After addition, the resulting mixture was stirred at room temperature for 18 hours. The reaction solution was concentrated in vacuo at 30-35°C, and the residue was purified by flash silica gel column chromatography (CHCl / MeOH = 15 / 1 to 12 / 1) to obtain 502.5 mg of Glu-1 in 96.0% yield.
[0298]
[0299] Step 2:
[0300] Et2NH (1.38 ml) was added to a 1 / 1 CH2Cl2 / MeOH (13.8 ml) solution containing Glu-1 (413.8 mg, 0.27 mmol). The mixture was stirred at room temperature for 24 hours. After the reaction was complete, the reaction mixture was concentrated under vacuum at 30-35°C and then azeotroped with toluene (5 mL x 3) to remove excess Et2NH. The resulting material was dried under high vacuum to obtain crude Glu-2. The crude product was used in the next step without further purification.
[0301]
[0302] Step 3:
[0303] HATU (157.8 mg, 0.45 mmol) and NMM (91.6 µL, 0.83 mmol) were added to a 5.5 mL solution of crude Glu-2 (352.3 mg, 0.27 mmol) and DBCO-acid (101.4 mg, 0.33 mmol). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was concentrated in vacuo at 30-35°C, and the residue was purified via a flash silica gel column (CH2Cl2 / MeOH = 15 / 1) to yield 367.9 mg of DBCO-1, with a yield of 85.2% based on Glu-1.
[0304]
[0305] Step 4:
[0306] A solution of DBCO-1 (350.0 mg, 0.22 mmol) in CH2Cl2 (6.9 mL) was cooled to 0°C. TFA (1.8 mL) was added dropwise. The reaction mixture was stirred at 0°C for 4–6 hours. After completion of the reaction, the reaction mixture was concentrated in vacuo at 30–35°C, and the residue was purified using a flash silica gel column (CH2Cl2 / MeOH = 12 / 1) to yield 175.4 mg of DBCO-2 in a 52.0% yield.
[0307]
[0308] Step 5:
[0309] N-PM-0018 (26.5 mg, 0.031 mmol), DBCO-2 (45.9 mg, 0.031 mmol), and HATU (13.9 mg, 0.037 mmol) were dissolved in DMF (0.61 mL). NMM (10.1 µL, 0.092 mmol) was added. The reaction mixture was stirred at room temperature for 20 hours. After the reaction was complete, the resulting mixture was purified by preparative HPLC to yield 48.9 mg of DL-2 in a 71.5% yield. 1 H NMR (600 MHz, d-MeOH) δ 7.70-7.50 (m, 6H), 7.46-7.36 (m, 5H), 7.33-7.10 (m, 3H), 5.56 (d, 1H, J = 16.0 Hz), 5.36 (dd, 1H, J =16.0, 6.2 Hz), 5.33-5.29 (m, 1H), 5.27 (d, 1H, J = 20.2 Hz), 5.21-5.13 (m,2H), 5.13-5.05 (m, 2H), 4.47-4.41 (m, 1H), 4.23-4.12 (m, 2H), 3.73-3.52 (m,102H), 3.50-3.46 (m, 1H), 3.43-3.38 (m, 1H), 3.35 (s, 3H), 3.27-3.17 (m, 1H),3.15-3.07 (m, 1H), 2.81-2.70 (m, 1H), 2.37 (s, 3H), 2.36-2.24 (m, 4H), 2.45-2.40 (m, 1H), 2.24-2.00 (m, 5H), 2.00-1.78 (m, 4H) 1.43 (d, 1H, J = 7.1 Hz),1.03-0.94 (m, 9H); HRMS (ESI) m / z found [(M+2H) / 2] + , 1121.0605 C 113 H 164 FN9O 36 2+ , expected value 1121.0553.
[0310] Table 8. HPLC conditions (column: YMC-Actus Trait C18 250 x 20 mm, 5 µL, 12 nm)
[0311]
[0312]
[0313] 16-3. Use of MCCA-PEG 24 -VA-PAB-exitecan (linker drug compound 1) to prepare ADC
[0314] R4702 and TX05 monoclonal antibodies (10 mg / mL, 50 mL total) in reaction buffer (50 mM histidine, 20 mM EDTA, pH 7.0) were cooled to 12-16°C. R4702 and TX05 were treated with TCEP-HCl (2.29 mg; 0.00799 mmol) in reaction buffer (0.46 mL) at 12-16°C for 2-6 hours. To reduce the antibody solution, the loaded drug-linker N-PM-0017 (39.94 mg; 0.0183 mmol) in DMSO was added and allowed to bind at 12-16°C for 1 hour. After binding was complete, the buffer was exchanged to storage buffer (20 mM sodium acetate, pH 5.0, containing 0.1% (w / w) polysorbate 80) using a UF / DF dialysis membrane to a final concentration of 10.14 mg / mL, in 41.9 mL total. The average drug-to-antibody ratios (DAR) of the final R4702-MCCA-ADC (ADC-1) and TX05-MCCA-ADC (ADC-3) were 4.5 and 4.7, respectively, as determined by hydrophilic chromatography (HIC).
[0315] 16-4. Using DBCO-PEG 24 -VA-PAB-Ixinotecan (linker drug compound 2) to prepare ADC
[0316] DL-2 (16.35 mg) was dissolved in 1635 μL of DMSO to form a DL-2 solution. This DL-2 solution (1614 μL) was slowly added to an R4702-(NSCT-diN3)2 solution (18 mL, 5 mg / mL antibody concentration, dissolved in 20 mM NaOAc, pH 5.0) and shaken at 25°C for 6.5 hours. After binding was complete, residual DL-2 was partially removed by buffer exchange (20 mM NaOAc, pH 5.0) using a PES Amicon. The crude ADC was further purified using a HIC column to obtain ADC-2. After buffer exchange with storage buffer (20 mM NaOAc, pH 5.0), the concentration of R4702-DBCO-ADC (ADC-2) was adjusted to 5.02 mg / mL and sterilized through a ProMax™ syringe filter (PVDF, 0.22 μm). Finally, 9.9 mL of ADC-2 was produced, with a drug-to-antibody ratio (DAR) value of 3.8 (determined by HIC).
[0317] Separately, DL-2 (34.58 mg) was dissolved in 1729 μL DMSO to form a DL-2 solution. The DL-2 solution (1108 μL) was slowly added to a TX05-(NSCT-diN3)2 solution (25.33 mL, antibody concentration 4.88 mg / mL, dissolved in 20 mM NaOAc, pH 5.0) and stirred at 25°C for 6 hours. After the binding was complete, the Spectrum ® The crude ADC was further purified using a hollow fiber filtration module (buffer: 20 mM NaOAc, pH 5.0) to yield TX05-DBCO-ADC (ADC-4). ADC-4 was adjusted to approximately 5 mg / mL and sterilized by passing through a ProMax™ syringe filter (PVDF, 0.22 µm). This yielded 17.7 mL of ADC-4 (concentration: 4.53 mg / mL) with a drug-to-antibody ratio (DAR) of 3.9 (determined by HIC).
[0318] Example 17: Glycan Engineering ADC Analysis
[0319] 17-1. CE-SDS analysis to determine deglycosylation and glycosylation
[0320] CE-SDS analysis was performed under reducing conditions. A Beckman Coulter PA800Plus system equipped with a UV photodiode array detector (220 nm wavelength) was used for this test. Bare fused-silica capillaries (50 m ID × 30 cm total length) with an effective capillary length of 20 cm were flushed with 0.1 M NaOH, 0.1 M HCl, and SDS gel buffer before injection. Electrokinetic injection mode was applied at -5 kV for 20 seconds with reverse polarity, followed by -15 kV for capillary separation. The total separation time was 35 minutes. A 60 µg sample of the test article was diluted in 120 µL of sample buffer (1% SDS in dilute PBS, pH 7.0). The diluted sample was then mixed with 5 µL of 2ME and 2 µL of a 10 kDa internal standard and incubated at 65°C for 10 minutes. Finally, the sample was cooled to room temperature for CE-SDS analysis.
[0321] EndoSz-D234M exhibits high deglycosylation and transglycosylation activity against the glycan ADC platform. The inventors used R4702 and TX05 monoclonal antibodies to generate R4702-DBCO-ADC (ADC-2) and TX05-DBCO-ADC (ADC-4), using EndoSz-D234M as a model for glycan ADC production. For ADC-2, the R4702 monoclonal antibody was deglycosylated using EndoSz-D234M and the additional enzyme EndoH to cleave high-mannose glycans. The yield of deglycosylated R4702 with one GlcNAc or potential fucose residue (R4702-GlcNAc(Fuc)) was approximately 96.42%. Next, R4702-GlcNAc(Fuc) was mixed with 20 equivalents of a modified complex N-glycan (NSCT-2) at 37°C for 1.5 hours to produce R4702-(NSCT-di-N3)2. CE-SDS analysis showed that EndoSz-D234M produced 96.51% of R4702-(NSCT-di-N3)2. For ADC-4, EndoSz-D234M was used to hydrolyze the biantennary hybrid glycans on the TX05 monoclonal antibody, yielding 94.5% TX05-GlcNAc(Fuc). During the transglycosylation step, NSCT-2 was added to the TX05-GlcNAc(Fuc) and EndoSz-D234M mixture. Using 15 equivalents of NSCT-2 to TX05-GlcNAc(Fuc), 96.7% of TX05-(NSCT-di-N3)2 ( Figure 13C). These data demonstrate that EndoSz-D234M effectively produces mAb-(NSCT-di-N3)2 for glycan ADC production.
[0322] 17-2. Intact MW Analysis by LC-MS
[0323] Intact molecular weight analysis was performed using a Q-Exactive mass spectrometer (Thermo Scientific) coupled to a Vanquish HPLC system (Thermo). LC separation was performed using an Agilent PLRP-S column and a gradient program. Prior to LC-MS analysis, test samples were diluted to 0.5 mg / mL with H₂O and no further deglycosylation or reduction was performed. Molecular weight analysis was performed using a full MS scan over the m / z range of 1500–5000. Raw data were processed using Protein Deconvolution 4.0 to determine molecular weights.
[0324] The intact molecular weight analysis and reduced MS analysis results of each species are shown in Figure 2. Figure 14 As shown in Figure 2, this demonstrates the deglycosylation and transglycosylation of EndoSz-D234M. The mass difference between R4702-GlcNAc(Fuc) and R4702 indicates that the N-glycan structure on R4702-GlcNAc(Fuc) is GlcNAc(Fuc). The N-glycans of R4702 can be cleaved to form R4702-GlcNAc(Fuc), as assessed by intact molecular weight analysis. The molecular weight of R4702-(NSCT-di-N3)2 indicates that NSCT-2 was successfully transferred to R4702-GlcNAc(Fuc) by EndoSz-D234M. The molecular weight of R4702-DBCO-ADC (ADC-2) indicates that four loaded drugs are conjugated to R4702. Furthermore, reduced molecular weight analysis also indicates that the modifications are located on the heavy chain.
[0325] 17-3. Drug-Antibody Ratio (DAR) Analysis in the Presence of Human Serum Albumin (HSA)
[0326] Maleimide linkers have been widely used to conjugate antibodies to drug payloads. However, thioether linkages can undergo deconjugation via a retro-Michael reaction, leading to loss of the drug payload and reduced efficacy. Maleimide-linked drug payloads can subsequently attach to plasma thiols (such as human serum albumin (HSA)), causing off-target toxicity. 1,2 To compare changes in DAR in the presence of HSA, R4702-MCCA-ADC (ADC-1) and R4702-DBCO-ADC (ADC-2) were added to PBS containing 3% HSA to a final concentration of 500 µg / mL and incubated in a shaking water bath at 37°C for 0, 24, and 144 hours. The incubated samples were purified using an anti-idiotypic antibody coated with streptavidin magnetic beads. The mixture was gently shaken at room temperature for 1.5 hours, then washed three times with HEPES-buffered saline, twice with deionized water, and extracted with 2% formic acid. For calculation of DAR changes, the eluted ADC was reduced with TCEP (final concentration, 20 mM) at room temperature for 30 minutes to form light chain (LC) and heavy chain (HC) fragments, followed by LC-HRMS analysis. The following equation was used to calculate the average DAR:
[0327] (LC1 / (LC0+LC1)) × 2 + (HC1 / (HC0+HC1+HC2+HC3)) × 2 + (HC2 / (HC0+HC1+HC2+HC3)) × 4 + HC3 / (HC0+HC1+HC2+HC3)) × 6.
[0328] LC0 and LC1 are light chain signal reconstruction regions with 0 and 1 drug-loaded molecules, respectively, and HC0, HC1, HC2, and HC3 are heavy chain signal reconstruction regions with 0, 1, 2, and 3 drug-loaded molecules, respectively.
[0329] The deconvoluted mass spectra of ADC-1 and ADC-2 cultured in HSA for 0 and 144 hours are shown in Figure 2. Figure 15 After 144 hours (six days) of culture, loss of the maleimide linker-loaded drug of ADC-1 was observed ( Figure 15 However, no additional peak corresponding to HC2 degradation product was detected for ADC-2 ( Figure 15 B). According to the formula of DAR, a time-dependent decrease in the average DAR of ADC-1 was observed ( Figure 15 C). The results indicate that ADC-2 does not undergo debinding via a reverse Michael reaction.
[0330] 17-4. Measurement of in vitro human plasma stability
[0331] R4702-MCCA-ADC (ADC-1) and R4702-DBCO-ADC (ADC-2) were added to pooled human plasma (prepared with heparin) to a final concentration of 200 μg / mL and incubated at 37°C in a shaking water bath for 0, 24, 96, 168, and 336 hours. To determine the amount of released drug, the incubated samples were deproteinized with acetonitrile (ACN) and an internal standard (IS) and subsequently analyzed by LC-MS / MS. The percentage of the theoretical maximum value was calculated as the amount of released drug / theoretical amount of drug loaded in the ADC DAR4 × 100%.
[0332] The stability of ADC-1 and ADC-2 in human plasma was monitored for 14 days at 37°C. Based on the ratio of released loaded drug to the theoretical loaded drug amount (DAR 4), the percentage of loaded drug released for ADC-1 and ADC-2 increased over time, as shown in Figure 4. Figure 16 As shown in Figure 3, after 14 days of incubation in human plasma, the percentage of drug released from ADC-1 and ADC-2 was approximately 2.2% and 0.6%, respectively. This result indicates that ADC-2 releases less drug than ADC-1 in human plasma.
[0333] Example 18: In vitro cytotoxicity analysis of glycan-engineered ADCs
[0334] Tumor cells (2 x 10 3 cells / well) were seeded in 96-well plates and treated with ADC for 6 days. ® Buffer was added to the lyophilized CellTiter-Glo ® CellTiter-Glo ® Reagent (Catalog No. G7572, Promega). After 6 days of treatment, the reconstituted CellTiter-Glo ® The reagent was added to the culture medium at a 1:1 ratio of cells. The plate was placed on an orbital shaker for 2 minutes to induce cell lysis, followed by incubation at room temperature for 10 minutes, after which the luminescence signal was recorded using a luminometer. The viability of each treated sample was compared to that of the untreated control. The IC value of each ADC was calculated using Prism. 50 .
[0335] The in vitro efficacy of the ADC was evaluated in several tumor cell lines using cytotoxicity assays ( Figure 17 IC values of R4702-MCCA-ADC (ADC-1) and R4702-DBCO-ADC (ADC-2) in NCI-H1975-C797S lung cancer cells 50In DU145 prostate cancer cells, the IC values of ADC-1 were similar (77.64 and 98.42 nM). 50 The results were slightly lower than those of ADC-2 (140.3 and 261.1 nM). Similar results were observed in TX05-MCCA-ADC (ADC-3) and TX05-DBCO-ADC (ADC-4). In NCI-N87 gastric cells, the IC 50 Slightly lower than ADC-4 (2.904 and 5.515 nM), while the IC values of ADC-3 and ADC-4 in Capan-1 pancreatic cancer cells were 50 These data indicate that the site-specific glycan-conjugated ADCs (ADC-2 and ADC-4) exhibit similar or slightly lower cytotoxicity than the cysteine-conjugated ADCs (ADC-1 and ADC-3).
[0336] Example 19: In vivo efficacy study of glycan-engineered ADCs in NCI-H1975-C797S lung cancer cell-derived xenografts
[0337] The in vivo efficacy of R4702-MCCA-ADC (ADC-1) and R4702-DBCO-ADC (ADC-2) was evaluated using NCI-H1975-C797 human lung cancer cells. Female BALB / c nude mice were housed under specific pathogen-free conditions. Mice were acclimated for at least 3 days prior to the start of the study. Food (LabDiet 5010, PMI, USA) and water (sterile RO water) were provided ad libitum throughout the study. All animal studies were approved by the Institutional Animal Care and Use Committee of the Laboratory Animal Center, Taiwan Province, China.
[0338] The tumor cells were washed and resuspended in PBS. Live cells (1 x 10 7 cells / mouse) were mixed with the same volume of Matrigel (Catalog No. 356234, BD) and injected subcutaneously into the right flank of female BALB / c nude mice (200 µL / mouse). 3Tumor-bearing mice were divided into different groups. ADC or vehicle control was treated with a single dose injected into the tail vein. The day of administration was designated as day 1. Tumor growth and mouse body weight were monitored twice a week until day 22. The efficacy of the ADC was evaluated by tumor growth inhibition (TGI). TGI was calculated using the following formula: TGI (%) = [1-(Ti-T1) / (Ci-C1)] × 100%. Ti and Ci represent the average tumor volumes of the treated and vehicle groups at the end of the study (day 22), while T1 and C1 represent the average tumor volumes of the treated and vehicle groups at the start of the test item administration. The experimental design, test articles, dose concentrations, dosing frequency, route of administration, and number of animals are listed in Table 9.
[0339] Table 9. Dosage regimen and sampling
[0340]
[0341] The in vivo efficacy of ADC-1 and ADC-2 was evaluated using the NCI-H1975-C797S lung cancer xenograft mouse model. NCI-H1975-C797S cancer cells were implanted into BALB / c nude mice. Tumor growth was recorded throughout the study. Figure 18 A) and mouse body weight ( Figure 18 B). Antitumor efficacy was assessed using tumor growth inhibition (TGI). TGI was calculated by comparing treated groups with the vehicle control group based on tumor size on days 1 and 22. Both ADC-1 and ADC-2 exhibited similarly excellent antitumor efficacy at a dose of 10 mg / kg (TGI > 100%, P = 0.24). At a dose of 3 mg / kg, ADC-1 and ADC-2 exhibited similar partial inhibition of tumor growth (TGI: 42.7% and 66.2%, respectively, P = 0.37). These results demonstrate that site-specific glycan-conjugated ADC-2 exhibits similar antitumor efficacy as cysteine-conjugated ADC-1.
[0342] The present invention discloses selected glycosynthase variants that exhibit excellent transglycosylation activity towards a broad range of N-glycans, including high mannose, hybrid, and complex types.
[0343] In preferred embodiments, the high mannose, hybrid, and complex N-glycans are in the active oxazoline form.
[0344] In some embodiments, the high mannose N-glycan described herein is selected from the group consisting of Man3GlcNAc, Man5GlcNAc, Man6GlcNAc, Man7GlcNAc, Man8GlcNAc, and Man9GlcNAc. In a preferred embodiment, the high mannose N-glycan is Man5GlcNAc.
[0345] In some embodiments, the hybrid N-glycans described herein comprise at least one α-2,6- or α-2,3-terminal sialic acid on the α-1,3 arm, wherein the α-1,6 arm contains a trimannosyl residue.
[0346] In some embodiments, the hybrid N-glycans described herein comprise at least one terminal galactose on the α-1,3 arm, wherein the α-1,6 arm contains a trimannose residue.
[0347] In some embodiments, the hybrid N-glycans described herein comprise at least one terminal GlcNAc on the α-1,3 arm, wherein the α-1,6 arm contains a trimannosyl residue.
[0348] In some embodiments, the complex glycans are bi-, tri-, and tetra-antennary complexes.
[0349] In some embodiments, the biantennary complex N-glycans described herein comprise at least one α-2,6 or α-2,3 terminal sialic acid. In preferred embodiments, the N-glycans comprise two α-2,6 and / or α-2,3 terminal sialic acids.
[0350] In some embodiments, the biantennary complex N-glycans described herein comprise at least one terminal galactose or GlcNAc. In preferred embodiments, the N-glycans comprise two terminal galactoses and / or GlcNAcs.
[0351] In some embodiments, the biantennary complex N-glycans described herein comprise at least one α-1,2-fucose. In preferred embodiments, the N-glycans comprise two α-1,2-fucoses.
[0352] In some embodiments, the biantennary complex N-glycans described herein comprise bisected α-1,3-fucose. In preferred embodiments, the N-glycans comprise two α-1,3-fucoses.
[0353] In some embodiments, the biantennary complex N-glycans described herein comprise a bisecting GlcNAc.
[0354] In some embodiments, the biantennary complex N-glycans described herein comprise at least one LacNAc repeating unit. In preferred embodiments, the N-glycans comprise two LacNAc repeating units.
[0355] In some embodiments, the triantennary complex N-glycans described herein comprise at least one α-2,6 or α-2,3 terminal sialic acid. In preferred embodiments, the N-glycans comprise three α-2,6 and / or α-2,3 terminal sialic acids.
[0356] In some embodiments, the triantennary complex N-glycans described herein comprise at least one terminal galactose or GlcNAc. In preferred embodiments, the N-glycans comprise three terminal galactose and / or GlcNAc.
[0357] In some embodiments, complex glycans are bi- and triantennary complexes comprising asymmetric antennae on the α-1,3 or α-1,6 arms.
[0358] In some embodiments, the hybrid, bi- and triantennary complex N-glycans described herein comprise α-2,6 or α-2,3 terminal sialic acids. In other embodiments, the hybrid, bi- and triantennary complex N-glycans comprise α-2,6 terminal sialic acids.
[0359] While the present invention has been described with respect to a limited number of embodiments, those skilled in the art having benefit of this invention will appreciate that other embodiments can be devised which do not depart from the scope of the invention as disclosed herein. Accordingly, the scope of the present invention is to be limited solely by the appended claims.
[0360] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications and patents specifically mentioned herein are incorporated by reference for all purposes, including the chemicals, cell lines, vectors, animals, instruments, statistical analyses, and methods reported in the publications that describe and disclose possible use in conjunction with the present invention. All references cited in this specification are to be considered indicative of the state of the art. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such disclosures by virtue of prior invention.
[0361] Before describing the materials and methods of the present invention, it should be understood that the present invention is not limited to the specific methods, protocols, materials, and reagents described, as these may vary. It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention, which is limited only by the appended claims.
[0362] Additional Embodiments
[0363] Example 1: A method for preparing an engineered biocomplex, comprising contacting a biomolecule with a glycosynthase and a modified glycan, thereby obtaining a first engineered biocomplex, wherein the biomolecule further comprises an N-linked initial glycan, wherein the glycosynthase comprises SEQ ID NO: 1 or SEQ ID NO: 2, and the glycosynthase comprises a mutation within residues 176-186, residues 225-237, or residues 273-289 of the sequence of SEQ ID NO: 1, or within residues 178-188, residues 227-239, or residues 275-291 of the sequence of SEQ ID NO: 2, wherein the modified glycan comprises a substrate moiety and a first reactive moiety, wherein the substrate moiety is configured to react with the glycosynthase, and wherein the biomolecule comprises an antibody or antigen-binding fragment thereof, a protein, or a peptide.
[0364] Embodiment 2: The method of embodiment 1, wherein the biomolecule comprises an antibody or an antigen-binding fragment thereof, and the N-linked initial glycan is located in the constant region of the antibody or antigen-binding fragment.
[0365] Embodiment 3: The method of embodiment 1 or embodiment 2, wherein the biomolecule comprises an antibody or an antigen-binding fragment thereof, and the N-linked initial glycan is located in the Fc region of the antibody or antigen-binding fragment.
[0366] Example 4: The method of Example 3, wherein the N-linked initial glycan is located at N297 of the Fc region.
[0367] Embodiment 5: The method of any one of embodiments 1 to 4, wherein contacting the biomolecule with a glycosynthase and a modified glycan comprises coupling the modified glycan to an N-linked initial glycan.
[0368] Embodiment 6: The method of any one of embodiments 1 to 5, wherein the substrate moiety of the modified polysaccharide is an oxazoline moiety.
[0369] Embodiment 7. The method of any one of Embodiments 1-6, wherein the first reactive moiety is configured to react with the unsaturated moiety in a biorthogonal reaction.
[0370] Example 8: The method of Example 7, wherein the biorthogonal reaction is copper-free click chemistry.
[0371] Embodiment 9. The method of any one of Embodiments 1-8, wherein the first reactive moiety comprises an azide group.
[0372] Embodiment 10: The method of any one of embodiments 1 to 9, wherein the modified glycan is a PEGylated glycan modified with a first polyethylene glycol (PEG) moiety.
[0373] Embodiment 11: The method of embodiment 10, wherein the first polyethylene glycol (PEG) moiety comprises 2 to 72 OCH2CH2 subunits.
[0374] Embodiment 12: The method of embodiment 10 or embodiment 11, wherein the first PEG moiety is a linear PEG, a branched PEG, or a star PEG.
[0375] Embodiment 13: The method of any one of embodiments 10 to 12, wherein the first end of the PEGylated polysaccharide is covalently coupled to the first reactive moiety.
[0376] Embodiment 14: The method of embodiment 13, wherein the first reactive moiety is covalently coupled to the PEG moiety.
[0377] Embodiment 15: The method of any one of embodiments 10 to 14, wherein the second end of the PEGylated polysaccharide is covalently coupled to a substrate moiety.
[0378] Embodiment 16: The method of embodiment 15, wherein the substrate moiety is covalently coupled to the ethylene glycol portion of the PEGylated polysaccharide.
[0379] Embodiment 17: The method of any one of embodiments 1 to 16, wherein the modified polysaccharide is a polysaccharide oxazoline.
[0380] Example 18: The method of Example 17, wherein the polysaccharide oxazoline comprises the formula:
[0381] ,
[0382] where R 1 is -H or N-acetylglucosamine linked via a β-1,4 bond, R 2 and R 3 are the same or different and are independently selected from the group consisting of:
[0383] .
[0384] Embodiment 19: The method of any one of embodiments 1 to 18, wherein contacting the biomolecule with a glycosynthase and a modified glycan comprises: removing the N-linked original glycan of the biomolecule to obtain a deglycosylated biomolecule; and contacting the deglycosylated biomolecule with a glycosynthase in the presence of the modified glycan.
[0385] Embodiment 20: The method of embodiment 19, wherein removing N-linked original glycans of the biomolecule to obtain the deglycosylated biomolecule comprises: mixing the glycosynthase and the biomolecule in the absence of modified glycans at a ratio of 1:500 to 1:1, 1:500 to 1:10, 1:500 to 1:20, 1:500 to 1:30, 1:500 to 1:50, 1:100 to 1:1, 1:100 to 1:10, 1:100 to 1:20, 1:100 to 1:30, 1:100 to 1:50, 1:50 to 1:1, 1:50 to 1:10, 1:50 to 1:20, or 1:50 to 1:30.
[0386] Embodiment 21: The method of embodiment 19 or embodiment 20, wherein the deglycosylated biomolecule comprises a GlcNAc monosaccharide.
[0387] Example 22: The method of Example 21, wherein the GlcNAc monosaccharide is fucosylated.
[0388] Embodiment 23: The method of embodiment 21, wherein the GlcNAc monosaccharide is non-fucosylated.
[0389] Embodiment 24: The method of any one of embodiments 1 to 23, wherein contacting the biomolecule with a glycosynthase and a modified glycan comprises contacting a plurality of biomolecules with a glycosynthase and a modified glycan, thereby obtaining a plurality of first engineered biocomplexes; wherein the plurality of first engineered biocomplexes are at least or greater than 80%, 85%, 90%, 95%, or 99% isomorphic.
[0390] Embodiment 25: The method of any one of embodiments 1 to 24, further comprising contacting the first engineered biocomplex with a loaded drug complex or a salt thereof, thereby obtaining a second biocomplex, wherein the loaded drug complex comprises the following formula:
[0391] CLD;
[0392] wherein C is a second reactive moiety configured to react with the first reactive moiety of the modified glycan in a biorthogonal reaction; wherein L is a linker unit comprising a hydrophilic moiety; and wherein D is a cargo drug.
[0393] Embodiment 26. The method of Embodiment 25, wherein the second reactive moiety comprises an unsaturated moiety (eg, an alkene moiety or an alkyne moiety).
[0394] Embodiment 27: The method of Embodiment 25 or Embodiment 26, wherein the second reactive moiety is a non-natural and non-perturbative chemical group.
[0395] Embodiment 28: The method of any one of Embodiments 25 to 27, wherein the second reactive moiety is dibenzocyclooctynyl (DBCO), bicyclononyne (BCN), cycloalkyne, maleimide, α,β-unsaturated carbonyl, or sulfonylpyrimidine.
[0396] Embodiment 29: The method of any one of embodiments 25 to 28, wherein the hydrophilic moiety comprises a second polyethylene glycol (PEG) moiety.
[0397] Embodiment 30: The method of Embodiment 29, wherein the second PEG moiety comprises 2 to 72 OCH2CH2 subunits.
[0398] Embodiment 31: The method of embodiment 29 or embodiment 30, wherein the second PEG moiety is a linear PEG, a branched PEG, or a star PEG.
[0399] Embodiment 32: The method of any one of embodiments 25 to 31, wherein the linker unit further comprises a cleavable moiety.
[0400] Example 33: The method of Example 32, wherein the cleavable moiety is a protease-sensitive peptide or a glycosidase-sensitive sugar unit.
[0401] Embodiment 34: The method of any one of Embodiments 25 to 33, wherein the linker unit further comprises a spacer containing an aromatic group or an aminomethylene group.
[0402] Embodiment 35: The method of any one of Embodiments 25 to 34, wherein the linker unit comprises the formula:
[0403] ,
[0404] wherein (PEG)m is a PEG moiety, and m is an integer selected from 2 to 72, Q SP is a spacer containing an aromatic group or an aminomethylene group, Q CL is a cleavable portion and is configured to be connected to a loaded drug, P is an adapter unit configured to be linked to the second reactive moiety.
[0405] Embodiment 36: The method of embodiment 35, wherein the PEG moiety comprises the formula:
[0406] ,
[0407] The wavy line indicates the P The site of covalent attachment, where R 20is a PEG attachment unit, wherein the PEG attachment unit is -C(O)-, -O-, -S-, -NH-, -C(O)O-, alkyl-C(O)-NH-, alkyl-NH-C(O)-, alkyl-CO2-, alkyl-S-, or , where R 21 PEG capping unit; wherein the PEG capping unit is selected from H, SO3H, PO3H2, sugar derivatives, C1-C 10 (hetero)alkyl, C3-C 10 (Hetero)cycloalkyl, C2-C 10 Alkyl-NH2, C1-C 10 Alkyl-COOH, C2-C 10 Alkyl-NH (C1-C3 alkyl), C2-C 10 Alkyl-N(C1-C3 alkyl)2, wherein n is selected from 8 to 72.
[0408] Embodiment 37: The method of any one of embodiments 25 to 36, wherein the linker unit has the following structure:
[0409] .
[0410] Embodiment 38: The method of any one of embodiments 25 to 37, wherein the loaded drug is a therapeutic agent.
[0411] Embodiment 39: The method of embodiment 38, wherein the therapeutic agent comprises an antiviral agent, an antibacterial agent, an immunomodulatory agent, an immunostimulatory agent, an antitumor agent, or a combination thereof.
[0412] Embodiment 40: The method of any one of embodiments 25 to 39, wherein the loading drug comprises a toxin, a cytokine, a growth factor, a radionuclide, a hormone, or a combination thereof.
[0413] Embodiment 41: The method of any one of embodiments 25 to 40, wherein the loaded drug is selected from pyrrolobenzodiazepines (e.g., PBD), auristatins (e.g., MMAE, MMAF), maytansines (e.g., maytansine, DM1, DM4, DM21), duocarmycins, nicotinamide phosphoribosyltransferase (NAMPT) inhibitors, terpyrrolecins, enediynes (e.g., calicheamicin), anthracycline derivatives (PNU) (e.g., doxorubicin), pyrrolyl spindle actuator protein (KSP) inhibitors, cryptophycins, drug efflux pump inhibitors, sandrocins, camptothecins (e.g., α-camptothecins), and camptothecins (e.g., exicnotecan, derutin).
[0414] Embodiment 42: The method of any one of embodiments 25 to 41, wherein the loaded drug complex comprises the following structure:
[0415] or
[0416] .
[0417] Embodiment 43: The method of any one of embodiments 1 to 42, wherein the mutation comprises a substitution at residue 183, 232, 234, 280, 281 or 282 of SEQ ID NO: 1 or at residue 181, 230, 232, 278, 279 or 280 of SEQ ID NO: 2.
[0418] Embodiment 44: The method of embodiment 43, wherein the mutation comprises: D234E, D234R, D234H, D234M, D234V, D234L, D234F, D234T, D234Q, T183Q, D232Q, D280Q, S281Q, T282Q in SEQ ID NO: 1, or D232E, D232R, D232H, D232M, D232V, D232L, D232F, D232T, D232Q, T181Q, D230Q, D278Q, S279Q, T280Q in SEQ ID NO: 2.
[0419] Example 45: The method of any one of Examples 1 to 44, wherein the biomolecule is an anti-Globo series antigen antibody or an antigen-binding fragment thereof, an anti-HER2 antibody or an antigen-binding fragment thereof, an anti-CD20 antibody or an antigen-binding fragment thereof, an anti-TNF-α antibody or an antigen-binding fragment thereof, an anti-PD-1 antibody or an antigen-binding fragment thereof, an anti-PD-L1 antibody or an antigen-binding fragment thereof, an anti-TROP2 antibody or an antigen-binding fragment thereof, an anti-EGFR antibody or an antigen-binding fragment thereof, an anti-Nectin-4 antibody or an antigen-binding fragment thereof, an anti-HER3 antibody or an antigen-binding fragment thereof, an anti-cMet antibody or an antigen-binding fragment thereof, an anti-B7H3 antibody or an antigen-binding fragment thereof, an anti-B7H4 antibody or an antigen-binding fragment thereof, an anti-VEGF antibody or an antigen-binding fragment thereof, an anti-claudin 18.2 antibody or an antigen-binding fragment thereof, an anti-Sirp-α antibody or an antigen-binding fragment thereof, a TROP2×HER2 bispecific antibody, or a combination thereof.
[0420] Example 46: The method of Example 45, wherein the Globo series antigens include Globo H, stage-specific embryonic antigen 4 (SSEA-4) or stage-specific embryonic antigen 3 (SSEA-3).
[0421] Embodiment 47: The method of any one of embodiments 1 to 46, wherein the biomolecule is selected from Herceptin (trastuzumab), TX05 (trastuzumab biosimilar), Perjeta (pertuzumab), Erbitux (cetuximab), Rituxan (rituximab), Vectibix (panitumumab), Humira (adalimumab), Keytruda (pembrolizumab), Bavencio (avelumab), and BSI04702 (anti-TROP2 antibody).
[0422] Example 48: An engineered biocomplex comprising: a biomolecule; and a modified glycan coupled to the biomolecule, wherein the modified glycan comprises (i) a first polyethylene glycol (PEG) moiety, and (ii) a first reactive moiety or a product thereof from a biorthogonal reaction; wherein the biomolecule comprises an antibody or antigen-binding fragment thereof, a protein, or a peptide.
[0423] Example 49: The engineered biocomplex of Example 48, wherein the biomolecule comprises an antibody or an antigen-binding fragment thereof, and the modified glycan is coupled to the antibody or the antigen-binding fragment thereof at its Fc region.
[0424] Example 50: The engineered biocomplex of Example 49, wherein the modified glycan is coupled to the antibody or antigen-binding fragment thereof at position N297 of the Fc region.
[0425] Example 51: The engineered biocomplex of Example 50, wherein the modified glycan is coupled to the GlcNAc monosaccharide at the N297 position of the Fc region.
[0426] Example 52: The engineered biocomplex of Example 51, wherein the GlcNAc monosaccharide is fucosylated.
[0427] Example 53: The engineered biocomplex of Example 51, wherein the GlcNAc monosaccharide is non-fucosylated.
[0428] Embodiment 54: The engineered biocomplex of any one of embodiments 48 to 53, wherein the first reactive moiety is configured to interact with the alkyne moiety in a biorthogonal reaction.
[0429] Embodiment 55: The engineered biocomplex of any one of embodiments 48 to 54, wherein the biorthogonal reaction is copper-free click chemistry.
[0430] Embodiment 56: The engineered biocomplex of any one of Embodiments 48 to 55, wherein the first reactive moiety comprises an azide group.
[0431] Embodiment 57: The engineered biocomplex of any one of embodiments 48 to 56, wherein the first PEG moiety comprises 2 to 72 (OCH2CH2) subunits.
[0432] Embodiment 58: The engineered biocomplex of embodiment 57, wherein the first PEG moiety is a linear PEG, a branched PEG, or a star PEG.
[0433] Embodiment 59: The engineered biocomplex of any one of embodiments 48 to 58, wherein the modified glycan is a first modified glycan, and the engineered biocomplex further comprises a first drug-carrying moiety, wherein the first drug-carrying moiety is coupled to the first modified glycan via a product moiety thereof.
[0434] Example 60: The engineered biocomplex of Example 59, wherein the first drug-loaded moiety has the formula:
[0435] -LD;
[0436] Wherein L is a linker unit comprising a hydrophilic portion and connected to the product portion, and D is a loaded drug.
[0437] Embodiment 61: The engineered biocomplex of Embodiment 59 or Embodiment 60, wherein the product moiety comprises a triazole moiety.
[0438] Example 62: The engineered biocomplex of Example 61, wherein the product moiety comprises a DBCO-derived moiety or a maleimide-derived moiety.
[0439] Embodiment 63: The engineered biocomplex of any one of embodiments 60 to 62, wherein the hydrophilic portion comprises a second polyethylene glycol (PEG) moiety.
[0440] Embodiment 64: The engineered biocomplex of embodiment 63, wherein the second PEG moiety comprises 2 to 72 OCH2CH2 subunits.
[0441] Embodiment 65: The engineered biocomplex of embodiment 63 or embodiment 64, wherein the second PEG moiety is a linear PEG, a branched PEG, or a star PEG.
[0442] Embodiment 66: The engineered biocomplex of any one of embodiments 60 to 65, wherein the linker unit further comprises a cleavable moiety.
[0443] Example 67: The engineered biocomplex of Example 66, wherein the cleavable moiety is a protease-sensitive peptide or a glycosidase-sensitive sugar unit.
[0444] Embodiment 68: The engineered biocomplex of any one of embodiments 60 to 67, wherein the linker unit further comprises a spacer containing an aromatic group or an aminomethylene group.
[0445] Embodiment 69: The engineered biocomplex of any one of embodiments 60 to 68, wherein the linker unit comprises the formula:
[0446] ,
[0447] wherein (PEG)m is a PEG moiety, and m is an integer selected from 2 to 72, Q SP is a spacer containing an aromatic group or an aminomethylene group, Q CL is a cleavable portion connected to the loaded drug, L P It is the junction subunit connected to the product part.
[0448] Example 70: The engineered biocomplex of Example 69, wherein the PEG moiety comprises the formula:
[0449] ,
[0450] The wavy line indicates the P The site of covalent attachment, where R 20 is a PEG attachment unit, wherein the PEG attachment unit is -C(O)-, -O-, -S-, -NH-, -C(O)O-, alkyl-C(O)-NH-, alkyl-NH-C(O)-, alkyl-CO2-, alkyl-S-, or , where R 21 PEG capping unit; wherein the PEG capping unit is selected from H, SO3H, PO3H2, sugar derivatives, C1-C 10 (hetero)alkyl, C3-C 10 (Hetero)cycloalkyl, C2-C 10 Alkyl-NH2, C1-C 10 Alkyl-COOH, C2-C 10 Alkyl-NH (C1-C3 alkyl), C2-C 10 Alkyl-N(C1-C3 alkyl)2, wherein n is selected from 8 to 72.
[0451] Embodiment 71: The engineered biocomplex of any one of embodiments 60 to 70, wherein the linker unit has the following structure:
[0452] .
[0453] Embodiment 72: The engineered biocomplex of any one of embodiments 59 to 71, wherein the loaded drug is a therapeutic agent.
[0454] Embodiment 73: The engineered biocomplex of embodiment 72, wherein the therapeutic agent comprises an antiviral agent, an antibacterial agent, an immunomodulatory agent, an immunostimulatory agent, an anti-tumor agent, a chemotherapeutic agent, or a combination thereof.
[0455] Embodiment 74: The engineered biocomplex of any one of embodiments 59 to 73, wherein the loaded drug comprises a toxin, a cytokine, a growth factor, a radionuclide, a hormone, or a combination thereof.
[0456] Embodiment 75: The engineered biocomplex of any one of embodiments 59 to 74, wherein the loaded drug is selected from pyrrolobenzodiazepines (e.g., PBD), auristatins (e.g., MMAE, MMAF), maytansines (e.g., maytansine, DM1, DM4, DM21), duocarmycins, nicotinamide phosphoribosyltransferase (NAMPT) inhibitors, terpyrines, enediynes (e.g., calicheamicin), anthracycline derivatives (PNU) (e.g., doxorubicin), pyrrolyl spindle actuator protein (KSP) inhibitors, cryptophycins, drug efflux pump inhibitors, sandrocins, ectocin (e.g., α-ectocin), and camptothecins (e.g., exicnotecan, derutin).
[0457] Embodiment 76: The engineered biocomplex of any one of embodiments 59 to 75, further comprising a second drug-loaded moiety, wherein the second drug-loaded moiety is coupled to the engineered biocomplex via a second modified glycan.
[0458] Example 77: The engineered biocomplex of Example 76, wherein the first drug-loaded moiety is different from the second drug-loaded moiety.
[0459] Embodiment 78: The engineered biocomplex of embodiment 76 or embodiment 77, wherein the first drug-loaded portion comprises a first drug-loaded portion (D1) and the second drug-loaded portion comprises a second drug-loaded portion (D2), and the first drug-loaded portion (D1) and the second drug-loaded portion (D2) are different.
[0460] Embodiment 79: The engineered biocomplex of any one of embodiments 76 to 78, wherein the first modified glycan is different from the second modified glycan.
[0461] Embodiment 80: The engineered biocomplex of any one of Embodiments 48 to 79, wherein the biomolecule is an anti-Globo series antigen antibody or an antigen-binding fragment thereof, an anti-HER2 antibody or an antigen-binding fragment thereof, an anti-CD20 antibody or an antigen-binding fragment thereof, an anti-TNF-α antibody or an antigen-binding fragment thereof, an anti-PD-1 antibody or an antigen-binding fragment thereof, an anti-PD-L1 antibody or an antigen-binding fragment thereof, an anti-TROP2 antibody or an antigen-binding fragment thereof, an anti-EGFR antibody or an antigen-binding fragment thereof, an anti-Nectin-4 antibody or an antigen-binding fragment thereof, an anti-HER3 antibody or an antigen-binding fragment thereof, an anti-cMet antibody or an antigen-binding fragment thereof, an anti-B7H3 antibody or an antigen-binding fragment thereof, an anti-B7H4 antibody or an antigen-binding fragment thereof, an anti-VEGF antibody or an antigen-binding fragment thereof, an anti-claudin 18.2 antibody or an antigen-binding fragment thereof, an anti-Sirp-α antibody or an antigen-binding fragment thereof, a TROP2×HER2 bispecific antibody, or a combination thereof.
[0462] Example 81: The engineered biocomplex of Example 80, wherein the Globo series antigens include Globo H, stage-specific embryonic antigen 4 (SSEA-4), or stage-specific embryonic antigen 3 (SSEA-3).
[0463] Embodiment 82: The engineered biocomplex of any one of embodiments 48 to 81, wherein the biomolecule is selected from Herceptin (trastuzumab), TX05 (trastuzumab biosimilar), Perjeta (pertuzumab), Erbitux (cetuximab), Rituxan (rituximab), Vectibix (panitumumab), Humira (adalimumab), Keytruda (pembrolizumab), Bavencio (avelumab), and BSI04702 (anti-TROP2 antibody).
[0464] Embodiment 83: The engineered biocomplex of any one of embodiments 48 to 82, prepared by the method of any one of embodiments 1 to 46.
[0465] Embodiment 84: A plurality of engineered biological complexes, each of the engineered biological complexes of any one of embodiments 48 to 83, wherein the plurality of engineered biological complexes are at least or greater than 80%, 85%, 90%, 95%, or 99% homologous.
[0466] Example 85: A pharmaceutical composition comprising a plurality of engineered biological complexes according to Example 84 and a pharmaceutically acceptable carrier.
[0467] Example 86: A method for treating cancer, comprising administering an effective amount of the pharmaceutical composition of Example 85 to a patient in need thereof.
[0468] Example 87: The method of Example 86, wherein the cancer is a cancer expressing Globo series antigens, HER2, TROP2, Nectin-4, HER3, cMet, B7H3, B7H4, VEGF, Claudin 18.2, or Sirp-α.
[0469] Example 88: The method of Example 86 or Example 87, wherein the cancer is selected from the group consisting of sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head and neck cancer, nasopharyngeal cancer, esophageal cancer, gastric cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervical cancer, endometrial cancer, ovarian cancer, testicular cancer, cheek cancer, oropharyngeal cancer, laryngeal cancer, prostate cancer, thyroid cancer and oral cancer.
[0470] Example 89: A therapeutic complex comprising the formula:
[0471] CLD;
[0472] wherein C is a reactive moiety configured to react in a biorthogonal reaction; wherein L is a linker unit comprising a hydrophilic moiety, a cleavable moiety, and a spacer; and wherein D is a therapeutic agent.
[0473] Embodiment 90. The therapeutic complex of Embodiment 89, wherein the reactive moiety comprises an unsaturated moiety.
[0474] Embodiment 91: The therapeutic complex of Embodiment 90, wherein the unsaturated moiety is an alkene moiety or an alkyne moiety.
[0475] Embodiment 92: The therapeutic complex of any one of Embodiments 89 to 91, wherein the reactive moiety is a non-natural and non-perturbative chemical group.
[0476] Embodiment 93: The therapeutic complex of any one of Embodiments 89 to 92, wherein the reactive moiety is dibenzocyclooctynyl (DBCO), bicyclononyne (BCN), cycloalkyne, maleimide, α,β-unsaturated carbonyl, or sulfonylpyrimidine.
[0477] Embodiment 94: The therapeutic complex of any one of Embodiments 89 to 93, wherein the hydrophilic portion comprises a polyethylene glycol (PEG) portion.
[0478] Embodiment 95: The therapeutic complex of Embodiment 94, wherein the PEG moiety comprises 2 to 72 OCH2CH2 subunits.
[0479] Embodiment 96: The therapeutic complex of embodiment 94 or embodiment 95, wherein the first PEG moiety is a linear PEG, a branched PEG, or a star PEG.
[0480] Embodiment 97: The therapeutic complex of any one of embodiments 89 to 96, wherein the cleavable moiety is a protease-sensitive peptide comprising Val-Cit, Val-Ala, Phe-Lys, Glu-Val-Cit, Glu-Val-Ala, Glu-Gly-Cit, Glu-Gly-Ala, Gly-Gly-Phe-Gly, Gly-Gly-Val-Cit, Gly-Gly-Val-Ala; or a glycosidase-sensitive sugar unit comprising glucuronic acid, iduronic acid, or galactose.
[0481] Embodiment 98: The therapeutic complex of any one of Embodiments 89 to 97, wherein the spacer comprises an aromatic group including 1,4-phenyl, 2,5-pyridyl, 3,6-pyridyl, 2,5-pyrimidinyl, 2,5-thienyl, or aminomethylene (eg, -NH-CH2-).
[0482] Embodiment 99: The therapeutic complex of any one of Embodiments 89 to 98, wherein the linker unit comprises the formula:
[0483] ,
[0484] wherein (PEG)m is a PEG moiety, and m is an integer selected from 2 to 72, Q SP is a spacer containing an aromatic group or an aminomethylene group, Q CL is a cleavable portion and is configured to be connected to a loaded drug, P is an adapter unit configured to be linked to the second reactive moiety.
[0485] Embodiment 100: The therapeutic complex of embodiment 99, wherein the PEG moiety comprises the formula:
[0486] ,
[0487] The wavy line indicates the P The site of covalent attachment, where R 20 is a PEG attachment unit, wherein the PEG attachment unit is -C(O)-, -O-, -S-, -NH-, -C(O)O-, alkyl-C(O)-NH-, alkyl-NH-C(O)-, alkyl-CO2-, alkyl-S-, or , where R 21 PEG capping unit; wherein the PEG capping unit is selected from H, SO3H, PO3H2, sugar derivatives, C1-C 10(hetero)alkyl, C3-C 10 (Hetero)cycloalkyl, C2-C 10 Alkyl-NH2, C1-C 10 Alkyl-COOH, C2-C 10 Alkyl-NH (C1-C3 alkyl), C2-C 10 Alkyl-N(C1-C3 alkyl)2, wherein n is selected from 8 to 72.
[0488] Embodiment 101: The therapeutic complex of any one of Embodiments 89 to 100, wherein the linker unit has the following structure:
[0489] .
[0490] Embodiment 102: The therapeutic complex of any one of Embodiments 89 to 111, wherein the therapeutic agent comprises a toxin, a cytokine, a growth factor, a radionuclide, a hormone, an antiviral agent, an antibacterial agent, an immunomodulator, an immunostimulator, an anti-tumor agent, or a combination thereof.
[0491] Embodiment 103: The therapeutic complex of any one of Embodiments 89 to 112, wherein the therapeutic agent is selected from a pyrrolobenzodiazepine (e.g., PBD), an auristatin (e.g., MMAE, MMAF), a maytansinoid (e.g., maytansine, DM1, DM4, DM21), a duocarmycin, a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, a terpyrrolecin, an enediyne (e.g., calicheamicin), an anthracycline derivative (PNU) (e.g., doxorubicin), a pyrrolyl spindle actuator protein (KSP) inhibitor, a cryptophycin, a drug efflux pump inhibitor, a sandrocin, a camptothecin (e.g., α-camptothecin), and a camptothecin (e.g., exicnotecan, derutin).
[0492] Embodiment 104: The therapeutic complex of any one of Embodiments 89 to 103, having the following structure:
[0493] or
[0494] .
[0495] SEQ ID NO: 1:
[0496] Name: EndoSd-D232M amino acid sequence
[0497] Organism: Streptococcus lactis subsp. lactis
[0498]
[0499] SEQ ID NO: 2:
[0500] Name: EndoSz-D234M amino acid sequence
[0501] Organism: Streptococcus equi subspecies zooepidemicus Sz105
[0502] MVAILAAQHDSLIRVKAEDKLVQTSPSVSAIDALHYLSENSKEFKEELSKVEKAQPEKLKEIVSKAQQADKQAKTLAEMKVPEKIPMKPLKGPLYGGYFRTWHDKTSDPAEKDKVNSMGELPKEVDLAFVFHDWTKDYSLWFQELATKHVPTLNKQGTRVIRTIPWRFLAGGDHSGIAEDAQKYPNTPEGNKALAKAIVDEYKYNLDGLDVMIERDSIPKVNKEESKEGIERSIQVFEEIGKLIGP KGADKSRLFIMDSTYMADKNPLIERGAPYIDLLLVQVYGTQGEKGGFDNANHKAVDTMEERWESYSKYIRPEQYMVGFSFYEEKANSGNLWYDVNVEDDTNPNIGSEIKGTRAERYAKWQPKTGGVKGGIFSYGIDRDGVAHPKKNGPKTPDLDKIVKSDYKVSKALKVMENDKSYELIDQKDFPDKALREAVIAQVGSRRGNLERFNGTLRLDNPDIKSLEGLNKKLAKLELIGLSQITKLDSSVL PENIKPTKDTLVSVLETYKNDDRKEEAKAIPQVALTISGLTGLKELNLAGFDRDSLAGIDAASLTSLEKVDLSSNKLDLAAGTENRQILDTMLATVTKHGGVSEKTFVFDHQKPTGLYPDTYGTKSSLQLPVANDTIDLQAKLLFGTVTNQGTLINSEADYKAYQEQEIAGHRFVDSSYDYKAFAVTYKDYKIKVTDSTLGVTDHKDLSTSKEETYKVEFSPINSTKPVHEAKIVVGEEKTMMVNLAEGATIIGGDADPTNAKVFDGLLNNDTTTLSTSNKASIIFELKEPGLVKHWRFFNDSKISKADYIKEAKLEAFVGHLEDSSKVKDSLEKSTEWVTVSDYSGEAQEFSQPLNNIGAKYWRITIDNKKSQYGYVSLPELQIIGHRLPEAATVMTTMAAAEELSQQKDKFSQEQQLKELEVKVAALKAALDNKMFNADTINASFADVKAYIDKLLADAAGKKTLGKATKEAQPVATDAKEKAESENPKADHHHHHH
[0503] SEQ ID NO: 3:
[0504] Name: EndoSd-D232M nucleic acid sequence
[0505] Organism: Streptococcus lactis subsp. lactis
[0506]
[0507] SEQ ID NO: 4:
[0508] Name: EndoSz-D234M nucleic acid sequence
[0509] Organism: Streptococcus equi subspecies zooepidemicus Sz105
[0510]
Claims
1. A method for preparing an engineered biocomplex, comprising contacting a biomolecule with a glycosylated synthase and a modified polysaccharide, thereby obtaining a first engineered biocomplex, wherein the biomolecule further comprises an N-linked initial glycan; wherein the glycosynthase comprises SEQ ID NO: 1 or SEQ ID NO: 2, and the glycosynthase comprises a mutation located within residues 176-186, residues 225-237, or residues 273-289 of SEQ ID NO: 1, or within residues 178-188, residues 227-239, or residues 275-291 of SEQ ID NO: 2; wherein the modified polysaccharide comprises a substrate portion and a first reactive portion; wherein the substrate moiety is configured to react with the glycosynthase; and The biomolecule comprises an antibody or an antigen-binding fragment thereof, a protein or a peptide.
2. The method of claim 1, wherein the biomolecule comprises an antibody or an antigen-binding fragment thereof, and the N-linked proto-glycan is located in the Fc constant region of the antibody or antigen-binding fragment.
3. The method of claim 2, wherein the N-linked initial glycan is located at N297 of the Fc region.
4. The method of claim 1, wherein contacting the biomolecule with the glycosynthase and the modified glycan comprises coupling the modified glycan to the N-linked original glycan.
5. The method of claim 1, wherein the substrate moiety of the modified polysaccharide is an oxazoline moiety.
6. The method of claim 1, wherein the first reactive moiety is configured to react with the unsaturated moiety in a biorthogonal reaction. The method of claim 6 , wherein the biorthogonal reaction is copper-free click chemistry.
8. The method of claim 1, wherein the first reactive moiety comprises an azide group.
9. The method of claim 1, wherein the modified polysaccharide is a PEGylated polysaccharide modified with a first polyethylene glycol (PEG) moiety.
10. The method of claim 9, wherein the first polyethylene glycol (PEG) moiety comprises 2 to 72 OCH2CH2 subunits.
11. The method of claim 9, wherein the first PEG moiety is a linear PEG, a branched PEG, or a star PEG.
12. The method of claim 9, wherein the first end of the PEGylated polysaccharide is covalently coupled to the first reactive moiety.
13. The method of claim 9, wherein the second end of the PEGylated polysaccharide is covalently coupled to the substrate moiety.
14. The method of claim 1, wherein the modified polysaccharide is polysaccharide oxazoline.
15. The method of claim 14, wherein the polysaccharide oxazoline comprises the formula: ; where R 1 is -H or N-acetylglucosamine linked via a β-1,4 bond, R 2 and R 3 are the same or different and are independently selected from the group consisting of: 。 16. The method of claim 1, wherein contacting the biomolecule with the glycosynthase and the modified glycan comprises: removing the N-linked initial glycans of the biomolecule to obtain a deglycosylated biomolecule; and The deglycosylated biomolecule is contacted with the glycosynthase in the presence of the modified glycan.
17. The method of claim 16, wherein removing the N-linked original glycans of the biomolecule to obtain a deglycosylated biomolecule comprises mixing the glycosynthetase with the biomolecule in the absence of the modified glycans at a ratio of 1:500 to 1:1, 1:500 to 1:10, 1:500 to 1:20, 1:500 to 1:30, 1:500 to 1:50, 1:100 to 1:1, 1:100 to 1:10, 1:100 to 1:20, 1:100 to 1:30, 1:100 to 1:50, 1:50 to 1:1, 1:50 to 1:10, 1:50 to 1:20, or 1:50 to 1:
30.
18. The method of claim 16, wherein the deglycosylated biomolecule comprises a GlcNAc monosaccharide.
19. The method of claim 18, wherein the GlcNAc monosaccharide is fucosylated or non-fucosylated.
20. The method of claim 1, wherein contacting the biomolecule with the glycosynthase and the modified glycan comprises contacting a plurality of the biomolecules with the glycosynthase and the modified glycan, thereby obtaining a plurality of the first engineered biocomplexes; wherein the plurality of the first engineered biocomplexes have an isomorphism greater than 80%.
21. The method of claim 1, wherein the mutation comprises a substitution at residue 183, 232, 234, 280, 281, or 282 of SEQ ID NO: 1 or at residue 181, 230, 232, 278, 279, or 280 of SEQ ID NO:
2.
22. The method of claim 21, wherein the mutation further comprises: In SEQ ID NO: 1, D234E, D234R, D234H, D234M, D234V, D234L, D234F, D234T, D234Q, T183Q, D232Q, D280Q, S281Q, T282Q or In SEQ ID NO: 2, D232E, D232R, D232H, D232M, D232V, D232L, D232F, D232T, D232Q, T181Q, D230Q, D278Q, S279Q, T280Q.
23. The method of claim 1, wherein the biomolecule is an anti-Globo series antigen antibody or an antigen-binding fragment thereof, an anti-HER2 antibody or an antigen-binding fragment thereof, an anti-CD20 antibody or an antigen-binding fragment thereof, an anti-TNF-α antibody or an antigen-binding fragment thereof, an anti-PD-1 antibody or an antigen-binding fragment thereof, an anti-PD-L1 antibody or an antigen-binding fragment thereof, an anti-TROP2 antibody or an antigen-binding fragment thereof, an anti-EGFR antibody or an antigen-binding fragment thereof, an anti-Nectin-4 antibody or an antigen-binding fragment thereof, an anti-HER3 antibody or an antigen-binding fragment thereof, an anti-cMet antibody or an antigen-binding fragment thereof, an anti-B7H3 antibody or an antigen-binding fragment thereof, an anti-B7H4 antibody or an antigen-binding fragment thereof, an anti-VEGF antibody or an antigen-binding fragment thereof, an anti-Claudin 18.2 antibody or an antigen-binding fragment thereof, an anti-Sirp-α antibody or an antigen-binding fragment thereof, a TROP2×HER2 bispecific antibody, or a combination thereof.
24. The method of claim 23, wherein the Globo series antigens comprise Globo H, stage-specific embryonic antigen 4 (SSEA-4), or stage-specific embryonic antigen 3 (SSEA-3).
25. The method of claim 1, wherein the biomolecule is selected from the group consisting of Herceptin (trastuzumab), TX05 (trastuzumab biosimilar), Perjeta (pertuzumab), Erbitux (cetuximab), Rituxan (rituximab), Vectibix (panitumumab), Humira (adalimumab), Keytruda (pembrolizumab), Bavencio (avelumab), and R4702 (anti-TROP2 antibody).
26. An engineered biological complex comprising: biomolecules; and a modified glycan coupled to the biomolecule; Wherein the modified polysaccharide comprises: a first polyethylene glycol (PEG) moiety, and a first reactive moiety or a product thereof from a biorthogonal reaction; wherein the product moiety comprises a triazole moiety, a DBCO-derived moiety, or a maleimide-derived moiety; and The biomolecule comprises an antibody or an antigen-binding fragment thereof, a protein or a peptide.
27. The engineered biocomplex of claim 26, wherein the biomolecule comprises an antibody or an antigen-binding fragment thereof, and the modified glycan is coupled to the antibody or the antigen-binding fragment thereof at the N297 position of the Fc region.
28. The engineered biocomplex of claim 26, wherein the modified polysaccharide is coupled to a fucosylated or non-fucosylated GlcNAc monosaccharide at N297 of the Fc region.
29. The engineered biocomplex of claim 26, wherein the first reactive moiety comprises an azide group and is configured to interact with an alkyne moiety in a biorthogonal reaction.
30. The engineered biocomplex of claim 29, wherein the biorthogonal reaction is copper-free click chemistry.
31. The engineered biocomplex of claim 26, wherein the first PEG moiety comprises 2 to 72 OCH2CH2 subunits.
32. The engineered biocomplex of claim 26, wherein the first PEG moiety is a linear PEG, a branched PEG, or a star PEG.
33. The engineered biocomplex of any one of claims 26 to 32, further comprising a drug-loaded moiety, wherein the drug-loaded moiety is coupled to the modified polysaccharide via the product moiety.
34. The engineered biocomplex of claim 33, wherein the drug-loaded moiety is a first drug-loaded moiety, and the engineered biocomplex further comprises a second drug-loaded moiety, wherein the first drug-loaded moiety is different from the second drug-loaded moiety.
35. The engineered biocomplex of claim 33, wherein the drug-loaded moiety is a therapeutic agent.
36. The engineered biological complex of claim 35, wherein the therapeutic agent comprises an antiviral agent, an antibacterial agent, an immunomodulatory agent, an immunostimulatory agent, an anti-tumor agent, a chemotherapeutic agent, a toxin, a cytokine, a growth factor, a radionuclide, a hormone, or a combination thereof.
37. The engineered biocomplex of claim 33, wherein the drug-loaded moiety is selected from the group consisting of pyrrolobenzodiazepines (e.g., PBD), auristatins (e.g., MMAE, MMAF), maytansinoids (e.g., maytansine, DM1, DM4, DM21), duocarmycins, nicotinamide phosphoribosyltransferase (NAMPT) inhibitors, terpyrines, enediynes (e.g., calicheamicin), anthracycline derivatives (PNU) (e.g., doxorubicin), pyrrolyl spindle actuator protein (KSP) inhibitors, cryptophycins, drug efflux pump inhibitors, sandrocins, ectocin (e.g., α-ectocin), and camptothecins (e.g., exicin, delutec).
38. The engineered biocomplex of claim 26, wherein the biomolecule is an anti-Globo series antigen antibody, an anti-HER2 antibody, an anti-CD20 antibody, an anti-TNF-α antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-TROP2 antibody, an anti-EGFR antibody, an anti-Nectin-4 antibody, an anti-HER3 antibody, an anti-cMet antibody, an anti-B7H3 antibody, an anti-B7H4 antibody, an anti-VEGF antibody, an anti-claudin 18.2 antibody, an anti-Sirp-α antibody, a TROP2×HER2 bispecific antibody, or a combination thereof.
39. The engineered biological complex of claim 38, wherein the Globo series antigens comprise Globo H, stage-specific embryonic antigen 4 (SSEA-4), or stage-specific embryonic antigen 3 (SSEA-3).
40. The engineered biocomplex of claim 26, wherein the biomolecule is selected from the group consisting of Herceptin (trastuzumab), TX05 (trastuzumab biosimilar), Perjeta (pertuzumab), Erbitux (cetuximab), Rituxan (rituximab), Vectibix (panitumumab), Humira (adalimumab), Keytruda (pembrolizumab), Bavencio (avelumab), and R4702 (anti-TROP2 antibody).
41. An engineered biocomplex according to claim 26, prepared by the method of any one of claims 1 to 25.
42. A pharmaceutical composition comprising a plurality of the engineered biological complexes of claim 40 and a pharmaceutically acceptable carrier.
43. A method for treating cancer, comprising administering an effective amount of the pharmaceutical composition of claim 41 to a patient in need thereof.
44. The method of claim 42, wherein the cancer expresses Globo series antigens, HER2, TROP2, Nectin-4, HER3, cMet, B7H3, B7H4, VEGF, Claudin 18.2, or Sirp-α.
45. The method of claim 42, wherein the cancer is selected from the group consisting of sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head and neck cancer, nasopharyngeal cancer, esophageal cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervical cancer, endometrial cancer, ovarian cancer, testicular cancer, cheek cancer, oropharyngeal cancer, laryngeal cancer, prostate cancer, thyroid cancer, and oral cancer.
46. A therapeutic composition comprising the formula: CLD; wherein C is a reactive moiety configured to react in a biorthogonal reaction; wherein L is a linker unit comprising a hydrophilic portion, a cleavable portion, and a spacer; and wherein D is a therapeutic agent.
47. The therapeutic complex of claim 45, wherein the reactive moiety comprises an unsaturated moiety.
48. The therapeutic complex of claim 46, wherein the unsaturated moiety is an alkene moiety or an alkyne moiety.
49. The therapeutic complex of claim 45, wherein the reactive moiety is a non-natural and non-perturbing chemical group.
50. The therapeutic complex of any one of claims 45 to 47, wherein the reactive moiety is dibenzocyclooctynyl (DBCO), bicyclononyne (BCN), cycloalkyne, maleimide, α,β-unsaturated carbonyl, or sulfonylpyrimidine.
51. The therapeutic complex of claim 45, wherein the hydrophilic moiety comprises a polyethylene glycol (PEG) moiety comprising 2 to 72 OCH2CH2 subunits.
52. The therapeutic complex of claim 51, wherein the first PEG moiety is a linear PEG, a branched PEG, or a star PEG.
53. The therapeutic complex of claim 46, wherein the cleavable moiety is a protease-sensitive peptide comprising Val-Cit, Val-Ala, Phe-Lys, Glu-Val-Cit, Glu-Val-Ala, Glu-Gly-Cit, Glu-Gly-Ala, Gly-Gly-Phe-Gly, Gly-Gly-Val-Cit, or Gly-Gly-Val-Ala; or a glycosidase-sensitive sugar unit comprising glucuronic acid, iduronic acid, or galactose.
54. The therapeutic complex of claim 46, wherein the spacer comprises an aromatic group including 1,4-phenyl, 2,5-pyridyl, 3,6-pyridyl, 2,5-pyrimidyl, 2,5-thienyl, or aminomethylene (-NH-CH2-).
55. The therapeutic complex of claim 46, wherein the linker unit comprises the formula: , wherein (PEG)m is a polyethylene glycol moiety, and m is an integer selected from 2 to 72, Q SP is a spacer comprising an aromatic group or an aminomethylene group, Q CL is a cleavable portion and is configured to be linked to the loaded drug, L P is an adapter unit configured to be linked to the second reactive moiety.
56. The therapeutic complex of claim 55, wherein the PEG moiety comprises the formula: , The wavy line represents the P Site of covalent attachment, where R 20 is a PEG attachment unit, wherein the PEG attachment unit is -C(O)-, -O-, -S-, -NH-, -C(O)O-, alkyl-C(O)-NH-, alkyl-NH-C(O)-, alkyl-CO2-, alkyl-S-, or , where R 21 PEG capping unit; wherein the PEG capping unit is selected from H, SO3H, PO3H2, sugar derivatives, C1-C 10 (hetero)alkyl, C3-C 10 (Hetero)cycloalkyl, C2-C 10 Alkyl-NH2, C1-C 10 Alkyl-COOH, C2-C 10 Alkyl-NH (C1-C3 alkyl), C2-C 10 Alkyl-N(C1-C3 alkyl)2, wherein n is selected from 2 to 72.
57. The therapeutic complex of claim 55, wherein the linker unit has the following structure: 。 58. The therapeutic complex of claim 46, wherein the therapeutic agent comprises a toxin, a cytokine, a growth factor, a radionuclide, a hormone, an antiviral agent, an antibacterial agent, an immunomodulator, an immunostimulator, an anti-tumor agent, or a combination thereof.
59. The therapeutic composition of claim 46, wherein the therapeutic agent is selected from the group consisting of pyrrolobenzodiazepines (e.g., PBD), auristatins (e.g., MMAE, MMAF), maytansinoids (e.g., maytansine, DM1, DM4, DM21), duocarmycins, nicotinamide phosphoribosyltransferase (NAMPT) inhibitors, terpilacitines, enediynes (e.g., calicheamicin), anthracycline derivatives (PNU) (e.g., doxorubicin), pyrrolyl spindle motor protein (KSP) inhibitors, cryptophycins, drug efflux pump inhibitors, sandrocins, ectocin (e.g., α-ectocin), and camptothecins (e.g., exicnotecan, derutin).
60. The therapeutic complex of any one of claims 46 to 59, having the following structure: or 。
Citation Information
Patent Citations
Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof
EP0404097A2
Immunoconjugates
EP0659439A2
Glycosynthase variants for glycoprotein engineering and methods of use
US11203645B2
Improvement in automatic fans
US151172A
Polylactide-drug mixtures
US3773919A
